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Opiates have been used historically for the treatment of depression. 
Renewed interest in the use of opiates as antidepressants has focused on 
the development of kappa opioid receptor (κ-receptor) antagonists. In this 
thesis I have tested the hypothesis that buprenorphine/naltrexone 
combination has antidepressant efficacy. Buprenorphine acts as a partial mu 
opioid receptor (μ-receptor) agonist and a κ-receptor antagonist. By 
combining buprenorphine with the non-selective opioid receptor antagonist 
naltrexone, the idea was that the activation of μ-receptors would be reduced 
and the κ-antagonist properties enhanced. First, the appropriate dose of the 
combination that would act as a short acting κ-receptor antagonist was 
investigated in the mouse-tail withdrawal test.  A dose of BU10119, a novel 
compound derived from buprenorphine, with pharmacology resembling 
buprenorphine/naltrexone combination was also investigated. It was 
established that a combination dose of buprenorphine (1 mg/kg, i.p.) with 
naltrexone (1 mg/kg, i.p.) functioned as a short acting κ-antagonist in the 
mouse-tail withdrawal test and BU10119 (1 mg/kg, i.p.) is a к-antagonist with 
a rapid onset and a duration of action not more than 24 hours. Furthermore, 
these doses of the buprenorphine/naltrexone and BU10119 were neither 
rewarding nor aversive in the conditioned place preference paradigm, and 
were without significant locomotor effects. Systemic co-administration of 
buprenorphine/ naltrexone (1 mg/kg, i.p.) and BU10119 in adult CD-1 male 
mice produced an antidepressant-like response in both the forced swim test 
and novelty induced hypophagia task. Behaviours in the elevated plus maze 





Moreover, pretreatment with buprenorphine/naltrexone and BU10119 
blocked stress- induced analgesia in adult male CD1 mice. However, they 
were not capable of blocking restraint stress-induced elevation of 
corticosterone levels. Gene expression of k-receptor, prodynorphin and 
Corticotropin-Releasing Hormone Receptor 1 were not significantly altered 
by restraint stress or к-receptor antagonist treatment in prefrontal cortex, 
nucleus accumbens, hippocampus and amygdala. I propose that the 
combination of buprenorphine with naltrexone and BU10119, both represent 
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1. Introduction  
1.1. Opioid receptors 
Opioid receptors were discovered in 1973 using opioid radioligand 
binding assays (Pert and Snyder, 1973a; Pert and Snyder, 1973b). It has 
been discovered that the endogenous opioid system is composed of four 
families of neuropeptides (endorphins, enkephalins, dynorphins and 
orphanin FQ/nociceptin) and four receptor subtypes which are called μ-
receptor (mu receptors), δ-receptor (delta receptors), NOP-receptor 
(nociceptin receptor), which also called ORL-1, and к-receptor (kappa 
receptors) (Pert and Snyder, 1973a; Terenius, 1973; Martin, 1979; Corbett et 
al., 2006; Koneru et al., 2009). In general, enkephalins interact with the δ-
receptor, dynorphins interact with the к-receptor, endorphins bind to both μ-
and δ-receptors. Also, orphanin FQ/nociceptin interact with the ORL-1 
receptors (Corbett et al., 2006; Koneru et al., 2009) (Figure 1.1). The 
endogenous opioid peptides play an important role in relieving pain by 
binding to the four primary opioid receptor. However, countenuse activiation 
of μ-receptor causes euphoria, tolerence and physical dependence (Corbett 














Figure1.1. illustration diagram shows the site of action of endogenous opioid. 












1.2. The kappa opioid receptors signalling pathway (к-receptor) 
The к-receptors are seven transmembrane G-protein coupled  
rceptors (GPCRs) that couple to heterotrimeric Gɑi/o proteins (Kieffer, 1995; 
Wu et al., 2012). Moreover, к-receptor (Figure 1.2) was shown to have seven 
transmembrane domains in the core  ɑ–helices, which is connected by three 
extracellular loops (ECL1, ECL2, ECL3) and three intracellular loops (ICL1, 
ICL2, ICL3) (Wu et al., 2012). The к-receptors have been cloned from the 
human (Simonin et al., 1995; Mansson et al., 1994), rat (Chen et al., 1993; 
Nishi et al., 1993; Meng et al., 1993), mouse (Yasuda et al., 1993; Nishi et 
al., 1994) and guinea pig (Xie et al., 1994). They have a high affinity for the 
endogenous neuropeptide dynorphins A and a variety of selective synthetic 
agonists and antagonists have been developed for the к-receptors (Chavkin 
et al., 1982) (Table 1.1). The к-receptors was originally studied for its 
involvement in the mediation of pain (Pasternak, 1980). However, the 
dysphoric side effects of к-receptors agonists, have limited the ability of 
these compounds to be developed as therapeutic agents (Pffeifer et al., 
1986; Bruchas et al., 2007). More recently, there has been growing interest 
in selective к-receptors agents for their possible role on mood and reward.  
 
Dynorphins are endogenous opioid peptides that are derived from 
prodynorphin, which include dynorphin A, dynorphin B, and big dynorphin 
(Schwarzer, 2009). Dynorphins bind and exert their effects through к- 
receptors (Chavkin et al., 1982). Activation of к-receptors causes coupling to 
the pertussis toxin-sensitive heterotrimeric Gαi/o subunit that in turn inhibits 
adenyl cyclase and cyclic adenosine monophosphate (cAMP) (Figure 1.3 
and Table 1.2) (Schoffelmeer et al., 1988; Lawrence and Bidlack, 1993; 
Konkoy and Childers, 1993). Also, the G beta(β) /gamma(γ) subunits of the 
trimeric G protein directly block calcium channels (Tallent, 1994) and open 
K+ channels (Henry et al., 1995) which produces an inhibitory effect in 
neurons (Schoffelmeer et al., 1988). The evidence for к- receptors positively 









Figure 1.2. Crystal packing and overview of the human k-receptor structure in complex with 
JDTic, and comparison with the inactive CXCR4 and β2-AR structures. a, k- receptor –T4L 
crystal packing. The parallel dimer in one asymmetric unit is highlighted by the insert. b, 
Overall architecture of k- receptor – T4L in complex with JDTic. The A molecule (yellow) and 
B molecule (blue) fromone asymmetric unit are aligned through the receptor part. The DRY 
and NPXXY motifs are highlighted in red and blue, respectively. JDTic is shown in a green 
sphere representation and the disulphide bond is coloured orange. c, d, Side (c) and 
extracellular (d) views of a structural alignment of the human k- receptor (yellow); CXCR4 
(PDB accession 3ODU; magenta) and β2-AR (PDB accession 2RH1; cyan). The graphics 
were created by PyMOL. ( adopted from Wu et al., 2012). 
 
 
has been confirmed in several cell types ranging from neurons of the 
hippocampus to the dorsal root ganglia, suggesting that these ion channel 
effectors are highly targets of к- receptors activation (Grudt and Williams 
1995). Also, it was suggest that activation of the к-receptors causes 
intracellular calcium mobilisation via the inositol trisphosphate pathway 
(Spencer et al., 1997), which can lead to an enhanced hyperpolarisation-
activated current in the rat nucleus raphe magnus (Pan, 2003). In vivo 
experments, it has been reporetd that activation к-receptors cause excitatory 





Table 1.1. к-receptor agonists and their binding affinities µ, к and δ (values extracted from 
IUPHAR receptor database; accessed 06/12/2016 
 






















Dynorphin A   8.3 – 10.8  Full agonist 
 
Dynorphin B   8.1 – 9.9  Full agonist 
 
 Ethylketocyclazocine  10 к-δ Full agonist 
 
 Enadoline  9.6 к Full agonist 
 
 U69593  9.5 к Full agonist 
 
 U50,488  7.8-9.7 к Agonist 
 
 Salvinorin A  7.8-8.7 к Full agonist 
 
  JDTic 9.5 – 11.2 к Antagonist 
 
  norBNI 9.6 – 10.7 к Antagonist 
 
  LY2456302 9.1 к Antagonist 
 
  naltrexone 8.4 – 9.4 к Antagonist 
 
  naloxone 7.6 – 8.6 к Antagonist 
 















Figure 1.3. К-receptor-mediated signal transduction. Cartoon depicting the current status of 
the KOR signal transduction pathways. Receptor activation by a variety of К-receptor -
selective ligands can result in activation of several kinase cascades. Arrows refer to 
activation steps, T lines refer to blockers or inhibition of function. Abbreviations are as 
follows: ɑG-protein alpha-i subunit, arrestin phosphorylation dependent GPCR scaffold, βγ 
G-protein beta-gamma subunit, cAMP cyclic adenosine monophosphate, ERK 1/2 extra-
cellular signal regulated kinase, GRK3 G protein coupled receptor kinase3, JMR JNK 
Modulated Regulator, JNK c-Jun N-terminal Kinase, p38 p38 MAPK, P phosphorylation, 
pCREB phospho-cyclic AMP response element binding protein, PI3K phosphoinositol 3-
kinase, PKCζ protein kinase C zeta, PTX pertussis toxin, Src short for sarcoma, member of 
the src family tyrosine kinases, zif268 transcription factor, also called Egr-1. Adapted from 














Table 1.2. Shows the characteristics of the cloned opioid receptors. 
 












Gene organization lntronic lntronic lntronic 
Amino acid length 398 372 380 
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The cloned opioid receptors have similar binding properties to the receptors characterized in 
brain homogenates. Examples of two receptor agonists and an antagonist that binds to each 
of these cloned receptors is presented above. Anatomical areas listed are examples of 
regions demonstrating high levels of µ- δ or к1-receptor mRNA expression. Abbreviations: 
7TM, seven transmembrane; CTOP, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr, DAMGO, D-
Ala2-MePhe4-Gly-ol5- enkephalin; DPDPE, D-Pen2-D-Pen5-enkephalin; DSLET, D-Ser2-D-
Leu5-enkephalin; U58488, 3,4-dichloro-N-[2-( I -pyrrolidinyl)- cyclohexyllbenzene acetamide; 
DYNA( l-17), dynorphina A( l-l 7); and norBNI, norbinaltorphimine. (Adapted from Mansour 









al., 2011; Rocha et al., 1997). Dual coupling to excitatory and inhibitory G- 
proteins (Gs and Gi) has been ducumented for all of the opioid receptor 
systems, and it has been proposed by these studies that к-receptors under 
some circumstances couple to can stimulatory G-proteins (Crain and Shen 
1990).  
 
1.2.1. к-receptors and mitogen-activated protein kinase (MAPK) 
cascade activation 
The mitogen-activated protein kinases (MAPKs) are the family of 
kinases that transduce signals from the cell membrane to the nucleus in 
response to a wide range of stimuli, including stress (Seger and Krebs, 
1995; Chang and Karin, 2001; Werlen et al., 2003). MAPK pathway is 
activated by trophic and growth factor receptors and has been identified as a 
critical mediator that regulate diverse cellular programs including: apoptosis, 
differentiation, embryogenesis, cell proliferation, transcription factor 
regulation, protein-protein interactions and ion channel phosphorylation 
(McClean et al., 2007; Raman et al., 2007; Werlen et al., 2003). MAPKs 
consist of three family members: the extracellular signal-regulated kinase 
(ERK); the c-Jun NH2-terminal kinase (JNK); and the p38- MAPK (Seger 
and Krebs, 1995; Tibbles and Woodgett, 1999; Widmann et al., 1999; Davis, 
2000; Chang and Karin, 2001; Johnson and Lapadat, 2002). К-receptor 
agonists have been shown to activate all three MAPK family members 
including the extracellular signal-regulated kinase (ERK), the stress kinase 
p38  and the stress kinase c-Jun N-terminal kinase (JNK ) (Bruchas et al., 
2007a; Bruchas et al., 2007; Belcheva et al., 2005) ( Figure 1.3). 
 
1.2.2. к-receptor and ERK 1/2 MAPK activation 
The extracellular signal-regulated kinase (ERK) family has its own 
subfamilies: ERK1 and ERK2 (Seger and Krebs, 1995; Tibbles and 
Woodgett, 1999). Acute activation of к, µ and δ receptors have been 
reported to cause ERK 1/2 phosphorylation in astrocyte cultures via different 
signalling pathways (Belcheva et al., 2005: Belcheva et al., 1998) (Figure 





stem cell fate decisions (Kim et al., 2006) and to stimulate proliferation of 
astrocytes (McLennan et al. 2008). Moreover, it has also been reported that 
к-receptor-induced ERK 1/2 phosphorylation occurs in a multi-phase manner 
(Gesty-Palmer et al., 2006), an arrestin-independent early phase (Arrestins 
are a small family of proteins important for regulating signal transduction at 
GPCRs) and an arrestin-dependent late phase in astrocytes (McLennan et 
al., 2008). It has been reported that repeated swim-stress, a test that induce 
a sufficient dynorphin release (McLaughlin et al., 2003), caused GRK3-
independent (G-protein-coupled receptor kinase 3), ERK 1/2 and pCREB 
phosphorylation in the nucleus accumbens (NAc) of mice (Bruchas et al., 
2008). They reported that these effects are mainly due to the к-receptor 
activation and it was blocked by the к-receptor antagonist, 
norbinaltorphimine (norBNI) and absent in к-receptor knockout mice.  
 
1.2.3. к-receptor and p38 MAPK activation 
P38 mitogen-activated protein kinases are a class of MAPK. P38-
MAPK is activated in response to a variety of cellular and environmental 
stresses such as ischemia, heat shock, DNA damage, inflammatory 
cytokines and UV irradiation ceramide (Seger and Krebs, 1995; Tibbles and 
Woodgett, 1999; Chang and Karin, 2001; Johnson and Lapadat, 2002). The 
p38-MAPKs were originally termed as mammalian homologues to the yeast 
protein Hog1 that sense osmolarity change (Han et al., 1994). In most 
cases, p38-MAPKs are simultaneously activated with JNKs (Werlen et al., 
2003). At least four isoforms of p38- MAPK have been known: p38-MAPKɑ, 
p38-MAPKβ, p38-MAPKδ, and p38-MAPKγ (Kyriakis and Avruch, 2001). К-
receptor-induced p38 MAPK phosphorylation has been confirmed in several 
systems in vivo including astrocytes, the spinal cord, GABAergic neurons in 
the NAc, the cortex and the hippocampus (Bruchas et al., 2006, 2007a; Xu 
et al., 2007). Moreover, it has been reported that the p38 MAPK pathway 
play a critical role in modulating chronic pain states (Watkins et al., 2001) 
and к-receptor-induced p38 MAPK activation in astrocytes has been involved 
in cellular reorganisation after nerve injury (Xu et al., 2007). The activation of 





phosphorylation at serine 369 by GRK3 and subsequent arrestin3 
recruitment in primary cultures and in vivo (Bruchas et al., 2006). It was 
reported by Bruchas et al (2006) that к-receptor induced p38 requires 
GRK3/arrestin and that was in contrast with к-receptor mediated ERK 1/2 
phosphorylation, which has both arrestin-independent (Bruchas et al., 2006, 
2008) and dependent phases (McLennan et al., 2008). 
 
Bruchas et al (2007a) reported that the selective p38 inhibitor 
SB203580 was able to block к-receptor agonist induced conditioned place 
aversion and stress-induced immobility after induction of p38 MAPK 
phosphorylation following behavioural stress in vivo, but the mechanisms 
whereby p38 mediates the к-receptor dependent effects are not clear.  
 
It has been reported that the potassium channel K (ir) V was shown to 
become tyrosine phosphorylated by a к-receptor dependent p38 MAPK-
induced Src activation (Clayton et al., 2009). They reported that к-receptor 
activation caused phosphorylation of Y12-K(ir)3.1 and channel inhibition 
through a GRK3-, p38 MAPK- and Src-dependent mechanism. It was 
suggested that the decrease in the inward potassium current after к-receptor 
activation may increase neuronal excitability and may contribute to к-
receptor mediated behavioural responses (Clayton et al., 2009). It was 
suggested that, p38 MAPK might cause a synaptic depression in some 
regions while increasing excitation in others. Moreover, it has been 
documented that p38 is involved in increasing serotonin reuptake through 
PP2A (phosphatase) and p38-dependent SERT modification (Zhu et al., 
2005; Prasad et al., 2005), and к-receptor activated p38 MAPK in the dorsal 
raphe nucleus, a serotonergic nucleus, has been suggested to be involved in 
the к-receptor dysphoric behaviours effect (Bruchas et al., 2011; Land et al., 
2009).  
 
1.2.4. к-receptor and JNK MAPK activation 
JNKs are also known as stress-activated protein kinases; SAPKs,   





signalling pathways that control a variety of cellular processes, including 
differentiation, cell growth, transformation, or apoptosis. The JNKs has its 
own subfamilies:  (JNK1, JNK2, and JNK3) (Seger and Krebs, 1995; Tibbles 
and Woodgett, 1999; Davis, 2000; Chang and Karin, 2001; Johnson and 
Lapadat, 2002; Werlen et al., 2003). Song et al (2009) reported that the 
activation JNK causes phosphorylation of specific sites on the amino-
terminal transactivation domain of c-Jun, a critical transcription factor in the 
AP-1 complex. It has been suggested that all arrestin isoforms have the 
capacity to scaffold JNK (McDonald et al., 2000). The к-receptor agonists 
U69,593, U50,48 and Dynorphin B cause JNK phosphorylation (Kam et al., 
2004; Bruchas et al., 2007b). It has been reported that U69,593 and 
U50,488 induced JNK phosphorylation are mediated through pertussis toxin-
sensitive Gɑ- activation (Kam et al., 2004; Bruchas et al., 2007b). Moreover, 
it has been shown that the к-receptor -induced Src stimulation and GTPase 
Rac-dependent activation of focal adhesion kinases were critical for к-
receptor -mediated JNK activation in immune cell types (Kam et al., 2004).  
The identification of the isoform of JNK that к-receptor activates remains 
unresolved. However, Melief et al (2011) using JNK knockout mice 
suggested that the JNK1 isoform mediates the к-receptor effects. 
 
1.3. к-receptor anatomical localisation 
К-receptors are widely expressed throughout the brain, spinal cord, 
and peripheral tissues. The expression of both к-receptors and prodynorphin 
is high in brain regions that are involved in mood, cognitive, stress 
responses and reward such as the amygdala (Amy), ventral tegmental area 
(VTA), hippocampus (Hip), nucleus accumbens (NAc), hypothalamus (HL), 
locus coeruleus (LC), substantia nigra (SN), and dorsal raphe nucleus (DRN) 
in human and rodent brains (DePaoli et al., 1994; Kitchen et al., 1997; Lin et 
al., 2006; Mansour et al., 1994; Crowley and Kash, 2015) (Figure 1.4). It has 
been documented that the к-receptors are also expressed at several levels 
of pain circuitry, including areas such as the dorsal root ganglia, dorsal 
spinal cord, rostral ventromedial medulla, periaqueductal gray, sensory 





Neugebauer et al., 2004). Moreover, it has been suggested through receptor 
binding studies that the к-receptor is composed of three subtypes named к1, 
к2, and к3 (Minami et al., 1993). However, only one cDNA clone for the к-
receptor has been documented (Simonin et al., 1995; Mansson et al., 1994). 
Also, it has been suggested that there is an interaction between к and δ-











Figure 1.4 . К-receptors modulate the interactions between major circuits involved in stress 
responses, anxiety, and addiction. К-receptors are found in many key brain regions known 
to be involved in a variety of diseases, such as anxiety and addiction. It has been found that 
KORs do not only mediate aversive or anxiogenic responses (red circles); literature has 
shown that KORs (red and white circles) can also be reinforcing, such as in the nucleus 
accumbens. In addition, dynorphin knockout mice show increased fear conditioning. Key: 
orbital frontal cortex (OFC); prefrontal cortex (PFC); nucleus accumbens (NAC); amygdala 
and extended amygdala (AMG); hippocampus (HIPP); ventral tegmental area (VTA); dorsal 










It has been reported that there is species differences between 
humans and guinea pigs expressing much higher levels of к-receptors in 
brain than rats and mice (Table 1.3). Moreover, studies have showed that 
guinea pigs, but not rats nor mice, have a similar distribution of к-receptor as 
humans, e.g., being abundant in cerebellum, layers V and VI of the cortex 
and in striosomes of the striatum  (Quirion et al., 1987; Quirion and Pilapil, 
1991). 
 
Table 1.3. Relative proportions of the opioid receptors in several species 































    
 
Opioid receptor binding in the forebrains of several species as determined by Scatchard 
analysis. The upper number of each pair refers to fmol per mg tissue. µ receptors were 
labelled with [3H]-DAMGO, δ sites with [3H]-DPDPE and к-receptors with [3H]-bremazocine 
in the presence of a 300-fold excess of unlabelled DAMGO and DPDPE. Given the total 
amount of opioid binding, the numbers beneath in parentheses are the relative abundance 
of these sites within brain tissue. The values reported here reflect the binding of human 
frontal cortex and forebrain tissue of the mouse rat, guinea-pig and pigeon (Source: 





1.4. Effects к-receptors on neurotransmitter release 
The majority of studies on dynorphin and к-receptor interactions with 
monoamine systems have focused on dopamine, especially on the 
mesolimbic dopamine system. The mesolimbic dopamine system have been 
documented to plays an important role in motivational and reward 
behaviours. It consist of the nucleus accumbens (NAc; ventral striatum) and 
its dopaminergic input from the ventral tegmental area (VTA) (Di Charo and 
Bassareo, 2007; Ikemoto, 2010). 
 
The principal neuron in the NAc is medium spiny projection neurons 
(MSNs), which make up approximately 90% of all neurons. Principal 
projection neurons contain γ-aminobutyric acid (GABA) as the primary 
neurotransmitter and a variety of neuropeptides, including, enkephalin, 
substance P and neurokinin B (Zahm and Heimer, 1988; Meredith et al., 
1993). Moreover, dynorphin is expressed in MSNs of the NAc and the dorsal 
striatum. The GABAergic MSNs in the NAc, predominantly co-express 
dopamine D1 receptors and dynorphin, which directly project back to the 
VTA (Conrad and Pfaff, 1976; Phillipson, 1979). In addition, dynorphin, in the 
dorsal striatum, is highly expressed in D1 receptor-expressing neurons that 
project to the substantia nigra (Fisone et al., 2007; You et al., 1994). 
Moreover, in the dorsal and ventral striatum, MSNs have axon collaterals 
that can release dynorphin. К-receptors are localised on the terminals and 
cell bodies of VTA DA neurons, which input onto the NAc (Shippenberg and 
Rea, 1997; Svingos et al., 1999) and can regulate local neurotransmitter 
such as DA, serotonin  and glutamate release within NAc (Chefer et al., 
2005; Schlosser et al., 1995; Spanagel et al., 1992; Svingos et al., 1999; 
Thompson et al., 2000; Hjelmstad and Fields, 2001; Hjelmstad and Fields, 
2003) (Figure 1.5). Indeed, it has been reported that к-receptor activation in 
the NAc region by dynorphin and к-receptor agonists decreases dopamine 
release. In contrast, it has been shown that к-receptor antagonist causes an 
increase in DA release (Spanagel et al., 1992; Maisonneuve et al., 1994). 
Moreover, it has been reported in vivo microdialysis studies that U50,488 





in those sites, suggesting that that к-receptor directly modulates 5-HT 
release at pre-synaptic terminals in target regions (Tao and Auerbach, 2002; 
































Figure 1.5. Summary of к-receptor modulation and downstream signalling in NAc, Cartoon 
summary of the sites of к-receptor modulation in a medium spiny neuron of the NAc and 
downstream effectors of к-receptor activation. Following release of dynorphin (light green 
circles), к-receptor (bright green squiggle) can inhibit the release of glutamate (red terminal), 
dopamine (green terminal), GABA (blue axon collateral), and serotonin (orange terminal). It 
has been shown that к-receptor increases dopamine uptake transporter (DAT) function 
(dark green box) to inhibit dopamine release. Post-synaptically к-receptor increases (line 
with ball at the end) ERK 1/2 and p38 MAPK activity through parallel pathways. Source: 










Using radioligand binding assays and in vivo microdialysis Berger et 
al (2006) investigated the effects of к-receptor activation on (noradrenaline) 
NA release in the forebrain. In this study, the effects of U50,488 on NA 
release from neocortical slices of rat and human were assessed using 
tritiated NA. In rats, the µ-receptor agonist DAMGO inhibited NA release in 
the neocortex, but neither к nor δ-receptor agonists had any effect. However, 
in human neocortical slices, DAMGO had no effect on NA release, but к and 
δ-receptor agonists were able to produce a small depression in NA release 
(Berger et al., 2006).  
 
 
1.5. Depression  
Depression is one of the most serious mental illness affecting 350 
million people worldwide (WHO 2016a) and it can influence the ability of the 
patient to function at school, at work and in the family. Depression is defined 
in DSM-IV (American Psychiatric Association, 1994), as condition 
characterized by the presence of loss of pleasure or interest in usually 
pleasurable activities (anhedonia), together with an array of other features, 
including anergia, changes in sleep and appetite, sadness, and suicidal 
ideation.  It is associated with decreased productivity in the workplace and 
an increased risk of absenteeism from work. Also in severe cases, a 
depressed patient may commit suicide. Each year, almost 800,000 people 
worldwide die because of suicide. It was estimated that almost 78% of 
suicide attempt were in patients affected by major depression (Broadhead et 
al., 1990; Holma et al., 2010; WHO 2016a). Depression is a debilitating 
recurrent psychiatric disorders and almost over three-quarters of all patients 
who recover from one attack of depression go on to one or more attacks in 
future (Keller, 2001). Many patients may suffer from chronic depression if not 
treated, lasting over 2 years in one-third of patients (Mental Health Policy 
Group, 2006). Depression is the fourth cause of disability worldwide and it 
exerts a huge economic cost (Mauskopf et al., 2009; Ustün et al., 2004) and 
by 2020 it’s predicted that depression will become the second leading cause 





in population is not well determined. However, it has been reported that 
lifetime prevalence of depression in general populations is in the range of 
10% to up to 15% (Lépine and Briley, 2011; Vos, 2012). Also, women are 
twice more likely to be diagnosed with depression than men (Kuehner, 
2003). 
 
Depression is characterized by a number of  signs and symptoms 
such as feelings of sadness, loss of pleasure or interest in all or most 
activities during the day, loss of interest in sex, severe reduction or increase 
in appetite, insomnia or excessive sleeping, agitation or slowness of 
movement, fatigue or lack of energy, feelings of guilt or low self-worth, 
recurrent thoughts of death and urge to commit suicide and reduced ability 
to think or concentrate (American Psychiatric Association, 2013). Depending 
on severity and number of the sign and symptoms, a depressive attack can 
be categorised into mild, moderate, or severe (WHO 20161a) which are 
important for treating depression (Bennett  and Torrance, 1996). Depressive 
disorders come in different forms such as major depression (unipolar 
depression), disruptive mood dysregulation disorder, postpartum depressive 
disorder, persistent depressive disorder (dysthymia), premenstrual dysphoric 
disorder and manic-depressive or bipolar disorder which is not predominant 
as other forms of depressive illnesses (American Psychiatric Association, 
2013; Katon, 1987). Of these forms, major depression represents the classic 
condition and is characterised the patient losing  his interest or pleasure in 
everyday activities, almost each day, and these symptoms and mood 
disturbance may last for at least 2 weeks in duration. These depressive 
symptoms may happen once, twice or several times in a lifetime. In 
persistent depressive disorder (dysthymia), these symptoms are chronic and 
less severe that do not disable the patient. However, it reduces the patient 
functionality and prevents him from feeling well. The mood disturbance in 
this form lasts for at least 2 years in adults or 1 year in children (American 






Patients diagnosed with depression also suffer from anxiety disorders 
and over half of patients with depression have a persistence chronic history 
of anxiety disorders (Kessler et al., 1996; Fava et al., 2000). This co-
morbidity is associated with an increase in severity and persistence of 
symptoms, for example, higher incidence of suicidality (Roy-Byrne et al., 
2000). Anxiety and depression disorders are different, but patient with 
depression generally experience symptoms similar to those of an anxiety 
disorder, such as feeling tense, or restless, irritable, significant tension in 
muscles, easily to become fatigued and difficulty in sleeping and 
concentrating. The presence of three or more of these symptoms for most 
days over the previous six months is a sign of generalized anxiety. However, 
each disorder has its own causes and its own signs and symptoms 
(American Psychiatric Association, 2013).  
 
1.6. The neurobiology of depression  
Unfortunately, the exact underlying etiology of the biological 
mechanisms behind depression is still unclear (Cryan et al., 2002). Several 
overlapping mechanisms and factors may contribute to the development of 
these disorders, including alteration of brain chemistry, genes, gender and 
exogenous stressors such as, trauma and environmental factors (Charney 
and Manji, 2004; Caspi et al., 2003; Belmaker and Agam, 2008). However, 
the possible mechanisms that have been investigated include the 
monoamine hypothesis, stress and the hypothalamic-pituitary-adrenal axis 
and neurogenic mechanisms (Figure 1.6).  
 
1.6.1. Monoamine hypothesis 
The monoamine hypothesis has been the dominant hypothesis of 
depression for decades.  It states that these disorders are accompanied by 
decreased monoamine transmission: in 5-hydroxytryptamine (5-HT), 
noradrenaline (NA) and dopamine (DA) (Nestler et al., 2002). DA and NA are 
synthesised from the precursor tyrosine. The monoamine serotonin (5-
hydroxytryptamine or 5-HT) is synthesised from tryptophan, which is 





rate-limiting enzyme tryptophan hydroxylase (TPH). After the release of 
monoamines, they are able to bind to specific receptors on both presynaptic 
and postsynaptic terminal membranes. NA, it is able to bind to three families 
of adrenergic receptors: α1, α2 and β. 5-HT bind to 7 main types of 5-HT 
receptors (1–7) (Barnes et al., 1999). Moreover, and DA is able to bind to 
D1-like receptors that includes the D1 dopamine receptor (D1DR) and D5DR or 
to D2-like receptors that include the D2DR, D3DR and D4DR (Missale et al., 
1998; Neve et al., 2004). Reuptake of the monoamines into the presynaptic 






Figure 1.6. The possible current hypotheses of depression. In the top oval, the possible 
hypotheses of depression and their associated drug targets are listed. In the middle oval, 
the possible biological courses involved in the etiology of depression are shown (source 







The development of monoamine hypothesis was by the chance 
finding that iproniazid, a drug intended for the treatment of tuberculosis, was 
able to elevate mood in depressed patients (Lopez-Munoz et al., 2009). The 
mechanism behind this was found to be the inhibition of the enzyme 
monoamine oxidase (Delay et al., 1952) which caused an increased in 
postsynaptic stimulation through increased neurotransmitter availability. 
Indeed, preclinical and clinical evidence suggests disturbances in 5-HT and 
NA neurotransmission in the central nervous system (CNS). For example, it 
was documented that a significant decrease in the levels of 5-
hydroxyindoleacetic acid (a serotonin metabolite) and homovanillic acid (a 
dopamine metabolite) in the cerebrospinal fluid are noticed in patients with 
depression (Post et al., 1980; Lakshmi et al., 1992). Moreover, it was 
reported that serotonin levels were significantly lower in patients with major 
depressive disorders (Quan-Bui et al., 1984; Malison et al., 1998). In 
addition, depression was induced after treatment with an antihypertensive 
drug known as reserpine, which depletes both 5-HT and catecholamines 
(Goodwin et al., 1971), whereas treatment with parachlorophenylalanine, a 
drug that depletes central 5-HT by inhibiting TPH, blocks the beneficial 
effects of tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors 
(MAOIs) (Shopsin et al., 1976; Shopsin et al., 1975). Also, it was reported 
that patients who have been treated successfully with NA reuptake inhibitor, 
suffer from relapse after the administration of a tyrosine hydroxylase inhibitor 
called α-methyl-para-tyrosine that causes catecholamine (DA and NA) 
depletion (Booij et al., 2003), although it does not induce depression in 
normal subjects. That’s way, a huge efforts and research were made to 
produce a novel drugs that increases monoamine function through inhibiting 
5-HT and NA transporters since the 1960s (Post et al., 1980; Lakshmi et al., 
1992; Dale et al., 2015). Moreover, an increasing evidence in literature 
suggests an important role for DA signalling in different brain regions 
(Nieoullon and Coquerel, 2003; Nestler and Carlezon, 2006). Moreover, it 
has been reported that a reduction in mesolimbic dopamine circuit that 
consists, in part, of dopaminergic neurons of the VTA that project to the NAc, 





et al., 2005), is responsible for the loss of pleasure (anhedonia) (Schultz et 
al., 1997; Nestler and Carlezon, 2006).  
 
The monoamine hypothesis is the most established mechanism of 
depression pathology. However, this hypothesis has unresolved issues. One 
of them is the temporal delay between the increase of monoamines at the 
synapse caused by antidepressant administration, which occur within hours, 
and the onset of therapeutic improvements in patients that take up to 4 
weeks to developed (Baldessarini, 1989). Moreover, an effort to induce 
depression on healthy volunteers through acute tryptophan depletion, which 
transiently lowers 5-HT brain activity through dietary restriction, has been 
shown to have no effect (Ruhe et al., 2007). That is way it is difficult to 
explain the whole mechanism of antidepressant action by the acute increase 
in monoamines, which does not provide a full understanding of the 
pathophysiology of depression. However, researcher has moved beyond the 
measurement of monoamine levels, but they focus on molecular 
components of monoaminergic signalling pathways that include receptors, 
enzymes and transporters. 
 
1.6.1.1. Serotonin  and depression  
The serotonergic pathways start from the brainstem raphe nuclei, 
which are found lying in or lateral to the midline regions of the pons and 
upper brainstem (Jacobs et al., 1992). The raphe nuclei are divided into the 
dorsal raphe nucleus (DRN), the median raphe nucleus (MRN), caudal linear 
nucleus, and supralemniscal region (Pineyro et al., 1999). The DRN is the 
largest of the brainstem serotonergic nuclei containing around 50– 60% of     
5-HT neurons in the human CNS and innervates the neostriatum and cortical 
regions (Baker et al., 1990; Descarries et al., 1982).  
 
The monoamine serotonin (5-hydroxytryptamine or 5-HT) is 
synthesised from tryptophan, which is converted inside the nerve terminal to 
5-hydroxytryptophan (5-HTP) by the rate-limiting enzyme tryptophan 





to specific receptors on both presynaptic and postsynaptic terminal 
membranes. 5-HT receptor is seven transmembrane G protein coupled 
receptor that inhibits adenyl cyclase through Gα proteins (Raymond et al., 
2001), and in particular Gαi and Gαo subunits (Raymond et al., 1993), and 









Figure 1.7. Schematic diagram depicting the major pathways involved in the synthesis, 
release, re-uptake and metabolism of serotonin in serotonergic neurons. TpH: tryptophan 
hydroxylase; 5- HTP: 5-hydroxy-L-tryptophan; 5-HT: serotonin; SERT: serotonin transporter; 
MAO: monoamine oxidase; 5-HIAA: 5-hydroxyindoleacetic acid; 5-HTR: serotonergic 













The important role of 5-HT and its level in depression was suggested 
in several studies (Quan-Bui et al., 1984; Malison et al., 1998; Post et al., 
1980; Lakshmi et al., 1992). Moreover, there is an increasing interest on the 
role of the 1A subtype of 5-HT receptors (5-HT1A) in depression pathology 
(Savitz et al., 2009). The 5-HT1A receptor is widely expressed 
somatodendritically (between the soma and dendritic branches) within the 
DRN (Sotelo et al., 1990) and postsynaptically on pyramidal cells and 
interneurons of the cortex, hippocampus, septum, hypothalamus and 
amygdala (Hensler et al., 1991). The stimulation of postsynaptic 5-HT1A 
receptors (by 5-HT1A agonists or 5-HT) is inhibitory on glutamatergic neurons 
(Sprouse et al., 1988). Indeed, it was reported from a number of human 
post-mortem and from 5-HT1A knockout mice that the 5-HT1A receptors are 
involved in depression pathology. Indeed, the analysis of depressed human 
patients post mortem has shown reduced 5-HT1A receptor ligand binding in 
the ventrolateral prefrontal cortex and the temporal cortex as determined by 
autoradiography studies (Bowen et al., 1989), reduction in the 5-HT1A 
receptor ligand binding in the caudal aspects of the dorsal raphe nucleus 
(Arango et al., 2001) and a reduced 5-HT1A receptor mRNA expression in 
the dorsolateral prefrontal cortex and hippocampus (Lopez-Figueroa et al., 
2004) as well as fewer serotonin transporter (SERT) binding sites ( Mann et 
al., 2000). Reduced 5-HT1A receptor expression and SERT binding site may 
reflect a compensatory mechanism in response to the hyposerotonergic 
state present in depressed patients (Mann et al., 2000). Moreover, it has 
been shown that the knockout mice of 5-HT1A receptor produce anxious-like 
effects such as reduced exploratory behaviour and enhanced reactivity to 
fear cues (Heisler et al., 1998; Parks et al., 1998). Moreover, these mice 
showed an increase in immobility times in the tail suspension test compared 
with wildtype mice and could not be blocked by paroxetine and fluoxetine 
(Mayorga et al., 2001).  
 
Other 5-HT receptors have been reported to be involved in 
depression such as the 5HT1B receptor (Sari, 2004). The 5-HT1B receptors 





1995) where they act as inhibitory autoreceptors by regulating 5-HT release 
(Sharp et al., 1989) and controlling serotonergic cell firing (Evrard et al., 
1999). Moreover, it has been reported that the activation 5-HT1B receptors 
inhibit the release of acetylcholine because they exist at the cholinergic 
terminals of the rat hippocampus (Maura et al., 1986). In addition, it has 
been reported that the levels of 5-HT1B receptors were significantly lowered 
in the frontopolar cortex, hippocampus (females only), orbitofrontal cortex 
(males only), and higher levels in the paraventricular nucleus of suicide 
victims compared with healthy controls (Anisman et al., 2008). On the other 
hand, it has been found in autoradiography study that 5-HT1B ligand receptor 
binding in the prefrontal cortex of suicide victims with major depression was 
not different from healthy volunteers (Huang et al., 1999). The link between 
depression and 5-HT1B receptors still unclear. However, preclinical studies 
have suggested a possible link between 5-HT1B receptors and the 
antidepressants mechanism of action. Indeed, chronic SSRI treatment can 
down-regulate and/or desensitize 5-HT1B receptors in rats (Blier et al., 1988; 
O'Connor et al., 1994). In addition, chronic treatment with fluoxetine was 
documented to reduce 5-HT1B mRNA in the rat dorsal raphe nuclei and 
would be reversed by stopping the treatment (Neumaier et al., 1996). 
Moreover, it was reported that fluoxetine and paroxetine treatment were able 
to augment the increase in the 5-HT levels (in the frontal cortex and dorsal 
raphe nucleus of rats, respectively) after pretreatment with 5-HT1B receptor 
antagonist GR 127935 (Davidson et al., 1995; Gobert et al., 1997). 
Moreover, the ability of fluoxetine to raise the 5-HT level was potentiated in 
the hippocampus in 5-HT1B receptor knockout mice (Knobelman et al., 
2001).  
 
There also interactions between different monoaminergic transmitter 
systems in different brain regions that leads to changes in neurotransmitter 
release and function. For example, 5-HT activates dopamine release 
(Parsons and Justice, 1993; De Deurwaerdère et al., 1998; Zangen et al., 
2001) in the NAc, through activation of the 5-HT 1B/1D (Yan and Yan, 2001) 





1.6.1.2. Noradrenaline  and depression  
Noradrenergic neurons are mainly located in the locus coeruleus of 
the brainstem and project to the cortical, subcortical areas and to the spinal 
cord (Ressler et al., 1999). Noradrenaline is synthesized from the amino acid 
tyrosine. The conversion of tyrosine to dopamine occurs mainly in the 
cytoplasm then dopamine is converted to noradrenaline by dopamine β-
monooxygenase that occurs predominantly inside neurotransmitter vesicles 
(Musacchio, 1975). After NA release, it binds to all three families’ of 
adrenergic receptors (α1Rs, α2Rs and βRs). The adrenergic receptors are 
seven transmembrane GPCRs and the activation of each family of these 
receptors causes different consequences.  
 
The important role of NA and its level in depression was suggested in 
several studies (Belmaker and Agam, 2008; Krishnan and Nestler, 2008). In 
addition, the adrenergic system may interact with other brain systems, which 
may take part in development of depression. It has been reported that the 
administration of α1 adrenergic receptor agonist phenylephrine stimulates 5-
HT firing activity in the DRN and MRN, which suggests that the excitatory α1 
adrenergic receptors may have a role in 5-HT firing in the raphe nuclei 
(Judge et al., 2006), whereas α1 adrenergic receptor antagonists suppress 
5-HT neuron firing activity (Baraban et al., 1980). Moreover, chronically 
treated rats with antidepressants were shown to have increased α1 binding 
(using [3H] prazosin as a ligand) in the cerebral cortex (Maj et al., 1985). In 
contrast, α2 receptors are localized presynaptically as autoreceptors to 
regulate neurotransmitter release and have been implicated in the inhibitory 
control of adrenergic and serotonergic pathways innervating the frontal 
cortex (Dennis et al., 1987; Limberger et al., 1986). Indeed, it was reported 
that the effects of α2 adrenergic receptors on serotonergic terminals are 
inhibitory and it regulate 5-HT release (Limberger et al., 1986). Moreover, 
the stimulation of α2 adrenergic receptors has been documented to 
decrease NA output and suppresses the firing activity of 5-HT neurons in the 
dorsal raphe nucleus of rats (Clement et al., 1992). Chronic treatment with 





NA in the dorsal hippocampus (Sacchetti et al., 2001). However, 
supersensitivity of the α2 receptor may be a predisposing factor for 
depression. Post-mortem studies of depressed suicide victims found an 
increased level of α2 adrenergic receptors in the prefrontal cortex compared 
with healthy controls (Garcia-Sevilla et al., 1999). In addition, it has been 
reported that the binding of NA transporter was decreased in locus 
coeruleus of postmortem samples from subjects diagnosed with major 
depression (Klimek et al., 1997). Moreover, it has been reported that the NA 
transporter knockout mice are resistant to the stress-induced depressive-like 
changes in behavior that are seen in wild-type mice (Haenisch et al., 2009). 
 
1.6.1.3. Dopamine and depression  
Increasing evidence and relationship between alterations in DA 
pathways and depression in the mesolimbic pathway has been suggested 
for many years (Nestler et al., 2006). Four main dopaminergic pathways 
were identified within the CNS include, nigrostriatal pathway that extends 
from the substantia nigra to the striatum, the tuberoinfundibular pathway 
which originates from the hypothalamus and projects to the pituitary gland, 
the mesocortical pathway and mesolimbic pathway (from the limbic area) 
which both originate from the ventral tegmental area and projects to the 
cortex (Dailly et al., 2004). DA receptors are located within these pathways 
and they are divided in two subfamilies: the D1-like receptor subtypes (D1 
and D5), which are coupled with the Gs protein activate adenylyl cyclase, 
and the D2-like subfamily (D2, D3, and D4), which are coupled with G proteins 
inhibit adenylate cyclase (Missale et al., 1998). 
 
D1 and D2 dopamine receptors are the most abundant subtypes in the 
CNS. D1 mRNA is localized in the nucleus accumbens, striatum, olfactory 
tubercule, hypothalamus and thalamus and is post-synaptic receptors. 
However, The D5 dopamine receptors distribution is localized to the 
hippocampus and thalamus and they are expressed at lower level than the 
D1 dopamine receptors. The D2 dopamine receptor is located mainly in the 





compacta, the ventral tegmental area and the pituitary gland. D2 dopamine 
receptors are pre- and post-synaptic receptors. D3 dopamine receptors are 
expressed in the limbic area and at a lower level in the striatum. The D3 
dopamine receptors exist as autoreceptors that inhibit neuronal dopamine 
synthesis and post-synaptic receptors. D4 dopamine receptors were found 
with a low expression in the basal ganglia and a higher expression in the 
frontal cortex, amygdala, medulla and hypothalamus (Dailly et al., 2004; 
Jaber et al., 1996).  
 
Increasing evidence from human and animal studies showed a 
possible relationship between dopamine and depression. Indeed, lower 
levels of DA and its metabolites have been documented in the serum and 
CSF of depressed patients (Engstrom et al., 1999). The deficits in 
dopaminergic signalling in the mesolimbic pathway have been suggested to 
cause the anhedonic symptoms often seen in depressed patient (Heinz et 
al., 1994; Nestler et al., 2006). Moreover, in human studies it was reported 
that there was a compensatory up-regulation of D2 receptor density in the 
basal ganglia/ cerebellum in comparison with healthy volunteers (D’haenen 
and Bossuyt, 1994). In addition, it has been reported that there was an up-
regulation of dopamine transporter that cause more re-uptake of dopamine 
into the pre-synaptic neurones in depressed patients (Laasonen-Balk et al., 
1999). In addition, animal studies have shown a link between the D2 receptor 
and depression. For example, Maj et al (1996) have reported an increase in 
the binding activity of the D2-like agonist N-0437 in the limbic areas of the rat 
forebrain including the nucleus accumbens after chronic treatment with 
imipramine, amitriptyline and mianserin treatment. Also, treatment with 
imipramine or Mianserin for 14 days increased the binding of the D2-like 
agonist quinpirole (Maj et al., 1998). Moreover, it was reported that the D2-
like agonists such as pramipexole (Willner et al., 1994) and quinpirole 
(Muscat et al., 1992) have antidepressive-like effects by increasing the 
sucrose consumption in stressed rats. Furthermore, reduction of immobility 





injection of the D2-like antagonist sulpiride in the nucleus accumbens (Cervo 
et al., 1988). 
 
1.6.2. Neurogenic theory of depression and other mechanisms 
 Neurogenesis in adult is the proliferation and functional integration of 
new neurons with existing neurons and occurs in two main areas: the 
subventricular zone lining the lateral ventricles and subgranular zone of the 
hippocampus (Lledo et al., 2006). It was suggested that Adult neurogenesis 
could underlie the chronic adaptive neuronal processes of depression 
pathology and antidepressant action, as opposed to acute monoamine-
mediated mechanisms (Castren et al., 2007).  It has been reported that 
antidepressant treatment, including chronic fluoxetine administration 
(Malberg et al., 2000) and electroconvulsive treatment (Madsen et al., 2000), 
increase hippocampal neurogenesis in animal models.  
 
The stimulation of the hypothalamic-pituitary-adrenal axis is one of the 
possible mechanisms through which the brain react to stress and consists of 
neurons in the paraventricular nucleus of the hypothalamus that release  
corticotropin-releasing hormone which in turn activate the synthesis and 
secretion of adrenocorticotropin from the anterior pituitary. 
Adrenocorticotropin then stimulates the production and release of 
glucocorticoids from the adrenal cortex in the form of corticosterone in 
rodents and cortisol in humans (Berton et al., 2006). It was observed that 
excessive activation of the hypothalamic-pituitary-adrenal axis was in 
approximately half of patient diagnosed with depression and this activation 
was corrected with antidepressant treatment (Arborelius et al., 1999; 
Holsboer, 2001). It was documented that antagonism of glucocorticod 
receptors have been reported to enhance the antidepressive effects of 
fluoxetine (Johnson et al., 2007; Johnson et al., 2009). It has been 
documented that glucocorticoids inhibit adult neurogenesis (Duman et al., 
2006) and this effect can be reversed by the glucocorticoid antagonist 
mifepristone (Oomen et al., 2007), these studies strengthens both the 





1.7. Current antidepressant pharmacotherapies 
A large number of antidepressants are available which target the 
monoamine neurotransmitters 5-HT, NA and DA (Figure 1.8). These 
antidepressants are categorized into: 
 
1.7.1. Tricyclic antidepressants (TCAs) 
TCAs were discovered in the early 1950s and introduced to the clinic 
later in that decade. They were named because of their three rings of atom 
structure. TCAs such as imipramine, amitriptyline, desipramine and 
nortriptyline act by blocking the amine pump and thereby inhibiting re-uptake 
of norepinephrine and serotonin at the presynaptic neuron without blocking 
the reuptake of DA (Klerman and Cole, 1965; Kerr et al., 2001). They were 
considered for a long time as the first line of choice for treatment of 
depression. However, because of their side effects and the development of a 
new generation of agents with an improved safe profile (e.g. SSRIs) they 
were no longer considered first line of therapy (Anderson, 2000; López-
Muñoz and Alamo, 2009). However, they are still occasionally used for 
treatment of patients that have failed to respond to other therapies (Broquet, 
1999). 
 
1.7.2. Monoamine oxidase inhibitors (MAOIs) 
MAOIs act by inhibiting the activity of monoamine oxidase enzyme, 
which prevents the breakdown of monoamine neurotransmitters and 
increases their availability and restore their balance (Remick and Froese, 
1990). Two isoforms of monoamine oxidase are known, MAO-A and MAO-B. 
MAO-A acts upon the following substrates 5HT, DA, NA. MAO-B acts upon 
phenylethylamine, DA and tyramine (Kanazawa, 1994). Phenelzine (Nardil) 
and tranylcypromine are examples of the non-selective irreversible MAOIs 
which are available clinically for the treatment of depression (Pitchot et al., 






 Figure 1.8 . Cellular and molecular mechanisms of antidepressant action (red arrows). 
Antidepressants act by increasing levels of 5HT (blue circles) and/or NA (green circles), 
which is generally achieved via inhibition of the 5HT and/or NA transporters. Serotonin then 
binds to 5-HT2B positive (stimulatory) auto-receptors located in the raphenuclei and to 5-
HT1A, 5-HT4 and 5-HT7 post-synaptic receptors within the hippocampus, as well as to 5-HT1A 
receptors located on hippocampal neural progenitor cells.NA binds to ɑ2 auto-receptors 
located in the locus coeruleus, and to hippocampal  β- adrenergic receptors. Within the 
post-synaptic hippocampal neurons, activation of both serotonergic and noradrenergic 
receptors elicits activation of a cytoplasmic cascade of intracellular messengers.                     
β adrenergic receptors as well as 5-HT4 and 5-HT7receptors are coupled to Gs, so their 
stimulation will sequentially activate cAMP and PKA. On the other hand, 5-HT1A receptors 
are coupled with Gi or Gq, which activatesCa2+-dependant cascades as well as MAPK. All 
of these pathways lead to phosphorylation of CREB in the nucleus of the cell, which induces 
transcription of the BDNF gene into pro-BDNF. In the cytoplasm, pro-BDNF will mature into 
mBDNF which is then trafficked to dendrites and axons. Once released, mBDNF binds to 
TrkB receptors located on neural progenitor cells, which will contribute to the maturation of 
these cells and their differentiation into new hippocampal neurons. The following actions 
have been shown to be essential for the neurogenetic and depression-relevant behavioural 
effects of SSRIs: stimulation of 5HT2B auto-receptors; inhibition of synaptic 5HT uptake; 
stimulation of post-synaptic 5HT1A receptors, and stimulation of MAPK, CREB, and BDNF. 
In parallel, antidepressants inhibit membrance pumps such as MDR-PGP and so increase 
access of Gc to the brain, resulting in a raised intracellular level of glucocorticoids (Gc), 
which bind to glucocorticoid receptors (GR). (These effects have been demonstrated in 
embryonic stem cells. The figure assumes that a similar process occurs in neural 
progenitors. It is unknown whether this also takes place in mature neurons.)Upon binding, 
GR activate PKA, leading to increased neurogenesis (probably via the CREB-BDNF 
pathway). GR also translocate to the nucleus, where the activated receptor can activate or 
repress transcription of specific genes, which inter alia causes a resensitization of GR. 
(Adopted from Willner et al., 2013) 





and drug interaction. They interact with tyramine containing foods, like 
cheese, through the iso-enzyme MAO-B, Thus patients may suffer from what 
is called ‘cheese effect’, which could lead to hypertensive crisis, which can 
be fatal (Finberg and Gillman, 2011; Grady and Stahl, 2012). Thus, they 
have been kept as a last line of treatment, when other antidepressant 
classes have failed. This led to the development of reversible monoamine 
oxidase A inhibitors, e.g. moclobemide (Fitton et al., 1992). The advantage 
of new generation inhibitors is the absence of the ‘cheese effect’ (Remick 
and Froese, 1990; Finberg and Gillman, 2011). 
 
1.7.3. The selective serotonin reuptake inhibitors (SSRIs) and 
Serotonin–noradrenaline reuptake inhibitor (SNRIs) 
SSRIs are the most widely used antidepressants and considered the 
first line of choice for the treatment of depression. Moreover, they are used 
in the treatment of other related disorders such as generalized anxiety 
disorder, obsessive-compulsive behaviour, panic disorders and social 
phobia (Soomro et al., 2008; Capasso et al., 2009). It has been documented 
that the SSRIs act by selectively blocking the 5-HT reuptake transporter 
(Figure 1.3). However, how this leads to therapeutic benefit for the patient is 
not clear. Blockade of the reuptake transporter happens acutely and 5-HT 
levels at the synapse would be expected to increase rapidly. However, the 
therapeutic effects of SSRIs are reported to take 4-6 weeks before patents 
symptoms improve. Interestingly, they don’t have improved efficacy 
compared to the TCAs and MAOIs but they are well tolerated and safer in 
overdose compared to other classes of antidepressants, because they are 
selective to 5-HT reuptake pumps, when compared to TCAs and MAOIs that 
affect other monoamine neurotransmitters and interact with other systems as 
well. SSRIs include Fluvoxamine, fluoxetine, citalopram, paroxetine and 
sertraline (Attard, 2012).  
 
The SNRIs are a class of antidepressants that inhibit the reuptake of 
both 5-HT and NA. They include venlafaxine immediate release and 





Venlafaxine was introduced by Wyeth in 1994 and was the first and most 
commonly used SNRI.  Both SNRIs and SSRIs share many of the same side                          
effects because they are both act similarly to elevate 5-HT levels (Attard, 
2012; Nezafati et al., 2015). While SNRIs are generally safer than TCAs, 
SNRIs may cause an increase in pulse and blood pressure caused by the 
increased level of NA. Thus, they should be used with caution patient at risk 
for heart disease and hypertension (Taylor et al., 2013).  
 
1.7.4. Atypical antidepressants 
Mianserin and Mirtazapine are atypical antidepressants are generally 
receptor-blocking drugs. Mianserin is an example of the atypical 
antidepressants that was released as an antidepressant by Organon in 
Europe in the 1970s (Marshall, 1983). Mianserin is safe drug, which is unlike 
TCAs, because it’s devoid of anticholinergic or cardiovascular side effects. 
However, sleepiness is the most common side effect, due to its high affinity 
for the histaminergic receptors (Shami et al., 1983; Marshall, 1983). 
Mianserin antidepressant action was suggested because its ability to 
increases 5-HT and NA neurotransmission by acting as an antagonist mainly 
at 5-HT2 and α2 adrenoceptor (Shami et al., 1983; Itoh et al., 1990).  
 
1.7.5. Newer antidepressants  
Within the past 5 years, two new antidepressant medications have 
become approved by the Food and Drug Administration for the treatment of 
major depression and became available in the united stat of America: 
vilazodone in January 2011and vortioxetine in September 2013 (Deardorff 
and Grossberg, 2014). It has been reported that the Vilazodone is a SSRI 
and a partial agonist at the 5-HT1A receptor. Also, tt has been shown that 
vortioxetine displays reuptake blockade of the serotonin transporter, agonist 
activity at the 5-HT1A receptor, partial agonist activity at the 5-HT1B receptor 
and antagonism at the 5-HT1D, 5-HT7, and 5-HT3 receptors. Even the new 
antidepressant are still targeting monoamines and it has not been 





its binding at various 5-HT receptors (Deardorff and Grossberg, 2014; Al-
Sukhni et al., 2015). 
 
 1.8. Limitations of the current antidepressant 
The current antidepressant are far from ideal, with a delay in their 
onset of action (4-6 weeks) (Claghorn et al., 1996; Taylor et al., 2006; Attard, 
2012), almost half of depressed patients don’t respond adequately (Fava 
and Davidson, 1996) and with significant side effects that may impair the 
patient’s compliance and safety, which include nausea, headache, increased 
appetite and weight gain, loss of sexual desire and sexual dysfunction, 
agitation, irritability, anxiety, in some cases they increase the suicide thought 
and attempt (Khawam et al., 2006; Attard, 2012). In addition, it has been 
reported that patients who suffer from comorbid depression and anxiety 
have poor response to classic antidepressant treatments (Fava et al., 2008). 
  
1.9. Evidence of involvement of kappa opioid receptor in depression 
and anxiety 
It has been reported that sustained stressful events can increase the 
risk of developing psychiatric disorders such as depression and anxiety 
(Gold and Chrousos, 2002; Hunter and McEwen, 2013). Dynorphin is 
released during stress exposure (Bruchas et al., 2009; Shirayama et al., 
2004; McLaughlin et al., 2003). It was documented that dynorphin released 
during exposure to chronic stress causes a prodepressive-like behaviour in 
rodents, including increased immobility in the forced-swim test (FST) 
(Shirayama et al., 2004). In addition, dynorphin reduced drug reward in 
reward models and this behavioral can be interpreted as a depressive-like 
effect, anhedonia (Bruchas et al., 2010; Todtenkopf et al., 2004), which is 
one of the main characteristics of depression.  
 
 
Pfeiffer et al (1986) reported that activation of к-receptor causes 
dysphoria in man. Moreover, it was reported in rats that microinjections of 





the VTA, NAc, medial prefrontal cortex (mPFC) and lateral HL produced 
place aversions (Bals-Kubik et al., 1993) (Table 1.4). Also, it has been 
reported by Carlezon et al (2006) that salvinorin A, a highly potent and 
selective к-receptor agonist, dependently increased immobility time in the 
FST and did not affect locomotion in open field which may gave an indication 
that the salvinorin A is prodepressive-like drug in rats. Thus, activation of к-
receptors is dysphoric in humans and prodepressive in preclinical studies. 
 
  In addition, к-receptor gene deletion or prodynorphin gene disruption 
has the ability to block stress induced prodepressive-like effects (McLaughlin 
et al., 2003). Indeed, Wittmann et al (2009) have reported that mice lacking 
prodynorphin showed an increase in the exploration ability in elevated plus 
maze (EPM) consistent with an anxiolytic-like response. Also, it has been 
demonstrated that the high affinity к-receptor antagonists, such as 
norbinaltorphimine (norBNI), effectively reduced stress induced 
prodepressive-like effects and produced a significant antidepressant-like 
effect in the FST (Mague et al., 2003; Filho et al., 2013; McLaughlin et al., 
2003) (Table 1.5  and 1.6 ). Moreover, Knoll et al (2007) reported that к-
receptor antagonist NorBNI and (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4- (3-
hydroxyphenyl)-3,4- dimethyl-1- piperidinyl]-methyl}-2- ethylpropyl)-1,2,3,4 
tetrahydro-3-isoquino-linecarboxamide (JDTic) dose-dependently raised 
open arm exploration in the elevated plus maze (EPM) without altering open 
field behaviour. They suggested that к-receptor antagonist may be effective 
in the treatment of comorbid depressive and anxiety illness. In addition, 
Wittmann et al (2009) reported that the к-receptor antagonist, 5’-
guanidinonaltrindole trifluoroacetic acid (GNTI) and norBNI, showed a 
significant anxiolytic-like effect in mice. Moreover, Casal -Dominguez et al 
(2013) showed that novel 5’-AMN and 5’-MABN, which are mixed к and μ-
receptor antagonists, have significant antidepressant and anxiolytic-like 










Table 1.4. К-receptor agonists that have shown prodepressant-like behaviours in animal 
models of depression. 
 
Drug Test Result Species Reference 
U50,488 FST 
Repeated forced-swim 
stress (FSS) increased  
immobility in wild-type 
C57Bl/6 mice, but not in 
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N-Methylacetamide ICSS 
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Table 1.5.  Sum
m
ary of the results of opioid receptors affinities (K
i ) and antagonist potencies (K











Table 1.6. К-receptor antagonists that have shown attenuation of stress, antidepressant- 
and anxiolytic-like behaviours in animal models. 
 
Time point 
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2- (3,4-dichlorophenyl)- N-methyl-N- [(1S)- 1-(3-isothiocyanatophenyl)- 2-(1-pyrrolidinyl) 
ethyl]acetamide hydrochloride (DIPPA), zyklophin, LY2444296, 5’-(2-aminomethyl) 
naltrindole (5’-AMN) and N-((Naltrindol-5-yl) methyl) pentanimidamide (5’-MABN), norBNI, 
GNTI, JDTic, and Arodyn are к-receptor antagonists; PDyn –/–, prodynorphin knockout 
mice; KOR –/–, kappa receptor knockout mice; HIP, intra-hippocampus microinfusions; NAc, 
intra-nucleus accumbens microinfusions; ICV, intracerebroventricular; IC, intracisternal; IG, 
intragastric; IP, intraperitoneal; CD, Sprague Dawley; CPP, conditioned place preference; 
NOR, novel object recognition. Notes: 1 Behavioral effects in the forced swim test and social 
defeat stress paradigms are those observed during the second day of testing. Unless noted, 
in the forced swim test studies there was either no effect during the first swim session or 
behavior during this session was not examined; 2 Carey et al., 2009 also found decreased 
immobility during the first swim session; 3 Filliol et al., 2000 used only one swim session; 4 





It has been reported that к-receptor agonists increases corticosterone 
level in rats (Laorden et al., 2000) and cortisol in humans (Ur et al., 1997) 
which are known as a stress hormones. On the other hand, norBNI (5 
mg/kg) was effective in blocking U50,488H (15 mg/kg) induced an increase 
in the corticosterone increase in rat (Alcaraz et al., 1993; Victoria et al., 
1994). There is evidence suggests that activation of the к-receptors, after 
stress, causes a reduction in dopamine release in different brain 
region(Spanagel et al., 1992; Carlezon et al., 2006 ; Ebner et al., 2010; 
Belujon and Grace, 2015). Indeed, it has been reported that к-receptor 
activation in the NAc region by dynorphin and к-receptor agonists decreases 
dopamine release. In contrast, it has been shown that к-receptor antagonist 
causes an increase in DA release (Spanagel et al., 1992; Maisonneuve et 
al., 1994). Moreover, Tejeda et al (2013) have showed that administration of 
the selective к-receptor agonist U69, 593 into mPFC causes a reduction in 
DA release. However, this effect was antagonized by norBNI. Furthermore, 
к-receptor has been shown to modulate 5-HT systems by reducing dorsal 
raphe and nucleus accumbens 5-HT efflux (Bruchas and Chavkin, 2010). 
These data could explain how к-receptor antagonists work as possible 
antidepressants and support the claim that к-receptors antagonist could play 
a critical role in regulating mood disorders.  
 
1.10. Limitations of the existing к-receptors antagonist  
К-receptor antagonists seem to play an important role in the 
regulation of mood states. However, all the existing high affinity selective к-
receptor antagonists (JDTic, 5’-acetamidinoethylnaltrindole (ANTI), GNTI 
and norBNI) have two distinct pharmacological properties; slow onset of 
antagonist activity and very long lasting effects in vivo (up to 56 days 
following a single dose) (Béguin  and Cohen, 2009), which limits and 
complicates experimental design for in vivo behavioural testing, 
interpretation and clinical trials if the blockade of к-receptors may not be 
easily reversed. For example, one injection of norBNI has peak effects 
starting about 24 h post-administration, maintained heights levels for 7–10 





Moreover, it has been reported by Horan et al (1992) that norBNI at high 
doses has duration of action that stays for several months in mice. 
Furthermore, GNTI and JDTic have similar long-lasting effects and produce 
antagonism for at least 10–14 days (Negus et al., 2002; Carroll et al., 2004). 
These findings are surprising because these antagonists do not covalently 
bind to к-receptors (Smith et al., 1990) 
 
It is unclear how the к-receptor antagonists produce their long-lasting 
effects in vivo. However, it has been suggested that they may become 
physically trapped in the lipid membrane of the nervous system and may not 
clear easily. Another explanation is that they could be bio-transformed in 
vivo to long-lasting metabolites that covalently bind to the receptor. 
Moreover, these к-receptor antagonists may acutely uncouple the к-receptor 
signalling complex, which prevent the agonists from activating the receptor 
(Bruchas et al., 2007). Therefore, there is a need to find a drug or 
combination that is short acting к-receptor antagonist to understand the к-
receptor antagonist activity.  
 
1.11. Recent short-acting к-receptors antagonists 
In the past few years, there were some considerable advances in the 
designing and production of short-acting к-receptors antagonists. Aldrich et 
al., (2009) were able to show that the systemic administration of zyklophin (3 
mg/kg s.c.) is active with much shorter of duration (less than 12 h) than 
norBNI in antagonizing U50,488-induced antinociception, in the warm water 
tail withdrawal assay, and in inhibiting stress-induced reinstatement of 
cocaine-seeking behavior in mice. Moreover, Melief et al (2011) examined 
various analogues of JDTic and diaryl ethers they used C57BL/6 wild type 
mice to determine the durations of antagonist action of novel к-receptor 
antagonist compared with conventional competitive antagonists. They 
showed that blockade of U50,488-induced antinociception, after systemic 
administration (i.p.) of RTI-5989-212 (10 mg/kg), RTI-5989-240 (10 mg/kg), 





(10 mg/kg), FP3FBZ (10 mg/kg) and naloxone (10 mg/kg) lasted less than 1 
d in the warm water tail withdrawal test. 
 
1.12. Hypothesis and aims of the study 
The hypothesis of this thesis is that the combination of 
buprenorphine/naltrexone and the novel compound BU10119 (Figure 1.4), 
which is buprenorphine analogue, could be a functional short-acting к-
receptor antagonist with antidepressant and anxiolytic activity.  
 
It is documented that buprenorphine is a semi-synthetic opioid with 
unique complex pharmacological activities; acting as a partial μ-receptor 
agonist and a к-receptor antagonist (Mello and Mendelson, 1985), NOP 
receptor agonist (Lutfy and Cowan, 2004) and δ receptor antagonist 
(Kajiwara et al., 1986). Clinically buprenorphine is used as a potent 
analgesic and as an alternative to methadone in the treatment of opioid 
addiction (West et al., 2000). Also, it was found to be effective in treatment 
of refractory depression (Bodkin et al., 1995). Buprenorphine has two 
properties that distinguish it from other opioids. It has a bell shaped 
analgesic dose–response curve (Lutfy et al., 2003) and a ceiling effect for 
respiratory depression (Dahan et al., 2006). Therefore, buprenorphine is an 
attractive compound for use in clinical trials because of low potential toxicity 
and overdose (Kakko et al., 2007; Hayes et al., 2008). However, the 
buprenorphine opioid agonist effects could pose a risk for abuse (Casati et 
al., 2012). A formulation combining buprenorphine with naltrexone, opiate 
antagonist, could discourage, reduce such abuse and may enhance к-
receptor antagonist of buprenorphine and such combination may work as a 
functional short acting kappa antagonist which could be helpful in treatment 
of depression and anxiety. Indeed, Cordery et al (2104) reported that a 
combination of 0.3 mg/kg buprenorphine and 1.0 mg/kg naltrexone, in adult 
Sprague Dawley rat, was neither rewarding nor aversive. Moreover, Gerra et 
al (2006) reported that buprenorphine and naltrexone combination may 
significantly reduce dysphoria, mood symptoms and craving of heroin in 





pharmacology resembling buprenorphine/naltrexone combination (Ridzwan, 
2012) and it is predicted that it may be helpful in treatment of depression and 
anxiety. 
 
All experiments were conducted in adult male CD1 mice. The first aim 
of this study was to establish appropriate dose of buprenorphine/naltrexone 
combination that produce the desired pharmacology and to test the duration 
of the к-receptor antagonist effect in the warm water tail withdrawal test 
(chapter 3). Alongside this, the in vivo opioid pharmacology of the novel 
compound BU10119 was investigated. An important aim was to establish 
that the combination of buprenorphine/naltrexone and BU10119 were not 
rewarding nor aversive if these compounds are to be developed in the clinic 
(chapter 4). The compounds were also assessed for their locomotion effects 
which is an important confound of behavioural experiments. Subsequently 
the antidepressant and anxiolytic-like potential of buprenorphine/naltrexone 
and BU10119 was established in pharmacologically validated behavioural 
tasks (chapter 5). The final aim was to test the ability of 
buprenorphine/naltrexone and BU10119 to block stress-induced changes in 
behaviour, corticosterone and k-receptor, prodynorphin and CRHR1 gene 









Figure 1.9. Chemical structures of buprenorphine and BU1119 (Adopted from   
































2. General material and methods 
2.1. Animals 
Adult (8–10 weeks, 27–38 g) male CD-1 mice, from University of Bath 
and Charles River, were housed in groups of 4 in cages provided with a 
shelf, wood shavings and nesting material with ad libitum access to food and 
water and maintained on a 12:12 hours light–dark cycle (lights on 7:00 am, 
lights off 7:00 pm). All experiments were performed in accordance with the 
UK Home Office guidelines and the Animals (Scientific Procedures) Act 
1986.  For all behavioural tasks animals were habituated to the behavioural 
room for one hour prior to the experiment beginning. Separate groups of 
animals, n=5-18 per treatment group, were used for studies of behaviour 
task. All behavioural experiments were performed between 9:00-16:00 h and 
mice were acclimatized to the behavioural room for 1h prior to starting. 
 
2.2 Drugs 
Diazepam and U50,488 were purchased from Sigma (Dorset, UK). 
Fluoxetine and naltrexone were supplied by Abcam Biochemicals 
(Cambridge, UK). Clocinnamox (CCAM) and norBNI were obtained from 
Tocris Bioscience (Bristol, UK). Buprenorphine was purchased from 
MacFarlan Smith (Edinburgh, UK) and BU10119 (Table 2.1) (µ agonist and 
k-antagonist) was synthesized in the Department of Pharmacy and 
Pharmacology, University of Bath (kindly provided by Prof S. Husbands). For 
in vivo experiments, all drugs were dissolved in 0.9% w/v saline (Hameln 
Pharmaceuticals, Gloucester, UK) and injected via the intraperitoneal route 
at a volume of 10 mL/kg, except for CCAM which was injected at a volume of 
20 mL/kg. All drugs were administered 1 hour before testing (naltrexone 10 
min before buprenorphine). However, The irreversible µ-antagonist CCAM (3 











Table 2.1. summary of the к-receptors selectivity on µ-к-δ and ORL-1 receptors (IUPHAR 
receptor database; accessed 06/12/2016) 
 












Naltrexone Antagonist Antagonist Antagonist   
U50,488  Agonist    
BU10119 Antagonist Antagonist Antagonist partial agonist  
CCAM Antagonist     

























                                                    Chapter 3 
Establishing the k-receptor antagonist properties of 


















 3.1. Introduction 
 Endogenous opioid neuropeptides and non-opioid analgesics are 
widely used in pain treatment. Opioids, such as morphine, acting through μ- 
opioid receptors, remain the first line for the treatment of severe pain 
(Gutstein and Akil, 2001; McNally and Akil, 2002). Morphine is effective in 
treating acute pain but there is a lack of its analgesic efficacy in neuropathic 
pain in many clinical studies (Arner and Meyerson, 1988; Cherny et al., 
1994). However, opioids may cause serious side effects such as respiratory 
depression and dependence which limits their use (Bohn and Raehal, 2006). 
Thus, numerous studies have been made to improve opioid analgesic 
properties and to reduce their adverse consequences.  
 
There is a potential role for the dynorphin-к-receptors system in 
analgesia of neuropathic pain (Kieffer and Gaveriaux-Ruff, 2002). 
Dynorphins and к-receptors are distributed widely in the brain, spinal cord 
and periphery (Mansour et al., 1995). Centrally к-receptors are involved in 
thermal nociception through spinal. Indeed, к-receptors are primarily located 
in the cell bodies of small myelinated and unmyelinated nociceptive afferents 
in the dorsal root ganglion and spinal cord (Peckys and Landwehrmeyer, 
1999). Peripherally activation of к- receptors produce antinociceptive effects 
in visceral pain (Iadarola et al., 1988: Horan and Porreca, 1993; Millan et al., 
1988; Vanderah, 2010). Enadoline, a selective k-receptor agonist, produced 
a good analgesic efficacy in animal models for mechanical and chemical 
noxious stimuli (Hunter et al., 1990). Moreover, in a postsurgical pain clinical 
study, enadoline at a dose of 25 mg significantly produced analgesic effect 
compared with placebo and the analgesia obtained was similar to that from 
10 mg of morphine injected intramuscularly (Pande et al., 1996). However, 
when enadoline crossed the blood-brain barrier dysphoria became a dose-
limiting side effect for these patients and the study was stopped. It has been 
reported that ADL10-0101, a peripherally acting selective k-receptor agonist, 
was effective in treating chronic visceral pain (Eisenach et al., 2003). Thus 





Analgesic effects of opioid compounds can also be identified in 
animals. Painful stimuli in animals can be induced by inflammation or by 
stimulation of nociceptors by various stimuli including electrical, chemical, 
mechanical and thermal (Le Bars et al., 2001).  In this thesis, the warm water 
tail withdrawal test has been used. There are two variants of the tail- 
withdrawal test (also called tail-flick test). The first one is the tail-flick test 
using radiant heat (a light beam) to a small surface of the tail. The second 
type is immersing the tail in the water at a certain temperature, either warm 
or cold (Le Bars et al., 2001). At a physical level, these two tests are 
different: the cutaneous temperature varies with the square root of time in 
the case of radiant heat and more rapidly in the immersion case. Moreover, 
stimulated surface areas can be very different. Tail immersion in warm water 
causes an immediate movement of the tail and sometimes the recoiling of 
the whole body. Both tests cause the tail to withdraw from noxious stimuli 
and this reflex is monitored (usually called tail-flick latency). An increase in 
the tail-flick latency is interpreted as an analgesic action. These methods are 
considered simple, easy to apply, sensitive to known analgesics and show 
little variability in the recording of the reaction time under a controlled 
condition (Le Bars et al., 2001). These tests have been widely used to 
characterise opioid ligands. It has been reported that lower temperatures in 
tail immersion test might be used to investigate the effects of minor 
analgesics and the test is useful to differentiate central opioid like analgesics 
from peripheral analgesics (Luttinger, 1985). Also, these tests have been 
widely used to characterise opioid ligands. It has been suggested that the 
tail-flick reflexes are a spinal reflex (Bonnycastle et al., 1953; Sinclair et al., 
1988). Also, these reflexes can be controlled by supraspinal structures 
(Mitchell and Hellon, 1977; Grossman et al., 1982; Carstens and Wilson, 
1993; Douglas and Carstens, 1997).  
 
It has been reported that opioid agonists exert their analgesic action 
in the mouse and rat tail withdrawal test by a dual mechanism: by direct 
inhibition of nociceptive neurones in the spinal cord and by acting in the 





Moreover, it has been reported that a synergistic interaction between these 
two sites produces the antinociceptive effect in the warm water tail 




























3.2. Chapter aims 
In this chapter, the warm water tail withdrawal assay has been used 
to establish the appropriate doses of buprenorphine and naltrexone required 
to achieve a functional к-receptor antagonist in vivo. Additionally, for the 
novel compound BU10119 it was essential to confirm its opioid receptor 
pharmacology profile in vivo. This assay was also used to establish the 
duration of the к-receptor antagonist effects. In addition, the potential 







3.3. Method  
3.3.1. Tail withdrawal test 
Each mouse was scruffed and held in a vertical position and the distal 
third of the tail (the last 2 cm of the end of the tail was then placed into the 
beaker of warm water) lowered into a 1-litre beaker of warm water 
maintained at a constant temperature at 52°C on a stirring hotplate. The 
latency for the tail withdrawal was recorded using a stopwatch. A 15-second 
cut-off was imposed to avoid tissue damage. Antinociception was calculated 
as percentage maximum possible effect (%MPE) = (test latency–control 
latency)/(15 s–control latency) ×100.  
 
To counteract any possible confounding effects of injection induced 
stress, in all experiments, animals received 0.9% w/v saline injections so that 
the total number of injections an individual mouse received, whether in 
control or drug-treated groups was equivalent (Almatroudi et al., 2015; 
Casal-Dominguez et al., 2013).  
 
To determine the time course of the antinociceptive effects of 
buprenorphine (0.3, 1 and 3 mg/kg) (Figure 3.1), baseline latencies were 
determined 30 minutes before injecting these drugs at time zero. Also, the к-
agonist U50,488 (10 mg/kg) antinociceptive effects were investigated and 
baseline latencies were determined 30 minutes before injecting at zero time 
(Figure 3.6). To determine effective µ and к-antagonist doses (Figure 3.3 (a–
b)), naltrexone (0.3, 1 and 3 mg/kg) was injected 10 minutes prior to 
buprenorphine or U50,488 administration. Tail withdrawal responses were 
measured at 30, 60, 120, 240 minutes and 24 hours post-injection. 
 
To examine the duration of the к-receptor antagonist actions (Figure 
3.8 (e)), tail withdrawal latency was measured at 1, 8, 24 and 48 hours post-
administration of the antagonist, naltrexone (1 mg/kg) alone, or in 
combination with buprenorphine (1 mg/kg). In these experiments, naltrexone 





was injected at time zero. U50,488 or saline was injected 30 minutes before 
taking a measurement to assess the extent of the к-receptor blockade. In 
experiments with the irreversible, selective µ-receptor antagonist CCAM 
(Broadbear et al., 2000), CCAM was administered 24 hours before treatment 
with buprenorphine/naltrexone (1 mg/kg) combination.  
 
BU10119 (0.3,1 and 3 mg/kg) and buprenorphine (1 mg/kg) were 
tested for antinociceptive effects at 60, 120, 240 minutes post-injection, 
baseline latencies were measured 30 minutes before injecting the drug 
(Figure 3.11A). To determine the duration of the к-receptor antagonist 
actions of BU10119 (0.3, 1 and 3 mg/kg) (Figure 3.11B), tail withdrawal 
latency was measured at 1, 8, 24 and 48 hours post-administration. 
BU10119 (1 mg/kg) and norBNI (1 mg/kg) or saline were injected at time 
zero. Baseline latencies were measured immediately before injecting 
U50,488 30 minutes before taking the measurement to assess the extent of 
the к-receptor blockade of к-receptor antagonists. 
 
The µ-receptor antagonist activity of BU10119 (0.3, 1 and 3 mg/kg) 
and the irreversible, selective µ-receptor antagonist CCAM (3 mg/kg), was 
tested against buprenorphine (1 mg/kg) and morphine (10 mg/kg). CCAM 
was administered 24 h before treatment with buprenorphine (1 mg/kg) or 
morphine (10 mg/kg) (Broadbear et al., 2000). Baseline latencies were 
measured immediately before injecting BU10119 or saline injection. 
Buprenorphine and morphine were injected 30 minutes after BU10119 
injection (Figure 3.11C). Also, tail withdrawal latency was measured at 60 
minutes after Buprenorphine and morphine injection ( Figure 3.11D).  
 
3.3.2. Locomotor activity test 
Locomotor activity was assessed in an open-field test. Testing was 
performed to establish the potential sedative effects of buprenorphine (0.3, 1 
and 3 mg/kg) alone or in combination with naltrexone (0.3 mg, 1 mg, and 3 
mg/kg). Naltrexone was injected 10 minutes before buprenorphine. One hour 





10 minutes under low light conditions (30 lux). Total activity was recorded by 
photobeam breaks using Motor Monitor software (Campden Instruments) 
(Almatroudi et al., 2015; Casal-Dominguez et al., 2013). 
 
3.4. Statistical analysis 
Locomotor data were analysed using one-way ANOVA and tail flick 
data were analysed using two-way repeated measures mixed model 
analysis (Clark et al., 2012). Then, Unadjusted Least Significant Difference 
(ULSD) were used as Post hoc test (InVivoStat 2.3). Only planned pairwise 
tests were carried out and p values adjusted for multiple comparisons with 
Benjamin–Hochberg correction. Values are reported as mean ± standard 
error of the mean (SEM) for each treatment group, n = 5 to 6 per treatment 









3.5.1. Establishing that a combination dose of 
buprenorphine/naltrexone and single dose of BU10119 is a functional 
kappa opioid receptor antagonist 
Doses of buprenorphine (0.3-3 mg/kg) that would provide robust 
antinociception via activation of µ-opioid receptors in the warm water tail 
withdrawal assay were established (Figure 3.1). Doses of naltrexone, a 
relatively nonselective opioid receptor antagonist (Giordano et al., 1990) that 
would block the partial µ-receptor agonist activity of buprenorphine using the 
warm water tail withdrawal test were established (Figure 3.3A, B, n=5 per 
group). In buprenorphine dose response curve, two-way repeated measures 
mixed model analysis showed a significant interaction of Treatment * Time 
(F (9,60) = 19.90, p< 0.001). Buprenorphine (1 and 3 mg/kg) produced a 
significant antinociceptive effect that peaked at 60 min post-administration 
(p<0.001, compared to saline injected controls, figure 3.1). However, only 
buprenorphine at the dose of 0.3 and 1 mg/kg returned to baseline after 240 
min. Furthermore, in this dose range, one-way ANOVA revealed no 
significant main effects of doses of treatment on locomotion (F(4, 25) = 3.66, 
p>0.05) (Figure 3.2).   
 
In the second experiment, two-way repeated measures mixed model 
analysis revealed a significant interaction of Treatment * Time (F (24,120) = 
2.46, p<0.001). Buprenorphine (1mg/kg) produced a significant 
antinociceptive effect that peaked at 60 min post-administration (p<0.001, 
compared to saline injected controls, figure 3.3 B) returning to baseline after 
240 min (Figure 3.3 A). Pre-treatment with naltrexone 1mg and 3mg/kg, but 
not 0.3mg/kg, significantly blocked the buprenorphine-induced 
antinociception at 30 min (p< 0.01), 60 min (p< 0.001) and 120 min (p< 
0.001). Moreover, naltrexone 1mg/kg alone or in combination at doses of 
0.3, 1 and 3 mg/kg were without a significant effect on locomotor activity 
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Figure 3.1. Antinociceptive effects of buprenorphine (Bup) (0.3,1 and 3 mg/kg) in the mouse 
tail withdrawal assay. Two-way repeated measures mixed model analysis was used. 
Buprenorphine was injected at zero time immediately after baseline measurement.   All 
values are mean  ±SEM, n= 6 per group. **p< 0.01 as compared between Bup 3 mg/kg and 
all treatment groups ; ***p< 0. as compared between Bup (1 and 3 mg/kg) and saline and 




































Figure 3.2. Locomotor activity in the open field in mice treated with buprenorphine (Bup) 
(0.3, 1 and 3mg/kg) and naltrexone (NTX) (3mg/kg). One-way ANOVA was used. All values 















































Figure 3.3. Antinociceptive effects of buprenorphine (Bup 1mg/kg) were blocked by 
naltrexone (NTX) in the mouse tail withdrawal assay. (A) The time course of the experiment. 
(B) The antagonist effects of naltrexone (NTX) at 60 min post-administration of agonist. 
Naltrexone (NTX) dose-dependently blocked buprenorphine-induced antinociception (**p< 
0.01; ***p< 0.001 compared to saline control. Two-way repeated measures mixed model 



























Figure 3.4. Locomotor activity in the open field in mice treated with buprenorphine (Bup 1 
mg/kg) combination with naltrexone (NTX 0.3, 1 and 3mg/kg). All values are mean ± SEM, 
n=5 per group. 
 
 
To determine the к-antagonist properties of naltrexone, the к- receptor 
agonist U50,488 (5 and 10mg/kg) was used to establish its effective 
antinociceptive dose (Figure 3.5, n=5 per group). Two-way repeated 
measures mixed model analysis showed a significant interaction of 
Treatment * Time (F (8,40) = 5.63, p<0.001). Only U50,488 (10 mg/kg) 
produced a significant antinociceptive effect that remained effective for 240 
min (all p’s <0.001, compared to saline). In the next experiment, U50,488 (10 
mg/kg) (Figure 3.6, n=5 per group ) was used and there was a significant 
Treatment * Time interaction (F (24,114) =2.12, p< 0.004). U50,488 produced 
a significant antinociceptive effect 30 min post-administration (p<0.01) that 
persisted for more than 240 min (p<0.05 compared to saline controls). 
Pretreatment with naltrexone 1mg and 3mg/kg, but not 0.3 mg/kg, 
significantly blocked the U50, 488-induced antinociception (all p’s <0.01 
compared to U50,488 alone). However, only naltrexone at a dose of 10 
mg/kg was able to block the significant sedative effect of U50, 488 (p<0.001) 






























Figure 3.5. Antinociceptive effects of U50,488 (U50, 5 and 10 mg/kg) in the mouse tail-
withdrawal assay. Two-way repeated measures mixed model analysis was used. ***p< 
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Figure 3.6. Antinociceptive effects of U50,488 (U50, 10 mg/kg) were blocked by naltrexone 
(NTX) in the mouse tail withdrawal assay. (A) The time course of the experiment. (B) The 
antagonist effects of naltrexone (NTX) at 60 min post-administration of agonist.  Naltrexone 
(NTX) dose-dependently blocked U50,488-induced antinociception (*p< 0.05;**p< 0.01; 
***p< 0.001 ) as U50 compared to saline control. Two-way repeated measures mixed model 































Figure 3.7. Locomotor activity in the open field in mice treated with U50,488 ( U50 10 
mg/kg) alone and in  combination with naltrexone (NTX 0.3, 1,3 and 10 mg/kg). *p< 
0.05,**p< 0.01; ***p< 0.001 as compared to saline control. ###p< 0.001  as compared to 
U50. All values are mean ± SEM, n= 5 per group.  
 
 
To determine whether naltrexone alone or buprenorphine/naltrexone 
in combination have long acting к-antagonist effects, their ability to block 
U50,488-induced antinociception was tested at 1, 8, 24 and 48 hours post-
administration of antagonist (Figure 3.8), n=5 per group). Two-way repeated 
measures mixed model analysis revealed that there was a significant 
interaction of Treatment*Time (F(12,64)=12.25, p<0.001). At 1 hour, post-
administration U50,488 produced an obvious antinociceptive effect that was 
significantly reduced by naltrexone alone, or in combination with 
buprenorphine (all p’s <0.001, compared to U50,488 alone). The к-receptor 
blockade by naltrexone and by the combination buprenorphine/naltrexone 
was not evident at 24 and 48 hours post-administration of antagonist (Figure 
3.8). At 8 hours post-administration, there was a reduction in the ability of 
naltrexone to block U50,488 induced antinociception, compared to 1 hour. 
Surprisingly, at 8 hours post administration of buprenorphine/naltrexone, 
U50,488 produced a clear potentiation in nociceptive effect (p<0.05 





mediated through the µ-opioid receptor, the irreversible µ-antagonist CCAM 
(3 mg/kg) was used. The ability of CCAM to block buprenorphine induced 
nociception was first confirmed. CCAM (3 mg/kg) was administered 24 hours 
before buprenorphine (1 mg/kg) and tail-withdrawal latency was measured at 
1, 8, 24 and 48 hours post-administration of CCAM (Figure 3.9). CCAM (3 
mg/kg) significantly reduced the antinociceptive effects of buprenorphine 1 
mg/kg at all time intervals but not at 48 hours. In the second experiment, 
CCAM was injected 24 hours before the experiment began to investigate the 
potentiation of U50,488 effects at 8 hours. CCAM blocked the apparent 
potentiation (p<0.001), suggesting that this potentiation results from µ-
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Figure 3.8. Duration of к-antagonist effects of naltrexone (NTX) alone or naltrexone/ 
buprenorphine combination. Significant blockade of U50,488 induced antinociception is 
evident at 1 h post-administration and reversed by 24 h. At 8h post-administration, the 
combination of buprenorphine/naltrexone, produced a significant potentiation of U50-488-
induced antinociception (***p<0.001 compared to all other treatment groups, ^^^p<0.001 
compared to all other treatment groups; ### p<0.001 for all treatment groups compared to 
NTX/Bup/saline controls; xx p<0.01 compared to NTX/Bup/saline controls and compared to 
NTX/Saline/U50 group. Two-way repeated measures mixed model analysis was used All 























Figure 3.9. Antinociceptive effects of buprenorphine (1mg/kg) was blocked CCAM (3 mg/kg) 
in the mouse tail withdrawal assay. CCAM was given 24 hr before Bup. Bup was 
administered 1 hr before starting the measurement.  Two-way repeated measures mixed 
model analysis was used. All values are mean ± SEM, n= 5 per group. *p< 0.05, **p< 0.01 







U50 10mg/kg Bup 1mg/kg+NTX 1mg/kg+U50











Figure 3.10. The irreversible μ-antagonist CCAM (3 mg/kg) administered 24 h before testing 
blocked the buprenorphine/ naltrexone (Bup/NTX) mediated potentiation of U50,488-
induced antinociception at 8h post-administration (*p< 0.05 compared to U50 alone, 
@@@p<0.001 as compared to Bup/NTX combination + U50 group). Two-way repeated 
measures mixed model analysis was used. All values are mean ± SEM, n= 5 per group. 
 
 


















BU10119 at a dose of 0.3, 1 and 3 mg/kg showed no antinociceptive 
effects in the warm water tail withdrawal assay (figure 3.11A).  Two-way 
repeated measures mixed model analysis revealed a significant interaction 
of Treatment*Time (F (12,60) = 19.35, p<0.001). Only buprenorphine (1mg/kg) 
produced a significant antinociceptive effect that peaked at 60 min post-
administration (p<0.001, compared to all injected groups) and returned to 
baseline after 240 min. BU10119 (1 and 3 mg/kg) and the irreversible µ-
antagonist CCAM (3 mg/kg) (Figure 11C) were significantly able to block the 
antinociceptive effect of buprenorphine (1 mg/kg) and morphine (10 mg/kg) 
60 min post-administration (F (7,28) = 18.68, p<0.001).  
 
To determine the к-antagonist properties of BU10119 (0.3, 1 and 
3mg/kg) and its ability to block U50,488 induced antinociception, latency 
measurements were taken at 1, 8, 24 and 48 hours post-administration 
(Figure 3.11B, n=5 per group). Two-way repeated measures mixed model 
analysis showed that there was a significant interaction of Treatment*Time 
(F (28,140)= 5.46, p<0.001). U50,488 produced a pronounced antinociceptive 
effect that was significantly blocked by BU10119 (1 and 3 mg/kg) at 1, 8 and 
24 h post-administration (p <0.001). Moreover, norBNI (1 mg/kg) was able to 
block U50,488 analgesic activity at all-time intervals (all p’s <0.001, 
compared to U50,488). Moreover, BU10119 at all doses was without a 
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Figure 3.11. Antinociceptive effects of buprenorphine (Bup, 1mg/kg) and U50,488 (U50, 10 
mg/kg) are blocked by BU10119  in the mouse tail withdrawal assay. The time course of the 
experiments is shown (A,B).  Locomotor activity in the open field in mice treated with 
BU10119 (0.3, 1 and 3mg/kg) (D). (A) Only buprenorphine (1 mg/kg) was able to increase 
latency time in the mouse tail withdrawal assay.(***p< 0.001 as compared between Bup (1 
mg/kg) and all groups). (B) Antinociceptive effects of U50,488 (10 mg/kg) was blocked by 
BU10119 (1 and 3 mg/kg) and norBNI (1 mg/kg). (***p< 0.001 as compared to BU10119 (1 
and 3 mg/kg) and norBNI (1mg/kg).  ###p<0.001 as compared between all group and 
norBNI (1mg/kg)). (C) BU10119 (1 mg/kg) blocked buprenorphine and morphine-induced 
antinociception ( ***p< 0.001 compared to BUP; $$$p< 0.001 to morphine).  The irreversible 
μ-antagonist CCAM (3 mg/kg) administered 24 h before testing blocked buprenorphine and 
morphine-induced antinociception at 60 min post-administration (***p< 0.001 compared to 
BUP; $$$p< 0.001 to morphine). Two-way repeated measures mixed model analysis was 








3.6. Discussion:  
Buprenorphine has a complex opioid receptor pharmacology; it is a 
partial agonist at µ and ORL-1 receptors and an antagonist at к and δ-
receptors (Lutfy and Cowan, 2004). Buprenorphine is widely used for its 
analgesic properties and for the treatment of opioid dependency (Cowan, 
1995; Rothman et al., 1995; Preston and Jasinski, 1991; Cowan and Lewis, 
1995; Lutfy et al., 2003). Despite the fact that buprenorphine is used for the 
treatment of opioid dependency it might carry a risk of abuse liability and 
dependence because it is a partial agonist at µ-receptors (Mello et al., 1988). 
However, it has been shown that naltrexone, a non-selective opioid 
antagonist, could discourage and reduce such abuse (Gerra et al., 2006). 
Here we have established for the first time doses of buprenorphine and 
naltrexone that, when combined, produce functional к-receptor antagonism 
in mice. Systemic administration of buprenorphine/naltrexone combination at 
a dose of (1 mg/kg) is functional short-acting к- receptor antagonist in the tail 
withdrawal test in adult CD-1 male mice. Also, BU10119 (1 mg/kg) is a к- 
receptor antagonist with a rapid onset and a duration of action not more than 
24 hours. Furthermore, the combination regimen and BU10119 were not 
sedative being without significant locomotor effects in the open field test at 
the doses used.  
 
In this chapter, buprenorphine (1 mg/kg) significantly increased the 
%MPE in tail-flick that was not enhanced at 3 mg/kg. These results are in 
agreement with previous studies that reported that the analgesic properties 
of buprenorphine at higher doses may reach a plateau level without a 
maximal response and the dose response curve is sometimes bell-shaped, 
in nociceptive assays, depending upon the intensity and nature of the 
noxious stimulus (Cowan et al., 1977; Dum et al., 1981; Lizasoain et al., 
1991; Lutfy and Cowan, 2004; Ide et al., 2004; Lutfy et al., 2003). The 
antinociceptive effects of buprenorphine result from activation of µ-receptors. 
Lutfy et al (2003) have shown that buprenorphine has no antinociceptive 
effect in µ-receptor knockout mice. Moreover, our data agree with studies 





the analgesic properties of both morphine and buprenorphine (Broadbear et 
al., 2000; Kögel et al., 2005). In our study we injected CCAM 24 hours 
before any measurement because CCAM was reported in radioligand 
binding assays to interact with all µ, к and δ-receptors. However, after 8 
hours or more of injection it becomes an irreversible selective µ-receptor 
antagonist (Chan et al., 1995; Zernig et al., 1996). Moreover, Lutfy et al 
(2003) reported that the antinociceptive effect of buprenorphine is 
significantly enhanced in ORL-1 receptor knock-out mice. In addition, they 
reported that the antinociceptive effect of buprenorphine was enhanced by J-
113397, an ORL-1 receptor antagonist (Lutfy et al., 2003).  In the locomotor 
studies, it has been reported that buprenorphine (0.50 to 5.0 mg/kg) causes 
an increase in locomotion in mice (Jackson et al., 1993). However, in this 
study, buprenorphine at the dose of 1mg/kg alone or in combination with 
naltrexone were neither hyperactive nor sedative in adult CD-1 male mice 
and this is an agreement with a previous study (Filibeck et al., 1981). This 
controversy could be explained by the different effect of the drug on different 
strains. 
 
 In this chapter, naltrexone pretreatment (1 and 3 mg/kg) was capable 
of blocking buprenorphine antinociception and that was in agreement with a 
previous study in mice (Kögel et al., 2005). Moreover, the antinociceptive 
effects of U50, 488 (10 mg/kg) were significantly reduced by pretreatment 
with naltrexone (1 and 3 mg/kg) and this is an agreement with previous 
studies (Dum and Herz, 1981; Stevens et al., 1994). In open field study, 
U50, 488 (10 mg/kg) significantly reduced locomotion in mice. Similar effects 
were reported by Paris et al (2011) and von et al (1983). Since U50, 488 is a 
highly specific for the к-receptor (von et al., 1983) it is likely that this effect is 
mediated by к-receptors. Von et al (1983) reported that U50, 488 at a dose 
of 10 mg/kg caused a significant hypoactivity in mice that was reversed by 
naloxone 10 mg/kg. In this study, naltrexone pretreatment with 10 mg/kg 






In this chapter, we have shown that BU10119 have no analgesic 
properties in tail flick assay. Also, it was able to suppress the increase in 
%MPE of both morphine and buprenorphine and this effect may be mediated 
through µ-receptor antagonism. These results are in consistence with rat vas 
deferens assay which found that BU10119 was a reversible competitive 
antagonist at µ-opioid receptors with a pA2 value of 10.08 (9.84-10.31) 
(Ridzwan, 2102). Moreover, BU10119 showed к-receptor antagonist activity 
by blocking the analgesic effect of U50,488 and this result is with consistent 
with mice vas deferens assay which found that BU10119 acts as a к- 
receptor antagonist with an average pA2 value of 9.83 (9.08-10.58) 
(Ridzwan, 2102) ( see table 3.1). Indeed, these effects were not mediated 
through general sedation because BU10119 was neither hyperactive nor 




Table 3.1. Table shows maximal stimulation of [35S] GTPγS binding to opioid and ORL-1 
receptors. Data are taken from Cueva et al. 2015. 
 
It has been reported that the existing selective к-receptors 
antagonists, such as norBNI and GNTI have very long lasting effects in vivo 
(Beguin and Cohen, 2009; Carroll and Carlezon, 2013). For example, one 
injection of norBNI has peak к- receptor antagonist effects starting at about 
24 hours post-administration, continuing at high levels for 7–10 days and 
returning to control levels after 3–4 weeks or persisting for months (Endoh et 
al., 1992; Horan et al., 1992). This limits in vivo behavioural testing and 
potentially clinical trials if the blockade of κ-receptors may not be easily 
reversed. In this study, buprenorphine/naltrexone combination and BU10119 
Compound к-receptor µ-receptor ORL-1 δ-receptor 
Buprenorphine 0 ± 6% (Ke = 0.14 ± 0.06 nM) 
20 ± 6% (EC50: 0.7 
± 0.3nM) 
39 ± 12% (EC50: 1480 
± 980 nM) 7 ± 3% 
BU10119 −2 ± 1% (Ke = 0.09 ± 0.04 nM) 
2 ± 4% (Ke = 0.28 ± 
0.04 nM) 
56 ± 1% (EC50: 147   





were demonstrated to have shorter durations of к-receptor antagonist action 
in comparison to norBNI, with potencies similar to that of norBNI, in blocking 
к-receptor agonist-induced antinociception. 
 
In summary, here we demonstrated that the buprenorphine 
/naltrexone (1 mg/kg) combination are mixed µ/k-receptor antagonist and a 
functional short acting к-receptor antagonist. Moreover, we established that 
the BU10119 (1 mg/kg) is mixed µ/k-receptor antagonist with a rapid onset 
and a duration of action, not more than 24 hours. Furthermore, the 
combination regimen and BU10119 were neither hyperactive nor sedative in 
locomotor activity assay and these actions are not mediated throughout a 




































                                           Chapter 4 
Establishing the rewarding properties of combination 
buprenorphine/naltrexone and single compound 

















Opioid compounds, both prescription analgesics and drugs like 
heroin, are associated with dependence and addiction. Addiction to opioid 
analgesics is a growing problem worldwide and can cause serious health 
side effects and can lead to deaths due to overdose (Fields, 2011; Hall et al., 
2008). In the general population, in 2011/12 in England, there were 8.4 
opiate users per 1,000 and 155,000 people were treated for opioid addiction 
(Strang et al., 2006). Indeed, almost one in nine deaths recorded among 
people in their 20s and 30s in Wales and England in 2014 were related to 
drug addiction (White and Hamilton, 2016). Drug addiction can be defined as 
a chronic relapsing disorder that is characterized by a compulsive drug use 
regardless of severe negative consequences or loss of control over drug use 
which can lead to long-lasting changes in certain brain regions (Hyman et 
al., 2006).  
 
The exact mechanism of opioid addiction is still unclear. However, 
numerous studies have been made in the past two decades to identify the 
brain regions and the cellular and molecular mechanism that mediate 
addiction (Hyman et al., 2006; Wang et al., 2012). The mesolimbic pathway, 
in particular, was reported as the key part in reward process. This pathway 
originates with dopaminergic cell bodies in the VTA, a dopamine-rich 
nucleus located in the ventral portion of the midbrain. These dopaminergic 
axons project and primarily end in the NAc in the ventral striatum, but also 
extend into the Amy, and lateral Hip (Adinoff, 2004). It was documented that 
the analgesic and rewarding properties of opioids depend on its actions at 
the µ-receptor (Sora et al., 1997; Zhang et al., 2009). Since the majority of µ-
receptors in the VTA are localized to the GABA cells (Dilts and Kalivas, 
1989; Garzon and Pickel, 2001), it has been proposed that µ-receptor 
activation produces dopamine release via disinhibition. Opioid binding to 
VTA GABA cells produces hyperpolarization of these neurons (Johnson and 
North, 1992) and causes the releases of dopamine and accounts for the 
rewarding properties of opioid (Ting-A-Kee and van der Kooy, 2012). Indeed, 





preference (CPP), in rats and mice, which can be blocked by injection of µ-
receptor selective antagonists into the VTA or genetic knockdown of µ-opioid 
receptor (Olmstead and Franklin, 1997, Zhang et al., 2009). Moreover, there 
are other sites that µ-receptor agonists, such as morphine, may act on to 
produce self-administration in mice which include the lateral and medial HL, 
NAc shell and the mesencephalic central gray area (David and Cazala, 
1994). Also, it was reported that naltrexone decreased ethanol consumption 
in human alcoholics (Volpicelli et al., 1992) and was effective in the 
treatment of heroin dependence (Callahan et al., 1980; Gerra et al., 2006). 
On the other hand, it has been reported к-receptor stimulation reduces the 
release of DA and leads to aversive condition (Spanagel and Shippenberg, 
1990; Adinoff, 2004; Lüscher and Malenka, 2011). 
 
Buprenorphine acts as a partial μ-receptor agonist and a κ-receptor 
antagonist with additional nociception/orphanin FQ receptor (NOP-receptor, 
also known as ORL1) partial agonist activity (Huang et al., 2001; Lutfy and 
Cowan, 2004). It has been used as an alternative to methadone in the 
treatment of opioid addiction (Maremmani and Gerra, 2010). However, 
buprenorphine treatment carries a risk of abuse liability and dependence. 
Naltrexone, a relatively non-selective opioid receptor antagonist, is licensed 
as an abstinence promoter for the treatment of alcohol addiction (Rosner et 
al., 2010). Combining naltrexone with buprenorphine could reduce the 
potential abuse liability of buprenorphine activating μ-receptors, while 
enhancing κ-receptor antagonist actions. Naltrexone has been reported to 
have some aversive side effects and it is important to make sure that the 
combination is not rewarding nor aversive. Also, BU10119 is a novel 
compound, which resemble the combination pharmacology, needs to be 
assessed for rewarding and aversive properties.  
   
The conditioned place preference (CPP) task is one of the most 
popular models to study motivational and the reinforcing effects of opioids 
(Tzschentke, 2007). CPP is a learned behavior reported in many animal 





location more than others because the preferred location has been paired 
previously with the motivational or the reinforcing events (Bardo and Bevins, 
2000; Tzschentke, 2007). Indeed, it has been reported that amphetamine 
users develop a CPP for where they consumed the drug (Childs and Wit, 
2009). The CPP procedure depends on a neutral stimulus which is paired 
repeatedly with an unconditioned stimulus, such as food (Spyraki et al., 
1982), sweet fluid (Agmo and Marroquin, 1997) and drug (Tzschentke, 2007; 
Olmstead  and Franklin, 1997), that elicits a response prior to conditioning 
which is called unconditioned response. At the end of the experiment and 
pairings the neutral stimulus will produce responses similar to the 
unconditioned response. The neutral environmental cues become 
associated with the motivational or the reinforcing properties of the 
unconditioned stimulus leading to either avoidance or approach of the 
environment (Huston et al., 2013).   
 
The apparatus used in CPP is composed of two compartments and 
they are designed differently so that a mouse or rat can distinguish between 
them. The apparatus consisted of a box with two compartments joined by a 
removable partition that allowed animals to explore freely or be restricted to 
a particular compartment (Ide et al., 2004). CPP procedure composed of 
three stages which include habituation, conditioning and preference testing 
(Cunningham et al., 2006). In the habituation stage, the animal is given a 
chance to explore the two compartments freely and that is performed to 
reduce the effects of novelty on animals. In the conditioning stage, the 
animals will be given the unconditioned stimulus each other day and will be 
paired to one compartment. In the preference testing stage, the animal is 
allowed to access freely to the two compartments and the time spent in each 
chamber is recorded. The CPP method is simple, sensitive to low doses of 
drugs, not expensive, allows both aversive and rewarding effects to be 
measured and different species can be used. Also, it has been used 
extensively to show the rewarding effects of opioids in mice (Tzschentke, 






4.2. Chapter aims 
In this chapter, we have tested whether naltrexone at 1mg/kg blocks 
any rewarding properties of buprenorphine. This dose of naltrexone has 
been shown to block buprenorphine’s analgesic properties mediated at µ- 
receptors and U50,488 induced analgesia without any sedative effects 
(Chapter 3). Also, BU10119 at a dose of 1 mg/kg was investigated for any 
































4.3.1 Conditioned place preference (CPP)  
Place preference conditioning was conducted in a CPP chamber with 
an auto monitoring system (Ethovision XT version 8.0). CPP was assessed 
by three phases (habituation, conditioning, and preference testing phase). 
The apparatus (UGO Basile) consisted of a box with two compartments 
(16×15 cm/compartment) joined by a removable partition that allowed mice 
to explore freely or be restricted to a particular compartment. The two 
compartments differed in appearance and texture: one compartment had 
black walls and a grey floor with round 2 mm holes, while the other 
compartment had walls with vertical black and white stripes and a grey floor 
with 4×4 mm square holes (Figure 4.1). Experiments were performed 
between 09:00 hours and 16:00 hours under dim light (approximately 15 
lux). During all test sessions, the time each mouse spent in each 
compartment was recorded using tracking software. Mice were randomly 
assigned to treatment groups and the pairing was counterbalanced (i.e. 
within each treatment group equal numbers of mice were always drug-paired 
to each compartment type). On days 1 and 2 mice were habituated to the 
entire chamber for 15 minutes (one session/day). On days 3–8 mice were 
conditioned (40 minutes) to one of the two compartments, and daily sessions 
alternated between drug treatment and saline (In all treatment groups mice 
received both drug and saline) ( Figure 4.2). Mice were given buprenorphine 
(0.3 or 1 mg/kg), BU10119 (1mg/kg) or saline (0.9 % w/v). Naltrexone (1 or 3 
mg/kg) was injected 10 min before the injection of buprenorphine or saline.  
CCAM (3 mg/kg) was injected and mice immediately returned to the home 
cage 24 hr before conditioning. In experiments with norBNI (10 mg/kg) mice 
were injected in the 2nd and 5th and immediately return to home cage and 
10 minutes between norBNI and CCAM injection were adopted. After 
buprenorphine injection, the mice were transferred directly to the place 














Day 1 2 3 4 5 6 7 8 9
Habituation Conditioning Test
 
Figure 4.2. The time line of the CPP experimental design. Naltrexone (NTX )(1 or 3 mg/kg) 
was injected 10 min before the injection of buprenorphine or saline. CCAM (3 mg/kg) was 
injected 24 hr before conditioning and 10 minutes between norBNI and CCAM injection 
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Chamber floors and trays were removed and cleaned with ethanol 70% and 
left for 5 minutes for ethanol to evaporate before the next trial. On day 9, 
mice were not injected with saline or drugs. In a free-to-explore test, lasting 
15 minutes, mice had free access to both compartments and their 









4.4.1. Establishing the rewarding properties of combination 
buprenorphine/naltrexone and single compound BU10119 in 
conditioned place preference (CPP) task 
The rewarding or aversive properties of BU10119 (1mg/kg), 
naltrexone (1 and 3 mg/kg), CCAM (3mg/kg) and norBNI (10 mg/kg) was 
investigated in the CPP task and buprenorphine (0.3 and 1 mg/kg) and 
morphine were used as positive controls. One way ANOVA revealed that 
mice receiving 1 mg/kg buprenorphine exhibited significant conditioned 
place preference, evident as a significantly increased time spent in the drug-
paired compartment of the CPP chamber, compared to pre-conditioning (F 
(5,42)= 2.84, p<0.027, n=8, p=0.05) (Figure 4.3). However, co-administration 
of 1 and 3 mg/kg naltrexone completely blocked the conditioned place 
preference elicited by buprenorphine. While not significant, there was a trend 
for 3 mg/ kg naltrexone to increase the time spent in the saline-paired 
compartment compared with preconditioning, suggesting that naltrexone at 
this dose may be eliciting an aversive response.  
 
In the second experiment we investigated the effects of BU10119 
(1mg/kg), higher dose of naltrexone (10 mg/kg) and buprenorphine (1 
mg/kg) was included as a positive control (Figure 4.4). One-way ANOVA 
revealed a significant effect of Treatment on the time spent in a drug-paired 
compartment in the CPP task (F (3,34)= 15.16, p<0.001) (Figure 4.4). Post 
hoc comparisons to saline treated controls revealed that buprenorphine (1 
mg/kg) increased the time spent in the drug-paired compartment (p<0.05). In 
contrast, naltrexone (10 mg/kg) increased the time spent in the saline-paired 
compartment (p<0.01). Naltrexone at higher doses increased the time spent 
in the saline-paired compartment compared with preconditioning, suggesting 
that naltrexone at a higher dose is eliciting an aversive response. Also, there 
was a non-significant increase in the time spent in the drug-paired 









































Figure 4.3. Conditioned place preference to buprenorphine (Bup, 1 mg/kg) in adult male 
CD1 mice, in the presence and absence of naltrexone (NTX) (1 and 3 mg/kg). In a 900 
second test, animals in all treatment groups did not show a preference for either chamber 
during habituation (pre-conditioning). After 6 days of conditioning, buprenorphine 
significantly increased the time spent in the drug-paired chamber. The analysis was done by 
one-way ANOVA followed Unadjusted Least Significant Difference (ULSD) post hoc test. 
































Figure 4.4. Effects of buprenorphine (Bup), naltrexone (NTX) (10 mg/kg) and BU10119 (1 
mg/kg) in conditioned place preference assay in adult male CD1 mice. Data are presented 
as preference for the drug (= time spent in the drug-paired side during test minus time spent 
in the drug-paired side at baseline (Naltrexone and BU10119), n=9 (Saline, Buprenorphine). 
The analysis was done by one-way ANOVA followed Unadjusted Least Significant 
Difference (ULSD) ) post hoc test. Values are mean ± SEM, n=10. *p<0.05 and **p<0.01 as 











To investigate whether the increase in time spent in the drug-paired 
chamber of BU10119 and buprenorphine is mediated through the µ-receptor, 
the irreversible µ-receptor antagonist CCAM (3mg/kg) was used (Figure 4.5). 
The selection of CCAM dose was based on our previous tail withdrawal 
results (Chapter 3). One-way ANOVA revealed a significant effect of 
Treatment on the conditioned place preference (F (5,48)= 6.78, p<0.0001). 
However, BU10119 showed a non-significant increase in time spent in the 
drug-paired compartment, compared to saline-treated groups (p< 0.0782). 
Moreover, CCAM (3 mg/kg) was able to reduce the time spent in the drug-
paired compartment to control level for BU10119 (1 mg/kg) treated mice 
(p=0.9 as compared to saline control). Interestingly, CCAM (3 mg/kg) failed 
to block or to reduce the significant increase in time spent of buprenorphine 
(1 mg/kg) in the drug-paired compartment (p<0.9139 as compared to 
buprenorphine alone, Figure 4.5). Importantly, CCAM (3mg/kg) alone was 
not rewarding or aversive (p<0.9139). In a subsequent experiment, CCAM 
(3mg/kg) was able to block the rewarding effects of morphine (10mg/kg) 
(unpaired Student t-test, p< 0.0119, n=8) (Figure 4.6) but not of 
buprenorphine (1 mg/kg) (p<0.3838). The ability of CCAM to block the 
rewarding effects of buprenorphine at a lower dose of 0.3 mg/kg was also 
investigated. This lower dose of buprenorphine increased the time spent in 
the drug-paired side of the CPP apparatus compared to saline-treated 
groups (one-way ANOVA (F (2,25)= 24.45, p< 0.0001,n=9-10) (Figure 4.7). 
However, CCAM (3mg/kg) failed to block the rewarding properties of 0.3 















CCAM 3mg+Bup 1 mg/kg
BU10119 1 mg/kg













Figure 4.5. Effects of buprenorphine (Bup) (1 mg/kg), BU10119 (1 mg/kg) and CCAM (3 
mg/kg) alone or in combination in conditioned place preference assay in adult male CD1 
mice. Data are presented as preference for the drug (= time spent in drug-paired side during 
test minus time spent in drug-paired side at baseline). The analysis was done by one-way 
ANOVA followed Unadjusted Least Significant Difference (ULSD) ) post hoc test. Values are 
























Morphine 10 mg/kg+CCAM 3mg/kg
Bup 1 mg/ kg














Figure 4.6. Effects of morphine (10 mg/kg), buprenorphine (Bup) (1mg/kg) alone or in 
combination with CCAM (3 mg/kg) in conditioned place preference assay in adult male CD1 
mice. CCAM (3 mg/kg) was administered 24 hr before morphine and Bup. Data are 
presented as preference for the drug (= time spent in drug-paired side during test minus 
time spent in drug-paired side at baseline) ± SEM, n=8. The analysis was done by unpaired 




























Figure 4.7. Effects of buprenorphine (Bup) (0.3 mg/kg) alone and in combination with CCAM 
(3 mg/kg) in conditioned place preference assay in adult male CD1 mice. CCAM (3 mg/kg) 
was administered 24 hr before Bup. Data are presented as preference for the drug (= time 
spent in the drug-paired side during test minus time spent in drug-paired side at baseline). 
The analysis was done by 1-way ANOVA followed Unadjusted Least Significant Difference 
(ULSD) post hoc test. Values are mean ± SEM, n=10 (Bup), n=9 (saline and Bup with 
CCAM). ***p<001 as compared to saline treated group.   
 
 
To determine whether this apparent rewarding effect by 
buprenorphine (0.3 mg/kg) may be mediated through the к-receptor, CCAM 
(3 mg/kg) and the к-receptor antagonist norBNI (10 mg/kg) were used alone 
or in combination (Figure 4.8). One-way ANOVA revealed a significant effect 
of Treatment on the time spent in the drug-paired compartment (F (7,64)= 
7.25, p<0.0001). Post hoc analysis showed that CCAM (3mg/kg) (p<0.725) 
and norBNI (10 mg/kg) (p<0.725), alone and in combination (p<0.684), were 
neither rewarding nor aversive as compared to saline treated group. Also, 
neither CCAM (3mg/kg) nor norBNI (10 mg/kg) (p<0.3), alone or in 
combination (p<0.725), were able to block the conditioned place preference 
induced by buprenorphine (0.3 mg/kg). Interestingly, there was a significant 
increase in the time spent in the drug-paired compartment of the CCAM/ 

















norBNI 10mg/kg+CCAM 3 mg/kg
Bup 0.3 mg/kg
Bup 0.3 mg/kg+CCAM 3mg/kg


















Figure 4.8. Effects of buprenorphine (Bup) (0.3 mg/kg), CCAM (3 mg/kg), norBNI (10 mg/kg) 
alone and in combination in conditioned place preference assay. Data are presented as a 
preference for the drug (= time spent in the drug-paired side during test minus time spent in 
the drug-paired side at baseline). The analysis was done by one-way ANOVA followed 
Unadjusted Least Significant Difference (ULSD) post hoc test. Values are mean ± SEM, 

















In this study buprenorphine (0.3 and 1 mg/kg) was rewarding in CPP 
and that is in agreement with previous studies in mice (Ide et al., 2004) and 
rats (Tzschentke, 2004). Also, naltrexone (1 and 3 mg/kg) was able to block 
this effect and that was in agreement with previously published findings in 
rats (Cordery et al., 2014). Furthermore, it was established for the first time 
that the combination dose of buprenorphine (1 mg/kg) with naltrexone           
(1 mg/kg) is neither rewarding nor aversive in the CPP paradigm in adult  
CD-1 male mice.  
 
Naltrexone is non-selective antagonist at the μ, к-receptor and to a 
lesser extent at the δ-receptor (Giordano and Cicero, 1990; Takemori et al., 
1988: Ghirmai et al., 2008). In this chapter, there was a trend for naltrexone 
to increase the time spent in the saline-paired compartment compared with 
preconditioning, which was significant when the dose was increased to 10 
mg/kg. This suggests that naltrexone at higher doses may be eliciting an 
aversive response. Indeed, naltrexone alone at a dose of 10 mg/kg was 
aversive in this study and this effect may be mediated by µ-opioid 
antagonism (Mucha et al., 1985; Parker and Rennie, 1992). Indeed, in one 
study naltrexone was reported to have aversive effects. It was reported that 
a single 50-mg dose of naltrexone led to a range of unpleasant symptoms, 
including dysphoria (Mendelson et al., 1978). In another study, naltrexone 
treatment did not lead to an increase in depressive symptoms. However, 
there was a trend for the symptoms depression to be lower while on 
naltrexone. Moreover, participants adherent to naltrexone treatment had less 
depressive symptoms than those not adherent to naltrexone treatment 
(Dean et al., 2006). 
 
 In this chapter, the surprising result that the irreversible u-receptor 
antagonist CCAM did not block place preference induced by buprenorphine. 
CCAM (3 mg/kg) was able to block the rewarding properties of morphine (10 
mg/kg) and this clearly shows that the morphine-induced increase in the time 





This is consistent with Matthes et al (1996) which reported a loss of a 
morphine-induced increase in place preference and physical dependence in 
mice lacking the µ-receptor gene.  
 
Buprenorphine reward could be mediated through several receptors 
which include к, δ and ORL-1 receptors. CCAM (3mg/kg) and norBNI (10 
mg/kg) alone or in combination failed to block the reward of buprenorphine 
(0.3 mg/kg), suggesting that k-receptors are not implicated in this effect. 
Interestingly, Ide et al (2004) reported that buprenorphine maintains its 
reward ability in homozygous µ-receptor knockout mice but pretreatment 
with the nonselective opioid antagonist naloxone abolished this ability. 
These authors also showed that there was a partial block by pretreatment 
with either the δ-receptor antagonist naltrindole or the к-receptor antagonist 
norBNI. Indeed, activation of µ-receptor and antagonism of к-receptors leads 
to increase of dopamine release in the different brain area, such as VTA and 
NAc, which may result in reward and the use of non-selective opioid 
receptors antagonist may prevent the release of dopamine and abolish this 
reward. Also, Ide et al (2004) suggested that µ- and δ- and/or к- receptors 
are each involved in the rewarding effects of buprenorphine. However, in 
another study Marquez et al (2007) reported that buprenorphine failed to 
induce CPP in µ-receptor knockout mice. This controversy between these 
two studies could be explained by using different strain and protocols in their 
studies. On the other hand, the failure of CCAM and norBNI in our study to 
block buprenorphine reward could be explained because the dose of both 
antagonists is low and CPP task is very sensitive to low doses of µ-receptor 
agonists and dopamine release. Also, to prevent buprenorphine reward we 
need to block µ-receptors completely. Ideally, in our study, we should have 
done a dose response curve for CCAM and norBNI in CPP at the beginning 
of the experiment. However, due to time limitation and resource we were not 
able to do that. Also, to investigate the effect of the opioid receptors in 







   The data in this chapter revealed that BU10119 (1 mg/kg) non-
significantly increased the time spent in the drug-paired compartment. 
However, this increase was close to being significant and CCAM was able to 
reduce this increase to the control level. It has been reported that sweet food 
(Agmo and Marroquin, 1997) and fluoxetine (2.5 mg/kg) (Collu et al., 1997) 
elicited CPP. Also, Collu et al (1994, 1996) have reported that both 
fluoxetine and imipramine, when given chronically, produce CPP for a single 
dose of cocaine ineffective in control rats. However, fluoxetine been reported 
to decrease cocaine and amphetamine self-administration in rats (Carroll et 
al., 1990). All these studies may suggest that any unconditioned stimulus in 
CPP which may have a positive effect or may possess antidepressant or 
anxiolytic effects may increase the time spent in the drug-paired 
compartment and this could explain the ability of BU10119 to increase the 
time spent in the drug-paired compartment. However, BU10119 is к-receptor 
antagonist and it may cause an increase in dopamine level in brain reward 
circuit and that may contribute its effect on CPP. Moreover, BU10119 may 
have a low partial µ-receptor agonist activity, which was not detected in the 
tail-flick assay, which could be responsible for that effect and that may 
explain why CCAM was able to reduce such an effect on CPP. On the other 
hand, BU10119 and CCAM are µ-receptor antagonists and given both of 
them in CPP may explain the ability of combination to reduce the time spent 
in the drug-paired compartment.    
  
In summary, buprenorphine (0.3 and 1 mg/kg) was rewarding in CPP. 
Also, naltrexone (1 and 3 mg/kg) was able to block this effect and it was 
established that the combination dose of buprenorphine (1 mg/kg) with 
naltrexone (1 mg/kg) is neither rewarding nor aversive in the CPP paradigm 
in adult CD-1 male mice. Also, BU10119 was without significant rewarding or 


















Effects of combination buprenorphine/naltrexone and 
single compound BU10119 on depression and 






















5.1. Can we model depression and anxiety in lab animals? 
Depression is a complex mental disorder and its diagnosis depends 
on patient symptoms, such as a feeling of sadness, low self-worth, 
anhedonia, feelings of guilt, and recurrent thoughts of death (American 
Psychiatric Association, 2013). The heterogeneity of this disorder suggests 
that there are multiple different biological mechanisms involved in its 
pathophysiology. Moreover, several possible causes and factors have been 
reported and claimed to increase the chance of depression, including, 
alteration of brain chemistry, genetic and environmental factors (Charney 
and Manji, 2004). Indeed, the wide range of signs and symptoms and the 
different possible etiologies of depression highlight the difficulty to mimic 
these features in animals in labs. Indeed, recurring urges to commit suicide 
or thoughts of death, or thoughts of guilt, are impossible to model in 
laboratory animals (Fuchs and Flügge, 2006; Fernando and Robbins, 2011). 
Therefore, it is almost impossible to know whether a laboratory animal is 
depressed or not. However, depression produces a wide variety of 
symptoms and features that can be reproduced independently and 
evaluated in animals, including physiological alterations, for example 
biochemical, endocrinological or neuroanatomical, and behavioural features 
such as cognitive impairments and despair (Hasler et al., 2004; van der 
Staay et al., 2009). 
 
5.2. Validity of the animal models of depression and anxiety  
The use of animal models is an important tool in investigating the 
pathophysiology of depressive disorders and also in screening and 
developing novel antidepressants (Nestler and Hyman, 2010; Fernando and 
Robbins, 2011). Animal models assessing depression-related behaviours 
depend on the exposing the animals to different kinds of stressors which 
cause behavioural changes similar to the depression, which can be stopped 







An ideal animal model of human depression and anxiety must satisfy 
minimal criteria as much as possible. It must be able to model pathological, 
physiological or behavioural changes by reproducing these conditions that 
are believed to cause depression (construct validity) and parallel the 
numerous symptoms of human depression (face validity). Also, the ability to 
reverse the behavioural changes by treatment which are effective in humans 
(predictive validity) is an important criterion in an animal model of depression 
and anxiety (Willner and Mitchell, 2002; van der Staay et al., 2009). 
 
In this chapter, a number of behavioural tasks for assessing 
antidepressent and anxiolytic drug action have been used and are discussed 
here in terms of their validity. 
 
5.3. Behavioural paradigms to assess depression- and anxiety-related 
behaviours 
5.3.1. Forced swim test 
The forced swim test (FST) was developed by Porsolt and colleagues 
(Porsolt et al., 1977) originally in the rat and subsequently in the mouse 
(Porsolt, 2000). In FST rats are placed for 15 min in the water then they are 
removed and returned to their home cages. Then they are placed in the 
cylinders 24 h later and the total duration of immobility is measured during a 
5 min test. However, in mice there is no need for the pre-swim session 
(Porsolt, 2000). In preclinical studies, this test is one of the most widely used 
tools for assessing antidepressant activity and this is because it's easy to be 
used, reliable between laboratories and its ability to detect the majority of 
antidepressants and discriminates antidepressants from neuroleptics and 
anxiolytics (Borsini and Meli, 1988). Even though it works after 30 minutes of 
drug administration, it is still highly efficient in predicting the antidepressant 
potential of tested drug (Petit-Demouliere et al., 2005) and it has been 
reported to have the highest rates of predictive validity for antidepressants 
(Holmes, 2003). It involves placing a rat or mouse in a glass cylinder with 
enough water so that it cannot touch the bottom with its hind paws (Porsolt 





will increase and eventually will adapt to an immobile position. However, the 
animal will make a necessary movement to maintain its head above the 
water. It is known that tricyclic antidepressants, atypical antidepressants, 
and monoamine oxidase inhibitors decrease the rats and mice immobility in 
a dose-dependent manner in this test (Porsolt et al., 1977; Borsini and Meli, 
1988). In this test immobility is considered as a depression-like behaviour 
(behavioural despair) (Cryan et al., 2005 a,b). A lot of efforts have been 
made to increase the sensitivity of the traditional FST. Therefore, an 
enhancement of the sensitivity of FST was made by several simple 
procedural changes (Lucki, 1997). These improvements include increasing 
the water depth to 30 cm from old depths of 15–18 cm and using a time of a 
5-s interval to rate the animal behaviour. These enhancements enable 
researchers to distinguish certain behaviours, particularly: (1) climbing 
behaviour, which is defined as upward-directed movements of the forepaws 
along the side of the swim chamber; (2) swimming behaviour, the movement 
(usually horizontal) throughout the swim chamber that also includes crossing 
into another quadrant. It has been reported that swimming behaviour 
predominates for serotonergic antidepressants and climbing predominates 
for drugs that are primarily noradrenergic, allowing the FST to detect this 
distinction (Lucki, 1997; Cryan and Lucki, 2000). Also, one of the 
distinguishing characteristics of the FST is that acute and chronic drug 
treatments are effective in this model. Indeed, acute administration of 
fluoxetine (4-64 mg/ kg, i.p.) reduced the time spent immobile in the FST 
with CD mice (Da-Rocha et al., 1997). On the other hand, Detke et al (1997) 
reported that chronic treatment with low doses (1-5 mg/kg) of antidepressant 
drugs which were not effective subchronic produced antidepressant-like 
effects and that these results support the validity of the FST as a behavioural 

























                                  Figure 5.1.The mouse FST set-up. 
 
 
5.3.2. Hyponeophagia paradigms 
Hyponeophagia tests include novelty induced hypophagia (NIH) and 
novelty suppressed feeding (NSF) that are used in rats and mice (Dulawa, 
and Hen, 2005; Bodnoff et al., 1988). These behavioural paradigms use the 
innate behaviour of rodents to explore a novel environment but introduce an 
approach-avoidance conflict. In these paradigms, animals are motivated to 
approach food or drink but the novel environment is aversive. These 
paradigms do not require sophisticated training, are not confounded by 
painful stimuli, are relatively simple and not costly (Blanchard et al., 1998; 
Belzung et al., 2001). Here, a NIH procedure based on the method of 
Dulawa and Hen (2005) has been used. In this paradigm, mice are not 
food/water deprived but are habituated to drink sweetened condensed milk 
and then given the chance to consume it in two test sessions. The first 
session occurs in the home cage (control) and the second session in a 





good predictive validity because it responds well to the anxiolytic effects of 
benzodiazepines and antidepressants such as fluoxetine (Dulawa and Hen, 
2005). Also, it's able to detect the anxiolytic effects of antidepressants after 
chronic treatment, which agrees with the clinical profile for this effect in 
humans (Bodnoff et al., 1989; Dulawa and Hen, 2005). Also, it has been 
reported that increased anxiety caused by an acute SSRI treatment in 
human can be detected in this paradigms, an effect that is not reliably 
detected in other paradigms (Dulawa and Hen, 2005). Thus, this test has a 
good predictive and construct validity for the anxiolytic effects of chronic 
antidepressant treatment (Dulawa and Hen, 2005). 
 
5.3.3. Elevated plus maze (EPM) 
The elevated plus maze (EPM) is one of the most widely used and 
straightforward methods for assessing anxiolytic drug effects in rodents 
(Pellow et al., 1985; Belzung and Griebel, 2001; File, 2001; Holmes, 2001).  
The EPM is a plus-shaped maze, raised off the floor with two closed and two 
open arms facing each other and separated by a central platform (Figure 
5.2). The concept of EPM is based on innate exploration and an approach-
avoidance conflict generated by the aversive elevated open arms. In 
general, the rodent behaviour is characterised by avoidance of open arm 
with a high preference for the closed arms (Pellow et al., 1985; Holmes, 
2001; Kumar et al., 2013). In literature review, there is a discrepancy in the 
results of EPM studies and this could be explained by variability in test 
conditions that may affects the outcome of these results, for example, using 
different strains, sex, procedures approach, routes of drug administration 
and method of scoring (Rodgers and Shepherd, 1993; Griebel et al., 2000; 
Holmes, 2001; King, 2001; Wahlsten et al., 2003;). However, the EPM has a 
good face and predictive validity and the drugs that are anxiolytic in humans 
(such as benzodiazepines) are capable of increasing the amount of time 


























5.3.4. The light-dark (LDB) box test 
Crawley and Goodwin designed the light-dark box test before the 
EPM test in the early 1980s. The LDB test has been used as a 
pharmacological tool for predicting the anxiolytic effects of novel compounds 
(Crawley and Goodwin, 1980; Crawley, 1981).  It’s a behavioural paradigm 
to assess anxiety that is simple, quick to use, without requiring the prior 
training of animals. Like the EPM, it is an approach-avoidance task, based 
on the nature of rodents to avoid the brightly illuminated areas and their 
spontaneous exploratory behaviours in a novel environment. The test 
apparatus consists of two interconnecting chambers. One arena is smaller, 
black and non-illuminated and the other is aversive being large, open and 
brightly lit (Figure 5.3). Thus, the measures of exploration in the illuminated 
area (time, locomotion, the number of transitions) is used as experimental 
indices of anxiety-related behaviour (Crawley and Goodwin, 1980; Ramos, 





spent in the lit compartment and increases the number of crossing between 
the two compartments (Crawley, 1981; Pellow et al., 1985; Lister, 1987; 
Hascoët and Bourin, 2009). However, treatment with psychomotor stimulants 
such as amphetamine or genetic-induced hyperactivity in basal locomotor 
activity could produce false positive results (Holmes, 2001). In general, LDB 
box has a reasonable good predictive validity when screening novel 






         





































5.4. Chapter aims 
The behavioural paradigms used were chosen because they have a 
good predictive validity for screening a novel antidepressant and anxiolytic 
drugs. In this chapter, FST, NIH, EPM and LDB were used to evaluate 
whether the combination buprenorphine/naltrexone (1 mg/kg) and BU10119 
(1 mg/kg) have antidepressant and anxiolytic effects in adult CD-1 male 
mice. Importantly, at the doses tested, none of these drugs affected 
locomotor activity which is a significant confound of behavioural experiment 











5.5.1. Forced swim test 
Mice were individually placed in a glass beaker (height 44 cm, 
diameter 22 cm) filled with water at a depth of 30 cm, at 25 ± 2°C and 
behaviour recorded (Sony DCR-SR52) for 6 minutes. Mice were removed, 
dried and returned to their home cages. Mice were scored, blind for 
treatment, for three measures: swimming, immobility, climbing and the time 
spent engaged in these behaviours in the last 4 minutes of the test reported. 
Drug treatments were saline-injected controls, buprenorphine (1 mg/kg) 
alone, naltrexone (1 mg/kg) alone, buprenorphine/naltrexone (1 mg/kg) 
combination, BU10119 (1 mg/kg) and the selective serotonin reuptake 
inhibitor (SSRI) fluoxetine (20 mg/kg). All drugs were administered 1 hour 
before testing (naltrexone 10 min before buprenorphine). However, The 
irreversible µ-antagonist CCAM (3 mg/kg), administered 24h before 
buprenorphine (Porsolt, 2000; Petit-Demouliere et al., 2005).   
 
5.5.2. Novelty-induced hypophagia 
Mice were individually housed for three days before training began. 
Training consisted of three consecutive days in which mice received 
concentrated milk (1:3, sweetened condensed milk: water) for 30 minute in 
their home cage and lighting levels were set to 20 lux. On day four mice 
underwent home cage testing. On day 5, novel cage testing was conducted 
by placing the mouse in a clean cage of the same dimensions as their home 
cage, but with no bedding or shavings and under bright lighting (300 lux, 
Figure 5.7; 500 lux, Figure 5.8A and 5.8B). The latency to drink was 
recorded during a 30-minute test period in both the home and novel cage 
environments. In the first experiment (Figure 5.7), mice received 
buprenorphine and naltrexone alone, or combined, or the SSRI fluoxetine 
(20 mg/kg) 1 h prior to testing (naltrexone 10 min before buprenorphine). 
Mice were also administered the к-antagonist norBNI (10 mg/kg; 24–48 
hours before testing, after training on day 3). In the second and third 
experiment (Figure 5.8A and 5.8B), the lighting was increased to make the 





investigated. Also, the ability of the irreversible µ-receptor antagonist CCAM 
(3 mg/kg) (Figure 5.8B) to block the effects of buprenorphine and naltrexone 
was investigated by the administration after training on day 3 (Dulawa et al., 
2004). 
 
5.5.3. Elevated plus maze (EPM) 
Mice were placed in the centre of an EPM (EPM2000 Mouse Plus 
Maze, Campden Instruments) facing an open arm and behaviour was 
recorded for 5 minutes (Casal-Dominguez et al., 2013). The time spent in, 
and entries into, the open and closed arms and total ambulation were 
recorded via infrared photobeams and analysed with Motor Monitor™ 
software (Campden Instruments). Illumination was 150 lux in the open arms 
and <1 lux in the closed arms. Mice (n=10/group) were treated with saline, 
buprenorphine (1mg/kg) alone, naltrexone (1mg/kg) alone, 
buprenorphine/naltrexone (1 mg/kg) combination, BU10119 (1mg/kg) and 
diazepam (2 mg/kg) as a positive control, 1h prior to testing (naltrexone 10 
min before buprenorphine). 
 
5.5.4. Light dark box (LDB) 
Mice were placed at the centre of the lit compartment (400 lux), facing 
the dark compartment and allowed free access to compartments for 10 
minutes (Open field SmartFrame, Campden Instruments) (Casal-Dominguez 
et al., 2013). The time spent in the lit and dark compartment in the LDB were 
recorded via beam-breaks using Motor Monitor™ software (Campden 
Instruments).  
 
5.6. Statistical analysis       
FST, EPM and LDB data were analysed using single measures one-
way analysis of variance (ANOVA). NIH data were analysed using two-way 
repeated measures mixed model analysis. Then, Unadjusted Least 
Significant Difference (ULSD) were used as Post hoc test (InVivoStat 2.3). 
Only planned pairwise tests were carried out and p values adjusted for 





reported as mean ± standard error of the mean (SEM) for each treatment 
group. The number of animals are, n=9 to 12 per treatment group depending 










5.7.1 Effects of combination buprenorphine/ naltrexone in the FST 
To determine an effective dose of fluoxetine to use as a positive 
control,  fluoxetine (10 and 20 mg/kg) was compared to saline in the forced 
swim test (Figure 5.4, n=10 per group). One-way ANOVA showed a 
significant effect of Treatment on the time spent swimming (F(2,25)=67.82, 
p<0.01) and time spent immobile (F(2,25)=4.19, p<0.05) in the last 4 min of 6 
min test session. Post hoc comparisons revealed that only the higher dose 
of fluoxetine (20 mg/kg) significantly increased the time spent swimming 
(p<0.01) and decreased the time spent immobile (p<0.05). 
 
Next the effects of buprenorphine (1 mg/kg) and naltrexone (1 mg/ 
kg), alone or in combination, were compared with the SSRI fluoxetine (20 
mg/kg) in the forced swim test (Figure 5.5, n=10 per group). One-way 
ANOVA revealed  a  significant  effect  of  Treatment  on  the  time  spent  
swimming (F(4,45) = 6.88, p<0.001) and immobile (F(4,45) =6.97, p<0.001). 
Post hoc comparisons to saline treated controls revealed that all drug-
treated groups increased the time spent swimming, and decreased the time 
spent immobile, compared to saline treated mice (all p’s <0.001). 
Interestingly, immobility times for buprenorphine (1 mg/kg) and naltrexone (1 
mg/kg) administered alone were not significantly different from the 
combination treatment. On the other hand, there was no significant 
difference on time spent climbing between all groups (p>0.05).  
 
Further investigation was carried out to determine whether the 
antidepressant-like effects of buprenorphine in the forced swim test were 
related to its partial µ-receptor agonist activity (Figure 5.6, n=10 per group). 
The irreversible µ-receptor antagonist CCAM (3mg/kg) was administered 24 
h before buprenorphine or saline were injected and activity assessed 1 h 
later in the FST. One-way ANOVA revealed a significant effect of Treatment 
on the time spent swimming (F(4,40) =8.84, p< 0.001) and immobile (F(4,40) = 
7.77, p< 0.001). Buprenorphine alone, or in combination with CCAM, 





compared with saline (p< 0.01). CCAM alone produced no significant effects 
on behaviour in the forced swim test as compared to saline control group 
(p>0.05). These data suggest that the antidepressant-like effects of 

























Figure 5.4. Effects of fluoxetine (10 and 20 mg/kg) in adult male CD1 mice in the forced 
swim test. Data are expressed as mean ± SEM (n=10 per group) counts of swimming, 
immobility and climbing behaviours during the last 4-min of a 6 min swim test period. *p< 
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Figure 5.5. Effects of buprenorphine (Bup 1mg/kg) and naltrexone (NTX 1mg/ kg), alone or 
in combination, in adult male CD1 mice in the forced swim test. The SSRI fluoxetine (20 
mg/kg) was administered as a positive control. (A) All compounds under test produced 
antidepressant-like effects in the forced swim test. Data are expressed as mean ± SEM 
(n=10 per group) of time spent swimming, climbing and immobile during the last 4 min of a 6 
min swim test.  * p< 0.05, ** p< 0.01, ***p< 0.001 compared to saline. 
 






















Figure 5.6. Effects of buprenorphine (Bup 1mg/kg) and CCAM (3mg/kg), alone or in 
combination, in adult male CD1 mice in the forced swim test. The SSRI fluoxetine (20 
mg/kg) was administered as a positive control. Data are expressed as mean ± SEM (n=10 
per group) counts of swimming, immobility and climbing behaviours during the last 4- min of 
a 6 min swim test period. **p< 0.01and ***p< 0.001 compared to saline. CCAM was 





5.7.2. Effects of combination buprenorphine/ naltrexone in the NIH 
paradigm 
Behaviour of mice administered buprenorphine (1 mg/kg) and 
naltrexone (1 mg/kg), alone or in combination, were compared with the SSRI 
fluoxetine (20 mg/kg) and the к-receptor antagonist norBNI (10 mg/kg) in the 
NIH task (Figure 5.7, n=10 per group). Two-way repeated measures mixed 
model analysis of the latency to drink times revealed significant main effects 
of Treatment (F(5,54)=11.64, p<0.001) and a significant 
Treatment*Environment interaction (F(5,54)=10.78, p<0.001). Post hoc 
comparisons of behaviours in the novel cage showed that, the novel cage 
was aversive, as demonstrated by the significant increase in the latency to 
drink in saline treated mice in the novel cage (Mean latency value = 7.52 ± 
0.86 minutes) compared with the home cage environment (Mean latency 
value = 0.53 ± 0.18 minutes, p<0.001). Naltrexone alone, or in combination 
with buprenorphine, significantly reduced the latency to drink milk in the 
novel cage (p<0.05, compared to saline controls). Moreover, the SSRI 
fluoxetine and the к-receptor antagonist norBNI, which was administered at 
the end of training on day 3, also significantly reduced the latency to drink in 
the novel cage (p<0.01, compared to saline). Interestingly, in the home cage, 
buprenorphine alone significantly increased the latency to drink milk 
(p<0.001) as compared to saline and all drug-treated groups. However, there 
was no significant difference between buprenorphine and saline treated 
controls in the novel cage (p=0.458).  
 
In the next experiment, we increased the lighting in the novel cage, 
from 300 lux to 500 lux, to enhance its aversive effects and fluoxetine (20 
mg/kg) was used to investigate the new environment (Figure 5.8A-B). Two-
way repeated measures mixed model analysis of the latency to drink times 
revealed significant main effects of Treatment*Environment interaction 
(F(1,18)= 5.56, p<0.05). Post hoc comparisons of behaviours in the novel cage 
showed that fluoxetine (20 mg/kg) significantly reduced the latency to drink 
milk in the novel cage (p<0.05, compared to saline controls) (Figure 5.8A), 





(3mg/kg) to block the effects of buprenorphine and naltrexone in the NIH test 
under this 500 lux condition (Figure 8B, n=9 per group). In CCAM treated 
mice,  CCAM  was  administered  at  the  end of training  on  day 3. Two-way 
 





























Figure 5.7. Effects of buprenorphine (Bup 1 mg/kg) and naltrexone (NTX 1 mg/kg), alone or 
in combination, in adult male CD1 mice in the novelty induced hypophagia task (novel cage 
300 lux). The latency to drink milk in both the home and novel cage environments is shown. 
The SSRI fluoxetine (20 mg/kg) was administered as a positive control and the selective κ-
antagonist norBNI (10 mg/kg) shown for comparison. All values are the mean ± SEM. (n=10 
per group). *p< 0.05, **p< 0.01 and ***p< 0.001 compared to saline. ^^^p< 0.01 compared 




repeated measures mixed model analysis revealed significant main effects 
of Treatment (F(6,56) =9.17 p<0.001) and interaction between Treatment * 
Environment (F(6,56)=26.39, p<0.001). Post hoc comparisons revealed that, 
under these conditions, buprenorphine alone significantly reduced the 
latency to drink in the novel cage  (p<0.05  compared to saline control). 
CCAM blocked the effects of buprenorphine in the home cage to increase 
the latency to drink (p<0.001) indicating that this effect was mediated by the 
µ-receptor. In both the home and novel cages, CCAM alone was without 
significant effect on the latency to drink, compared to saline controls. 





in the novel cage, indicating that these effects on latency to drink in the 
novel cage are not µ-receptor mediated.  














































Figure 5.8. Effects of buprenorphine (Bup 1 mg/kg) and naltrexone (NTX 1 mg/kg), alone or 
in combination, in the mouse novelty induced hypophagia task. The latency to drink milk in 
both the home and novel cage environments is shown (n=9 per group). (A) The SSRI 
fluoxetine (20 mg/kg) was administered as a positive control in the new lighting condition ( 
500  lux). (B) The irreversible μ-antagonist CCAM (3 mg/kg) blocks the effects of 
buprenorphine (1 mg/kg) on latency to drink in the home cage, but not in the novel cage 
(n=9 per group). All values are the mean ± SEM. *p< 0.05, **p< 0.01 and ***p< 0.001 
compared to saline. ^^^p< 0.01 compared to buprenorphine alone. ### p< 0.001 for 







 5.7.3. Effects of combination buprenorphine/ naltrexone in the EPM 
and LDB 
 To determine an effective dose to use as a positive control, the 
effects of diazepam (1 and 2 mg/kg) in the EPM test were investigated 
(Figure 5.9, n=10 per group). One-way ANOVA, revealed significant effects 
of Treatment on the time spent in (F(2,26)= 3.76, p< 0.037), number of entries 
into (F(2,26) = 3.34, p<0.05) and distance travelled in (F(2,26)= 3.24, p< 0.05) 
the open arms. Within treatment comparisons to saline treated controls 
revealed that only the benzodiazepine diazepam (2 mg/kg) significantly 
increased these parameters (p<0.05). However, there was no significant 
difference in total locomotion between groups (p>0.05).  
 
The effects of buprenorphine (1 mg/kg), naltrexone (1 mg/kg), alone 
or in combination, and diazepam (2 mg/kg) are shown in Figure 5.10. 
Analysis of behaviours in the EPM, using one-way ANOVA, revealed 
significant effects of Treatment on the time spent in (F(4,45)=3.32, p< 0.05), 
number of entries into (F(4,45)=4.42, p<0.05) and distance travelled in  
(F(4,45)= 3.13, p<0.05) the open arms (Figure 5.10), n=10 per group). Within 
treatment comparisons to saline treated controls revealed that only the 
benzodiazepine diazepam (2 mg/kg) significantly increased these 
parameters (p<0.05). Neither buprenorphine nor naltrexone, alone or in 
combination, significantly affected behaviours in the EPM. Total ambulation 
in the EPM was not affected by drug treatment (F(4,45)=0.95 p=0.441), 














































































































































Figure 5.9. Effects of diazepam (1 and 2 mg/kg) in adult male CD1 mice in the elevated plus 
maze. The time spent in open arm  (A),  the number of entries into the open arm (B), total 
locomotion (C) time spent in the closed arm  (D)number of entries in the closed arm (E) 
distance travelled in open arm (F) was recorded.  Each column represents the mean ± SEM 
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Figure 5.10 Effects of buprenorphine (Bup 1 mg/kg), naltrexone (NTX 1mg/kg), alone or in 
combination and diazepam 2 mg/kg in the elevated plus maze. (A) The time spent in open 
arm (B) the number of entries into the open arms (C) distance travelled in the open arm (D) 
total locomotion (E) the number of entries into the closed arms (F) distance travelled in the 
open arm (F) was recorded.  Each column represents the mean ± SEM of 10 adult male 







In a separate group of mice, behaviours in the LDB task were 
examined. There were no significant effects of treatment with buprenorphine 
and naltrexone, alone or in combination on anxiety-related behaviours in the 
LDB (Figure 5.11, n=18 per group). One-way ANOVA revealed a significant 
main effect of Treatment on the time spent in the light (F(4,85)=3.02, p< 0.05) 
and dark (F(4,85) =2.81, p< 0.05) compartment. Within-treatment comparisons 
to saline controls showed that only diazepam (2 mg/kg) significantly 
increased the total time spent in the light compartment (p<0.05). As with the 
EPM, total ambulation in the LDB was not significantly affected by drug 
treatment (F(4,85)= 2.0, p= 0.102), confirming that locomotor effects were not 
a confound in these experiments. 
 
5.7.4. Effects of BU10119 in the FST 
The antidepressant-like potential of the novel compound BU10119 
was assessed in the FST. Analysis of behaviours after administration of 
BU10119 (1mg/kg) and buprenorphine/naltrexone (1 mg/kg) combination in 
FST, were compared to saline and to the positive control SSRI fluoxetine (20 
mg/kg) (figure 5.12A) (n=10). One-way ANOVA revealed a significant effect 
of Treatment on the time spent swimming (F(3,36)=6.58, p<0.001) and 
immobile (F(3,36)=7.02, p<0.001). Post hoc analysis to saline treated controls 
revealed that all drug-treated groups increased the time spent swimming and 
decreased the time spent immobile during in the last 4 minutes of the test 
(all p’s <0.001). There was no significant difference in time spent climbing 
between all groups (p>0.05).  
 
5.7.5. Effects of BU10119 in the NIH paradigm 
The effects of buprenorphine/naltrexone (1 mg/kg) combination and 
BU10119 (1 mg/kg), were compared with fluoxetine (20 mg/kg) and the       
к-antagonist norBNI (10 mg/kg) in the novelty induced hypophagia task 
(Figure 5.12B), n=10 per group). Two-way repeated measures mixed model 
analysis of the latency to drink times revealed significant main effects of 
Treatment (F(4,75)=6.13, p<0.001) and a significant Treatment*Environment 


































































Figure 5.11. Effects of buprenorphine (Bup1 mg/kg) and naltrexone (NTX 1 mg/kg), alone or 
in combination, in the light-dark box (LDB) (A–C). The benzodiazepine diazepam (2 mg/kg) 
was included as a positive control. The time spent in the light box (A), in the dark box (B) 
and total ambulation (C) in the LDB are shown (n=18 per group). All values are the mean ± 

















































Figure 5.12. (A) Behaviour in the forced swim test for adult CD-1 male mice treated with 
BU10119 (1mg/kg), buprenorphine/naltrexone (Bup/NTX) (1mg/kg) combination and 
fluoxetine (20 mg/kg). All values are the mean ± SEM (n=10 per group).***p <0.001 as 
compared to saline. The analysis was done by one-way ANOVA. (B) Effects of BU1019 
(1mg/kg) and buprenorphine/naltrexone (1 mg/kg) combination in the mouse novelty 
induced hypophagia task. The SSRI fluoxetine (20 mg/kg) was administered as a positive 
control and the selective κ-antagonist norBNI (10 mg/kg) shown for comparison. All values 
are the mean ± SEM (n=10 per group). ***p< 0.001 compared to saline. ###p< 0.001 for 








treated controls revealed that all drug-treated groups decreased latency to 
drink milk in a novel cage (all p’s <0.001). Also, the novel cage was aversive 
by increasing the latency to drink milk in saline control mice (Mean latency 
value = 7.32± 0.94 minutes, 300 lux) as compared to the home cage (Mean 
latency value = 0.48± 0.10 minutes) (p<0.001).  
 
5.7.6. Effects of BU10119 in the EPM and LDB 
In the EPM, one-way ANOVA, showed significant effects of Treatment 
on the time spent in (F(3,36)=3.29, p<0.05), number of entries into                    
(F(3,36)=3.89, p<0.01) and  distance travelled in (F(3,36)= 3.48, p<0.05) the 
open arms (Figure 5.13, n=10 per group). Post hoc comparisons to saline 
treated controls revealed that only the benzodiazepine diazepam (2 mg/kg) 
significantly increased these parameters (p<0.01). Interestingly, both 
buprenorphine/naltrexone (1 mg/kg) combination and BU10119 (1 mg/kg) 
did not show any significant changes in behaviours in the EPM. Total 
ambulation in the EPM was not affected by drug treatment (F(3,36)=1.15 
p=0.342), showing an absence of any sedative effects. 
 
In the LDB there were no significant changes of treatment with 
BU10119 (1 mg/kg) and the combination of buprenorphine/naltrexone            
(1 mg/kg) (Figure 5.14, n=18 per group). One-way ANOVA revealed 
significant main effects of Treatment on the time spent in the light 
(F(3,60)=3.59, p<0.01) and dark F(3,60)=3.59, p<0.01) compartment. Within-
treatment analysis to saline controls showed that only diazepam (2 mg/kg) 
significantly increased the total time spent in the light compartment (p<0.01). 
As with the EPM, total ambulation in the LDB was not significantly affected 
by drug treatment (F(3,60)= 1.26, p= 0.29), which shows that these drugs were 
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Figure 5.13. Effects of buprenorphine/naltrexone (Bup/NTX) (1 mg/kg) combination, 
BU10119 1mg/kg and diazepam 2 mg/kg in the elevated plus maze. (A) The time spent in 
open arm (B) the number of entries into the open arms (C) distance travelled in the open 
arm (D) total locomotion (E) the number of entries into the closed arms (F) distance 
travelled in the open arm (F) was recorded. Each column represents the mean ± SEM of 10 











































































Figure 5.14. Effects of BU10119 (1mg/kg) and buprenorphine/naltrexone (1 mg/kg) 
combination in the light– dark box. The benzodiazepine diazepam (2 mg/kg) was used as a 
positive control. The time spent in the light box (A), in the dark box (B) and total ambulation 
(C) in the LDB are shown (n=18 for buprenorphine/naltrexone, saline and DZP, n=10 for 









This is the first study to show that the systemic co-administration of 
buprenorphine (1 mg/kg) with naltrexone (1 mg/kg) in adult male CD-1  mice, 
produced an antidepressant-like response in behaviours in both the FST and 
NIH test. The novel compound BU10119 (1 mg/kg),  also decreased the time 
spent immobile in the FST and decreased the latency to drink in the novel 
cage in NIH task, indicating an antidepressant-like behaviour. These data 
indicate that these drugs have potential as antidepressant. Interestingly, the 
combination of buprenorphine with naltrexone and BU10119 were without 
significant effect on anxiety-related behaviours in the EPM and LDB.   
 
Behavioural paradigms used in this thesis to assess the 
antidepressant and anxoyltic-like effects of the combination regimen and 
novel compound BU10119 were validated by using the positive controls 
fluoxetine and diazepam. Indeed,  fluoxetine at the acute and high dose ( 20 
mg/kg) reduced the immobility and increased the swimming time in FST, 
which was in agreement with the previous studies that reported fluoxetine 
anti-immobility in FST in adult CD-1 male mice, only  at high doses 
(DeGraafet al., 1985; Cesana et al., 1993; Da-Rocha et al., 1997; Sánchez 
and Meier, 1997). Moreover, fluoxetine was effective in reducing latency to 
drink condensed milk in a novel environment in NIH, which was in 
agreement with previous studies (Dulawa et al., 2004; Dulawa and Hen, 
2005; Surget et al., 2008). However, in these studies fluoxetine was given 
chronically but in our study it was given acutely. Also, citalopram, the SSRI, 
was effective only when it was repeatedly given (3 injections of citalopram; 
10mg/kg, i.p. over 24 hours) in NIH in mice (Mombereau et al., 2010). The 
discrepancies between our result, Mombereau et al (2010) and other studies 
can be explained by the differences in the route of administration, strain, 
species variability and in the SSRI used which limit the comparison between 
these studies. Also, Balu et al (2009) reported a notable difference in the 
sensitivity to chronic administration of fluoxetine between C57Bl/6J and 
MRL/MpJ mice in the NIH paradigm. In their study, 21 days of treatment with 





it significantly changed the behaviour in MRL/MpJ mice. Moreover, SSRI, 
when given acutely, may have some anorectic activity which can be seen in 
some strains and species which may explain the increase in latency to 
approach food in this paradigm. The anorectic activity could disappear after 
adaptation with chronic administration, and that could explain why some 
SSRI work only after chronic administration. Indeed, acute administration of 
SSRI, such as sertraline, has been reported to decrease food intake in the 
rat (Grignaschi et al., 1998; Lucki et al., 1988).  
 
In our study, the classical benzodiazepine, diazepam (2 mg/kg) was 
used to validate the behavioural paradigms used to assess anxiety related 
behaviours. Diazepam effects were in agreement with previous studies 
which reported the increase in the time spent in open arm in the EPM 
(Pellow et al., 1985; Rodgers et al., 1995; Walf and Frye, 2007) and  
increase in the time spent in the light compartment in the LDB in mice 
(Crawley, 1981; Imaizumi et al., 1994, b; Hascoët et al., 2001). 
 
In this chapter, our data are consistence with the previous studies that 
reported that the к-antagonists GNTI, norBNI and ANTI have shown 
antidepressant-like effects (Newton et al., 2002; Mague et al., 2003; 
Shirayama et al., 2004; Carr et al., 2009) when measured in FST. Moreover, 
it has been demonstrated that к-antagonists such as norBNI, GNTI and 
JDTic decrease anxiety-like behaviours in mouse tests in EPM (Wittmann et 
al., 2009; Jackson et al., 2010; Van’T and Carlezon, 2013; Hang et al., 
2015). Moreover, it has been reported that the к-antagonists 2- (3,4-
dichlorophenyl)- N-methyl-N- [(1S)- 1-(3-isothiocyanatophenyl)- 2-(1-
pyrrolidinyl) ethyl]acetamide hydrochloride (DIPPA) produced anxiolytic-like 
effects in NIH in the rat (Carr and Lucki, 2010). Also, they reported that the 
anxiolytic-like effects of DIPPA were obvious after acute treatment which is 
with an agreement with our result. 
 
In this thesis, buprenorphine, a partial µ-receptor agonist and a к-





Previously, buprenorphine has been shown to have antidepressant effects in 
depressed patients (Emrich et al., 1982) and treatment-resistant depressed 
patients (Bodkin et al., 1995; Karp et al., 2014). A number of preclinical trials 
have also demonstrated antidepressant effects of µ-receptor agonist 
activation. Endogenous enkephalins and endorphins reduced immobility and 
increased the activity of swimming in rats (Kastin et al., 1978). In the mouse 
tail suspension test endomorphins (Fichna et al., 2007), morphine, codeine 
and other agonists reduced the time spent immobile (Berrocoso et al., 2013). 
More recently, low doses of buprenorphine (0.25 mg/kg and 0.5 mg/kg) have 
been shown to have antidepressant-like effects in the NIH and FST in 
C57BL/6 J mice (Falcon et al., 2015). Moreover, Falcon et al (2016) reported 
that buprenorphine did not reduce immobility in mice with к-receptor deletion 
or after pretreatment with norBNI. In contrast, buprenorphine reduced 
immobility in µ-receptor and δ-receptor knockout mice and in mice 
pretreated with the ORL-1 antagonist JTC-801. They concluded that the к-
receptor plays an important role in facilitating the effects of buprenorphine in 
tests sensitive to antidepressant drugs in mice. Our data with the selective 
irreversible µ-receptor antagonist CCAM supports this idea. In both the FST 
and NIH task, blockade of µ-receptors did not affect the antidepressant-like 
response produced by treatment with buprenorphine indicating that these 
effects are mediated via к-receptors, rather than µ-receptors. 
 
In this study, it was shown that naltrexone alone produced a 
significant antidepressant-like effect in the FST and NIH paradigm. This was 
somewhat surprising since naltrexone is often reported to have aversive 
effects. Naltrexone is a relatively non-selective opioid receptor antagonist, 
with a higher affinity for µ- rather than к-receptors (Giordano et al., 1990). 
Hence, it was anticipated that naltrexone would reduce buprenorphine’s 
activation of µ-receptors while enhancing its к-receptor antagonist actions. 
Also, it was previously shown that mixed µ-к-receptor antagonists produce 
both antidepressant and anxiolytic effects in adult CD-1 male mice (Casal-
Dominguez et al., 2013). In healthy overweight volunteers, a daily 200 mg 





10 week period (Malcolm et al., 1987). However, in opioid-dependent 
patients, with a high baseline affective burden, depot naltrexone treatment 
produced a significant improvement in depression scores (Mysels et al., 
2011). Perhaps there is therapeutic potential for exploiting the mixed, 
relatively nonselective opioid receptor antagonists as antidepressant 
treatments, especially in patients with comorbid substance misuse and mood 
disorders (Pettinati et al., 2013). Indeed, the antidepressant potential of 
buprenorphine and naltrexone arises from studies of this combination as a 
treatment for opioid dependence (Gerra et al., 2006; Rothman et al., 2000). 
Naltrexone is well established as a treatment for opioid and alcohol 
dependence, but patient compliance is low. Possible reasons for low 
adherence include the aversive side effects of naltrexone treatment and the 
fact that naltrexone has little effect on anhedonia symptoms associated with 
opioid withdrawal (Bouza et al., 2004; Gerra et al., 2006). The combination 
of naltrexone (50 mg oral dose) plus buprenorphine (4 mg sublingual) 
improves mood and reduces the intensity of dysphoria, leading to improved 
retention of addicts in treatment (Gerra et al., 2006; Rothman et al., 2000). 
These authors have suggested that this drug combination produces к- 
receptor antagonism which improves mood states.   
 
One important caveat with our findings is that they are based on 
mouse behavioural paradigms. The forced swim test is not a model of 
depression but is a well-validated and well-established behavioural task for 
assessing acute antidepressant efficacy (Cryan et al., 2002; Petit -
Demouliere et al., 2005). Interestingly, in the FST, antidepressants that 
target the serotonergic system increase swimming behaviour, whereas those 
that target noradrenergic systems increase climbing behaviour, thereby 
decreasing immobility (Detke et al., 1995). In our experiments, 
buprenorphine/naltrexone combination and BU10119 treatment decreased 
immobility with a concomitant increase in swimming behaviour, without an 
effect on climbing behaviour. This may indicate that serotonergic pathways 
are implicated in the opioid-mediated antidepressant effects seen here, as 





argued that the FST has limited predictive validity and that behavioural 
paradigm responding to chronic antidepressant treatments have greater 
validity (Mitchell and Redfern, 2005). The novelty induced hypophagia task 
is a procedure that has been developed to assess anxiety-related 
behaviours but has been shown to be sensitive to the chronic anxiolytic 
effects of antidepressants in rodents (Dulawa and Hen, 2005). In our study, 
the combination of buprenorphine and naltrexone and the single compound 
BU10119 have been shown to have antidepressant-like effects in both the 
FST and the NIH test in adult CD-1 male mice. Further studies are required 
to assess whether buprenorphine/ naltrexone and BU10119 have any utility 
in animal models of depressive symptoms such as the Flinders Sensitive 
Line rat or the chronic unpredictable mild stress model (Overstreet and 
Wegener, 2013; Monteiro et al., 2015).  
 
Anxiety-related behaviours have been reported to be regulated by the 
dynorphin к-receptor system. For example, dynorphin-induced significant 
anxiogenic-like effects in mice in the LDB and EPM (Narita et al., 2006), 
while к-antagonists produced acute and persistent anxiolytic-like effects 
(Knoll et al., 2007). Interestingly, buprenorphine, over a similar dose range 
used here (0.3, 1 and 3 mg/kg) has been reported to show anxiogenic 
effects in NMRI mice in the LDB test (Lelong-Boulouard et al., 2006). 
However, in our experiments there was no evidence of buprenorphine’s 
reported anxiogenic effects. On the contrary, in the LDB, there was an 
apparent trend for buprenorphine (and buprenorphine/naltrexone 
combination) to increase the time spent in the lit compartment although 
these results did not achieve statistical significance. The absence of a robust 
anxiolytic-like response for both combination treatment and BU10119 in the 
EPM and LDB was surprising but this may be because the mice were not 
sufficiently stressed in these paradigms to activate dynorphin release and 
alter anxiety behaviours (Shirayama et al., 2004; McLaughlin et al., 2006b; 
Wittmann et al., 2009). Hyponeophagia, such as tested in the novelty 
induced hypophagia task, is an anxiety-related measure that is sensitive to 





benzodiazepines and SSRIs (Dulawa and Hen, 2005). Both acute and 
repeated administration of low dose buprenorphine has recently been shown 
to reduce the latency to approach food in a novelty induced hypophagia task 
(Falcon et al., 2015). The NIH test is a conflict-based anxiety test where the 
aversive novel cage environment suppresses the approach to a highly 
palatable food. The demonstration of an effect of combination 
buprenorphine/naltrexone and the single compound BU10119 in the novelty 
induced hypophagia task, but not in EPM and LDB, supports the potential of 
к-receptor antagonists in stress-related tasks (Cryan and Sweeney, 2011). 
Indeed, Huang et al (2016) investigated the short-acting к-receptor 
antagonists effects of zyklophin and LY2444296 in the NIH and EPM tests in 
mice 1 h postinjection and compared with norBNI (10 mg/kg) 48 h post-
administration. In the NIH test, norBNI (10 mg/kg), zyklophin at 3 and 1 
mg/kg, or LY2444296 at 30 mg/kg reduced the latency of palatable food 
consumption in novel cages. In the EPM test, norBNI (10 mg/kg) increased 
open arm time and % open arm entries or time, but zyklophin at all doses 
and LY2444296 (30 mg/kg) had no effects. They concluded that all three к-
antagonists had anxiolytic-like effects in the NIH test. However, only the 
long-acting one norBNI showed anxiolytic-like effects in the EPM test. Their 
results are quite similar to our study.  
 
In summary, systemic co-administration of buprenorphine (1 mg/kg), 
naltrexone (1 mg/kg) or in combination and BU10119 (1 mg/kg) in adult     
CD-1 male mice have antidepressant-like effects in behaviours in both the 
FST and NIH test and these effects are possibly mediated through к-
receptors, suggesting that these drugs have potential as an antidepressant. 
However, all drug treatment were without significant effect on anxiety-related 
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6.1. Introduction  
Stress can be defined as a nonspecific reaction to internal and 
external environmental stressors that might affect the body and is usually 
accompanied by several cognitive, physiological and psychological changes 
(Li et al., 2012). Indeed, several studies have reported that stress exposure 
may increase the risk of developing depression and anxiety in humans 
(Mazure, 1998; Blazer and Hybels, 2005; Hammen, 2005). To induce stress 
responses in animals, different models have been established. One of them, 
restraint stress is widely used and well accepted as a model of stress in 
rodents, as it is painless and does not cause physical harm to the animals 
(Buynitsky and Mostofsky, 2009). In addition, acute restraint produces 
several emotional and autonomic responses that include increase in mean 
arterial pressure and heart rate (Walker et al., 2003). Moreover, it has been 
reported that rodents subjected to restraint suffer from behavioral changes 
such as decreased exploratory activity in an open field (Kennett et al., 1985), 
decreased exploration of the open arms of an EPM (Guimaraes et al., 1993) 
and increased immobility in a FST (Sevgi et al., 2006). In addition, it was 
reported that rats exposed to a 21-day-long stress protocol, including 
immobilization, electric shocks, swimming in cold water, suffer from a 
reduction in sucrose intake, which is a model of anhedonia and a major sign 
of depression (Katz, 1981). Moreover, Strekalovae et al (2004) reported that 
chronic restraint stress in mice caused a significant decrease in sucrose 
preference, an  increase in the immobile time in the FST and that stressed 
mice spent less time in the open arms of the zero-maze and in the lit 
compartment of the dark/light box in comparison to control mice. Restraint 
stress also induces unconditioned and unavoidable neuroendocrine 
responses, such as increase in plasma corticosterone in rat (Kennett et al., 
1985) and mice (Rademacher et al., 2008; Sadler and Bailey, 2013). 
Moreover, mice when exposed to stress showed an increase in the 
dynorphin secretion and к-receptor activation in several brain areas (Bruchas 
et al., 2007a), and pretreatment with the selective к-receptor antagonist nor-






Several limbic brain regions have been recognized to be involved in 
mood disorders that include the PFC, NAc, Amy, and Hip (McEwen, 1999; 
Newton et al., 2002; Shirayama et al., 2004; Pandya et al., 2012; Falcon et 
al., 2016). For example, the Hip is sensitive to stress due to the high levels 
of glucocorticoid receptors expressed in this area (McEwen, 1999). It has 
been reported that stress leads to neurochemical as well as structural 
changes in the Hip in animal models (McEwen, 1999; Duman et al., 2001). 
Moreover, these structural changes might be similar to the atrophy of Hip 
observed in brain imaging studies of depressed patients (Sheline et al., 
1996; Bremner et al., 2000). Many studies have shown that the 
antidepressant treatment can decrease the atrophy of Hip, as well as the 
cognitive impairments in depressed patients (Riedel et al., 2002; Sheline et 
al., 2003; Vermetten et al., 2003). Another example, microinfusions of 
norBNI into the NAc produced antidepressant-like effect that implicates the 
importance of this brain region in mood disorders (Newton et al., 2002). 
Also, it has been reported that the к-receptor, Pdyn and CRHR1 receptors 
are expressed in these area and play an important role in mood disorders 
during stress conditions (DePaoli et al., 1994; Kitchen et al., 1997; Lin et al., 
2006; Mansour et al., 1994; Falcon et al., 2016). Indeed, it was reported by 
Falcon et al (2016) that the exposure to unpredictable chronic mild stress for 
3 weeks and chronic buprenorphine treatment caused region-specific 
changes in the mRNA expression of к-receptor and Pdyn, emphasizing the 
potential role of opioid in the treatment of mood disorders. They reported 
that chronic stress significantly altered opioid gene expression in a number 
of brain regions (к-receptor increased in striatum and decreased in Amy and 
reduced Pdyn in Hip). Interestingly, buprenorphine reversed the effects of 
chronic stress in some regions (к-receptor in FC and striatum and Pdyn 
receptors in FC and Str) which shows the possible interactions between 









6.2. Chapter aims 
The aim of this chapter was to investigate whether 
buprenorphine/naltrexone (1 mg/kg) and BU10119 (1 mg/kg) were able to 
block stress-induced effects. Different approaches were taken to assessing 
the effects of stress with and without drug treatment: measurement of 
plasma corticosterone, development of stress-induced analgesia (SIA), 
investigating anxiety and depression-related behaviours, and gene 
expression analysis. The stressor used was a 2h restraint stress 






























6.3.1. Restraint Stress  
Adult CD1 mice in restraint-stressed groups were restrained by a well-
ventilated modified 50 ml syringe tube for 2 h for one or three consecutive 
days from 09:00-11.00 h and they were unable to move forwards or 
backwards (Poleszak et al., 2006; Sadler and Bailey, 2013). At the end of 2 
h restraint mice were returned to their home cage or blood samples taken 
(section 6.3.2). Stressed mice were daily monitored for signs of stress using 
a scoring system adapted from Lloyd and Wolfensohn, (1999) (see 
appendix). All mice were weighed daily immediately prior to being placed in 
the restraint tube. Non-stressed control mice were weighed daily and 
returned back to their home cage. 
 
6.3.2. Measurement of corticosterone level 
All blood samples of mice were collected at baseline (24 h before 
restraint) and immediately following the end of restraint stress. Blood 
samples, 40 µl, were taken from lateral tail vein between 11:00-13:00 h. 
Heparinised capillary tubes (Hawksley, Sussex, UK) were used to collect 
blood samples. Blood was collected in centrifuge tubes containing  
Ethylenediaminetetraacetic acid (EDTA) (2.5 µl) and kept on ice until being 
centrifuged for 20 min at 4°C at 2000 rcf. Plasma was taken and stored at -
20°C until analysis. ELISA, which is enzyme-linked immunosorbent assay, 
(IBL International, Hamburg, Germany), was used to determine the level of 
corticosterone according the manufacturers protocol (Sadler and Bailey, 
2013). 
 
ELISA Kit contains the following materials: 
1. Microtiterwells, 12 x 8 (break apart) strips, 96 wells coated with an anti-
Corticosterone antibody (polyclonal). 
2. Standard (Standard 0-6), 7 vials, 1 mL, ready to use; Concentrations: 0, 5, 
15, 30, 60, 120, 240 nmol/L. 





4. Enzyme Conjugate 250X Concentrate, 1 vial, 150 μL; Corticosterone 
conjugated to horseradish Peroxidase.  
5. Conjugate Diluent, 1 vial, 25 mL, ready to use. 
6. Substrate Solution, 1 vial, 25 mL, ready to use; Tetramethylbenzidine. 
7. Stop Solution, 1 vial, 14 mL, ready to use.  
8. Wash Solution, 1 vial, 30 mL (40X concentrated). 
 
Before the beginning of the measurement, all reagents and required 
number of strips were brought to the room temperature before use. The 
plasma specimens were diluted to 1/10 dilution with Standard 0. Also, 
dilution of 30 mL of concentrated wash solution with 1170 mL deionized 
water to a final volume of 1200 ml was made. In addition, dilution of 100 μL 
enzyme conjugate with 25 mL conjugate diluent was made, to cover the 
whole plate. Then, 20 μL of each standard, control and samples were added 
into the appropriate wells. Followed by dispensing 200 μL enzyme conjugate 
into each well. Then, the strips were thoroughly mixed for 10 seconds. Then 
they were incubated for 60 minutes at room temperature. Followed by 
rapidly shake out and removing the contents of the wells. Then the wells 
were rinsed with diluted wash solution 3times (400 μL per well). The wells 
were sharply struck on absorbent paper to remove residual droplets. 100 μL 
of substrate solution were added to each well. They were incubated for 15 
minutes at room temperature. Then the enzymatic reaction was stopped by 
adding 50 μL of stop solution to each well. Finally, the reading were 
recorded at 450 ± 10 nm with a microtiter plate reader within 10 minutes 
after adding the stop solution was done. 
 
6.3.3. Assessing stress-induced analgesia by warm water tail-
withdrawal test 
The warm water tail-withdrawal test was carried out according to the 
method used previously in chapter 3.2.1. It was used to assess stress-
induced analgesia (SIA), after repeated restraint stress for 3 consecutive 
days (Figure 6.1). norBNI (10 mg/kg) was given once 24 h before the first 





the first and third day of restraint. BU10119 (1 mg/kg) or 
buprenorphine/naltrexone (1 mg/kg) combination was given daily 1h before 
restraint, naltrexone (1 mg/kg) was injected 10 minutes prior to 
buprenorphine. Tail-withdrawal latency was measured 5 minute after 
restraint ended in the first and third day.  
     










Figure 6.1. Time-line of the warm water tail-withdrawal experimental design, illustrating the 




6.3.4. Behavioural testing 
Behavioural testing in the EPM, SPT and FST occurred on day one 
and day three following 2 hr from the end of restraint (Figure 6.2 A-B). In 
addition, all blood samples of mice were collected at baseline (24 h before  
restraint) and immediately following the end of restraint stress. Separate 
groups of mice were used for each behavioural test. In addition, behavioural 
testing was done in different room to restraint stress room. 
 
6.3.4.1. Forced swim test (FST) and elevated plus maze (EPM) 
FST (section 5.5.1) and EPM (section 5.5.3) were carried out as 
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Figure 6.2. (A) one day and (B) 3 days time-line of the restraint stress protocol used. The 
time points of daily restraint, blood sampling and behavioural testing when assessing 
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6.3.4.2. Sucrose preference test (SPT) 
Before the last day of restraint, mice were habituated to drinking from 
2 bottles of water, for 12h (7pm-7am). The following day, mice were given 
the choice to drink either water or 1, 2.5 or 5% w/v sucrose during a 12h test 
(7pm-7am). Bottles were weighed before and after the test, and the 
preference for sucrose was determined as a percentage of the total volume 
consumed. (Lewis et al., 2005). 
 
6.3.5. Gene expression 
The effects of 3 days of repeated restraint stress in the absence and 
presence of  BU10119 (1 mg/kg) or buprenorphine/naltrexone (1 mg/kg) 
combination, (given daily 1h before restraint, on gene expression of к-
receptor, prodynorphin and CRHR1 in PFC, NAc, Hip and Amy were 
assessed. Moreover, norBNI (10 mg/kg) was given once 24 h before 
restraint. Also, naltrexone (1 mg/kg) was injected 10 minutes prior to 
buprenorphine. 
     
6.3.5.1. Brain dissection  
Mice were killed by cervical dislocation with subsequent decapitation 
after 2 hr of restraint stress ended, starting from 13 PM. The whole brain was 
removed immediately and kept on dry ice.  Dissection of the prefrontal cortex 
was done by making a coronal cut of the anterior part of the brain and the 
olfactory bulb was removed with a razor blade. The mouse brain atlas was 
used as a reference for brain regions (Paxinos and Franklin, 2001). This was 
followed by cutting coronal slices and by using multiplex biopsy punch with a 
tissue punch tool (diameter 2.0 mm) (Miltex GmbH-Japan) then NAc, Hip 
and Amy were collected from each hemisphere. All microdissection 
procedures were done on dry ice. All samples were stored at -80°C. 
 
6.3.5.2 RNA isolation  
TRIzol (Ambion) reagent was used according to the manufacturer’s 
protocol for the isolation of high quality RNA from mouse brain tissue. 





with a pellet pestle (Sigma). A further 0.5ml of TRIzol was added and the 
homogenate was passed through a 23G needle (BD Microlance, Fisher) (A 
total of 1ml TRIzol per 50-100mg tissue were used). Then 20µl of glycogen 
(1mg/ml) were added to the samples and briefly mixed. Homogenized 
samples were then left to stand for 5 min at room temperature, before 200μl 
of chloroform was then added in a fume hood. Tubes were shaken 
vigorously for 15 s and then left to incubate at room temperature for 2-3 min. 
The samples were subsequently centrifuged at 12,000rpm for 15 min at 4°C. 
In a fume hood, the upper aqueous phases (≈50% of total volume) were 
taken into a new tube. Then, the RNA was precipitated by adding 0.5ml of 
100% propanol per 1ml TRIzol used and incubated at room temperature for 
30 min. After centrifugation (at 12,000rpm for 15 min at 4°C) for 15 min, the 
supernatant was removed and 1ml of 75% ethanol (Fisher) was added to 
wash the RNA pellet. Eppendorfs were centrifuged at 7500 rpm for 5 min at 
4°C and the liquid was removed, leaving the RNA pellet to air dry (5- 10 
min). The air-dried RNA pellet was resuspended in 30μl of RNAse-free water 
and samples incubated at 55-60°C for 15 mins. To remove DNA 
contamination of RNA, a DNAse digest was carried out: 4µl 10X Reaction 
Buffer, 1µl RNAsin (40U/µl, Fermentas), 4µl DNAse (1U/µl, Fermentas) and 
1 µl RNAse free water. Then sample were centrifuged for 15 mins at 12000g 
at 4°C. Then the supernatant was removed and the pellet was washed with 
250µl of 75% ethanol and vortexed. Samples were centrifuged for 5 mins at 
12000g at 4°C then supernatant was removed and the pellet was left to air 
dry for 15 mins at 37°C (completely dry). Then pellet was resuspended in 
20µl RNAse free water and stored at -80°C.  
 
6.3.5.3. One step reverse transcription PCR (RT-PCR) 
To confirm the presence of our genes of interest (GOI) in non-
stressed adult CD-1 male mice in PFC, Hip, NAc and Amy one-step RT-PCR 
(Invitrogen) was done with the gene specific primers (Sigma) shown in Table  
6.1. One-step RT-PCR reactions were performed using Superscript™ One-
Step RT-PCR with ®PlatinumTaq (Invitrogen) according to the 





quantities for each PCR reaction were as follows: 12.5μl 2X Reaction Mix 
containing 0.4mM of each dNTP, 24mM MgSO4, 10.1μl RNA-free water, 
0.4μl of RT/Platinum Taq Mix, which equal 23 ml into 0.2ml PCR tubes then 
and 1μl template RNA (0.1μg/μl), forward and reverse primers (0.5μl at 
10μM) were added. Master mix with primers were mixed with a pipette, 
before being placed in the PCR machine (DNA Engine Peltier Thermal 
Cycler, PTC-200, MJ Research). Positive controls were made by amplifying 
the housekeeper gene ribosomal RNA (18s rRNA). Also, no template 












к-receptor F: GTGGGCTTAGTGGGCAATTCT R:GTGGTAGTAACCAAAGCATCTG 120 
 
Primer Bank 
Prodynorphin F: CTCCTCGTGATGCCCTCTAAT R: AGGGAGCAAATCAGGGGGT 110 
 
Primer Bank 
















Table 6.1: Gene-specific forward and reverse primers for GOI. Forward and reverse primers 
sequences were derived Basic Local Alignment Search Tool (BLAST) analysis to confirm 
the presence of the correct amplicon and expected amplicon size (in base pairs). Primers 
were used for both one-step RT-PCR and real-time RT-PCR.  
 
Conditions for one-step reverse transcription PCR amplification are 
shown in table 6.2.  
 
 
A: cDNA synthesis 
and pre-denaturation B: PCR amplification C: Final extension 
 
Perform 1 cycle of:  
50°C for 30 minutes  
94°C for 2 minutes 
 
Perform 40 cycles of: 
Denature, 94°C for 15 seconds 
Anneal, 60°C for 30 seconds 
Extend, 72°C for 1 minute/kb 
 
1 cycle of 72ºC for 5 minutes  
 
 








Then PCR products were electrophoresed on a 1.2% agarose gel 
(110 min at 85 mV). GeneSnap (SynGene, 3.00.15) software was used to 
capture gel pictures. 
 
6.3.5.4. Quantitative real-time RT-PCR 
Quantitative real-time RT-PCR was done using SYBR green detection 
in a two-step process to quantitatively measure the expression of our GOI in 
mouse brain regions. First step was done by, reverse transcribing the 
template RNA into cDNA using the Applied Biosystems™ High-Capacity 
cDNA Reverse Transcription Kit. This was accomplished by adding 2.0μl of 
10X RT buffer, 0.8μl of 25✕ dNTP Mix (100 mM) and 2μl 10✕ RT Random 
Primers random, 1μl MultiScribe™ Reverse Transcriptase,0.25 μl RNase 
Inhibitor(Ribolock 40U/ µl), 11.45μl of RNA-free water and 2.5μl of RNA 
(0.1μg/ μl ) in PCR tubes. The resulting mixture was pipetted up and down 
several times to mix. Then the tubes were incubated and following thermal 
condition were used: 
 
A: cDNA synthesis 
and pre-denaturation B: PCR amplification C: Final extension 
 
Perform 1 cycle of:  
50°C for 30 minutes  
94°C for 2 minutes 
 
Perform 40 cycles of: 
Denature, 94°C for 15 seconds 
Anneal, 60°C for 30 seconds 
Extend, 72°C for 1 minute/kb 
 
1 cycle of 72ºC for 5 minutes  
 
 
Then the samples were diluted in 450µl (20 µl cDNA+430 Nuclease-free 
water) and stored at -20ᵒC or second step was started.   
 
Diluted cDNAs (9.2μl = 5 ng cDNA/ reaction) were added to a 
reaction mix containing GOI-specific forward and reverse primers (0.4μl at 
10μM) and 10µl of SYBR green PCR mastermix (Applied Biosystems). The 
housekeeper genes 18 s rRNA was also amplified. To control against non-
specific amplification, a no template control was created by the absence of 
cDNA template in the reaction mixture. All mixtures were vortexed and 
centrifuged at 4000rpm for 20 s at 4°C, before insertion into the real-time 






The real-time RT-PCR amplification conditions for к-receptor, 
prodynorphin, CRHR1 and 18s rRNA gene were: 95°C for 10 minutes, 
followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. This 
was followed by melt curve analysis to check the specificity of the primers 
and amplified PCR product. 
 
6.4. Analysing quantitative real-time RT-PCR Data 
The exponential amplification of PCR products, known as the 
crossing point or threshold cycle (CT) number, was automatically 
calculated using Applied Biosystems-StepOne Software v2.1. Gene 
changes were quantified using the comparative threshold cycle method (2 -
ΔΔCt). Firstly, ΔCT is calculated by normalizing the threshold cycle number 
of the GOI to the housekeeping gene 18s rRNA. The ΔCT value is 
calculated by for example, subtraction of the average expression levels of 
a target CT value from the sample of the average housekeeping gene (18s 
rRNA) CT value. Then, the difference between the averaged ΔCT of  
stressed treated or stressed non-treated tissue from the averaged ΔCT of 
control tissue gives ΔΔCT and is subsequently transformed to the equation 
2 -ΔΔCt (Schmittgen et al., 2000).  
 
6.5. Statistical analysis 
All data were analyzed using two-way repeated measures mixed 
model analysis or single measures one-way ANOVA followed by 
Unadjusted Least Significant Difference (ULSD) post hoc test. In some 
cases unpaired student t-test were used (Invivostat 2.3). Only planned 
pairwise tests were carried out and p values adjusted for multiple 
comparisons with Benjamin-Hochberg correction. Values are reported as 










6.6. Result  
6.6.1. Acute and repeated restraint stress increase plasma 
corticosterone level 
Exposure to 1 and 3 days restraint stress increased plasma 
corticosterone level (Figure 6.3). At 1 and 3 days, two-way repeated 
measures mixed model analysis revealed that there were no significant 
differences between control and stressed groups in baseline plasma 
corticosterone measures (p>0.05, n=8). However, post hoc comparison 
showed  that 1 day restraint exposure significantly increased (≈1000%) 
plasma level of corticosterone as compared to baseline levels (F(1,8)=38.59, 
p<0.001). Similarly, 3 days restraint produced a 900 % significant increase in 
corticosterone, as compared to baseline levels (F(1,12)=54.8, p<0.001). 
 
  The ability of к-receptor antagonists to block restraint stress induced 
increase in plasma corticosterone were investigated (Figure 6.4). Two-way 
repeated measures mixed model analysis revealed that there was no 
significant difference (between control and stressed groups) in baseline 
plasma corticosterone levels (p>0.05). However, following 3 days of restraint 
stress, there was a significant effect of stress on plasma corticosterone level 
of all treated groups compared to control non-stressed (F(4,21)=13.14, 
p<0.001). Neither buprenorphine/naltrexone nor BU10119 were able to block 
stress-induced increase in corticosterone (p>0.05). while norBNI ( 10 mg/kg) 
appeared to attenuate stress-induced corticosterone level, this effect was 
not significant. 
 
6.6.2. Effects of acute and repeated restraint stress on analgesia  
In preliminary studies, stress-induced analgesia was evaluated after 
1 and 3 days of restraint stress by using tail withdrawal assay (Figure 6.5). 
Two-way repeated measures mixed model analysis revealed that there 
was a significant interaction of Treatment*Time (F(1,3)= 12.86, p<0.001, 
n=8). The restraint stress paradigm used produced a significant increase 






The ability of к-receptor antagonists to block stress-induced 
analgesia was subsequently investigated (Figure 6.6). Two-way repeated 
measures mixed model analysis revealed that there was a significant 
interaction of Treatment*Time (F(12,75)= 23.3, p<0.001). Stress-induced 
analgesia was evident after both 1 and 3 days restraint stress with a 
significant  increase in the latency to withdraw the tail as compared to non-
stressed mice (p<0.001). Interestingly, BU10119 (1 mg/kg), 
buprenorphine/naltrexone (1 mg/kg) combination and norBNI (10 mg/kg) 
were able to block stress-induced analgesia (p<0.001) caused by both 1 















































Figure 6.3. Effect of 1 day (A) and three day (B) repeated restraint stress (09:00-11:00) on 
plasma corticosterone of CD1 male mice. All blood samples were taken from 11:00-13:00 h. 
Results are expressed as mean ± SEM, n=8. ***p<0.001 as compared to control. 
###p<0.001 as compared to baseline stress group. Analysis done repeated measures 
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Figure 6.4. Effect of three-day restraint stress (09:00-11:00) and buprenorphine/naltrexone 1 
mg/kg (Bup/NTX), BU10119 (1 mg/kg) and norBNI (10 mg/kg) on plasma corticosterone of 
adult male CD1 mice. norBNI was given once and 24 h before the first restraint stress 
session. All blood samples were taken from 11:00-13:00 h. Results are expressed as mean 
± SEM, n=8. **p<0.01, ***p<0.001 as compared to non-stressed saline.  ##<0.001 
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Figure 6.5. (A) Effect of 1 day and 3 day restraint stress (09:00-11:00) on stress-induced 
analgesia in CD1 male mice. (B) Baseline latency on day 3. Results are expressed as mean 
± SEM, n=4. ***p<0.001 as compared to non-stressed controls. Analysis done repeated 
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Figure 6.6. Effect of one day and three-day restraint stress (9-11am) on stress-induced 
analgesia in CD1 male mice. All drug treatments tested blocked stress-induced analgesia. 
Results are expressed as mean ± SEM, n=6. ***p<0.001 as compared all groups. Analysis 










6.6.3. Effects of restraint stress on behaviour in the elevated plus maze  
The effects of 1 and 3 days immobilization for 2 h on behaviours in 
the EPM are shown in figures 6.7 and 6.8. Using unpaired student t-test, 
revealed no significant effects of Treatment on the time spent in (p>0.05) 
and number of entries into (p>0.05) the open arms in acute and three days 
restraint. However, there was a significant increase in total locomotion 
(p<0.05) after 3 days repeated restraint stress when compared to non-
stressed.   
 
6.6.4. Effects of restraint stress on behaviour in the forced swim test  
The effects of 1 and 3 days restraint stress in the FST are shown in 
(Figure 6.9, n=10 per group). Unpaired t-test showed no significant effects 
of restraint stress on the time spent swimming or immobile in the last 4 min 
of a 6 min test session (p>0.05) and immobile (p>0.05) as compred to non-
stressed mice.  
 
6.6.5. Effects restraint stress on sucrose preference test (SPT) 
Preliminary studies established the effects of bottle position and 
sucrose concentration in adult CD-1 male mice (Figure 6.10 and 6.11). The 
position of the sucrose and water bottles were randomly assigned in the 
cage. There were no significant preference for the position of bottle filled 
with water placed at front or back of the cage (Figure 6.10, F(5.42) = 47.81 , 
p>0.05, n=8, one way ANOVA). The dose response curve of sucrose 
preference at 1, 2.5 and 5 % of sucrose in adult male CD1 mice is shown 
in figure 6.11 (F(5.42) = 36.28, p<0.001, n=8, one way ANOVA). Post hoc 
comparison revealed that sucrose at 1, 2.5 and 5 % all significantly 
increased preference for sucrose compared to water (p<0.05, p<0.001, 
p<0.001 respectively). Also, there was an increase in total consumption as 
body weight % in 5% sucrose group as compared to the other groups 
(p<0.05). Therefore, 5% sucrose was chosen for future experiment. 







































































































































Figure 6.7. Effects of acute restraint stress on behaviour in the elevated plus maze. The 
time spent in open arm  (A),  the number of entries into the open arm (B), time spent in the 
closed arm (C), number of entries in the closed arm (D),  distance travelled in open arm (E) 
and total locomotion (F) was recorded. Each column represents the mean ± SEM of 10 adult 







































































































































Figure 6.8. Effects of 3 days repeated restraint stress on behaviour in the elevated plus 
maze. The time spent in open arm  (A),  the number of entries into the open arm (B), time 
spent in the closed arm (C), number of entries in the closed arm (D), distance travelled in 
open arm (E) and total locomotion (F) was recorded. Each column represents the mean ± 




































Figure 6.9. Effect of 1 day (A) and 3 days (B) restraint stress on behaviour in the FST in 
CD1 male mice. Time spent swimming and immobile were recorded in the last 4 minutes of 



























































Figure 6.10. Baseline preference for bottle position in sucrose preference test for the  front 
and back bottle (A) and total consumption as body weight % (B) in adult CD1 male mice. 
Preference was measured over a 12h test period (7pm-7am). Results are expressed as 











































































Figure 6.11. Preliminary study to show effects of sucrose concentration on sucrose 
preference in adult CD-1 male mice . Preference for 1, 2.5 and 5% sucrose solution (A), 
total consumption of both sucrose and water (B) and sucrose consumption (C) were 
measured over a 12h test period (7pm-7am). Results are expressed as mean ± SEM, 
n=6-8/group. *p<0.05, **p<0.01, ***p<0.001 as compared to water presence. ##p<0.01 as 
compared to 1% sucrose. & p<0.05 as compared to 2.5% sucrose. Analysis was done by 







The baseline preference for bottle position in 5 % sucrose 
preference test for the front and back bottle and total consumption for 1 
and 3 day stressed and non–stressed groups is shown in figure 6.12 and 
6.14. There was no significant difference in baseline measurement of 
preference from front and back bottle in 1 and 3 day stressed (p>0.05, 
unpaired t-test, n=8). Then, the effect of 1 and 3 days restraint stress was 
assessed in the SPT (Figure 6.13 and 6.15). There were no significant 
difference in sucrose preference in 1 and 3 day in stressed mice when 
compared to non-stressed group (p>0.05, unpaired t-test, n=8). However, 
there was a significant reduction in total consumption as % of body weight 
(p<0.01, unpaired t-test, n=8) and sucrose consumption (p<0.001, 
unpaired t-test, n=8) in 1 day stressed mice as compared to non-stressed 
mice. Since the restraint stress paradigm did not yield a significant change 
in the anxiety and depression related behaviour it was not possible assess 
к-receptor antagonist effects on these behaviours.     
 
6.6.6. Effects of restraint stress on gene expression 
 
One-step RT-PCR was carried out to qualitatively establish the 
absence or presence of the GOI in PFC, Hip, NAc and Amy tissue isloated 
from adult CD-1 male mice brains. The GOI analysed were the к-receptor, 
Pdyn and CRHR1, while 18s rRNA was used as a house keeping gene.  
 
The expression profile of genes are shown in Figures 6.16 A and B. 
gel electrophersis showd  asingle RT-PCR product of the predicted 
amplicon size comfirming expression of all GOI in these brain regions. In 
the quantitative real-time RT-PCR experiments, the PCR products were 
detected by using fluorescent SYBR green. In general, SYBR green binds 
to all double stranded DNA. Therefore the melting peak analyses was 
conducted in all experiments to determine whether non-specific binding of 
additional double-stranded DNA products had occurred. Figures 6.17 





analysis which demonstrate the specific amplification of the houskeeping 
gene and GOI in PFC region.  
 
Gene expression changes were examined in the PFC, NAc, Hip and 
Amy of adult CD-1 male mice to determine the effects of 3 days restraint 
stress and effects к-receptor antagonist treatment. The restraint stress and 
к-receptor antagonist treatment of adult male CD1 mice had no significant 
effect on the gene expression for all GOI in all regions test (P>0.05, one 































































Figure 6.12. Baseline preference for front and back water bottle (A) and total consumption 
as body weight % (B) in adult CD-1 male mice before 1 day restraint stress. Preference was 
measured over a 12h test period (19:00-07:00 h). Results are expressed as mean ± SEM, 





































































Figure 6.13. Effects of 1 day restraint stress on sucrose preference in adult CD-1 male 
mice. Preference for 5% sucrose solution (A), total consumption of both sucrose and 
water (B) and sucrose consumption (C) were measured over a 12h test period (19:00-
07:00 h). Results are expressed as mean ± SEM, n=8. **p<0.01, ***p<0.001 as compared 





















































Figure 6.14. Baseline preference for front and back water bottle (A) and total consumption 
as body weight % (B) in adult CD-1 male mice. Preference was measured over a 12h test 
period (19:00-07:00 h). Results are expressed as mean ± SEM, n=8. **p<0.01 as compared 






































































Figure 6.15. Effects of 3 days restraint stress on sucrose preference test in adult CD-1 male 
mice. Preference for 5% sucrose solution (A), total consumption of both sucrose and water 
(B) and sucrose consumption (C) were measured over a 12h test period (19:00-07:00 h). 

































Figure 6.16. Expression of kappa-receptor (k-receptor), prodynorphin (Pdyn) and 
corticotropin-releasing hormone receptor1 (CRHR1) mRNAs in adult CD-1 male mice in 
prefrontal cortex (PFC), nucleus accumbens NAc (A) hippocampus (Hip) and amygdala 

















   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




















   
   
   
   
   
   
   
   
   
   
   
   
   
   
    
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




















   
   
   
   
   
   
   
   
   
   
   
   
   
   
    
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




















   
   
   
   
   
   
   
   
   
   
   
   
   
   
 




   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




















   
   
   
   
   
   
   
   
   
   
   
   
   
   
    
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




















   
   
   
   
   
   
   
   
  
    
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




















   
   
   
   
   
   
   
   
   
   
   
   
   
   
 

















































Figure 6.17. Quantitative real-time RT-PCR amplification and melting points using 18s rRNA 
(A), к-receptor (B), Pdyn (C) and CRHR1 (D) primers in vehicle non-stressed adult CD-1 
male mine in PFC tissue. Amplification curves shows increasing fluorescence on x-axis and 
PCR cycle number over 40 cycle of PCR amplification. Melting curves shows Δ fl/dt on x-






    18s rRNA                                                         к1-receptor 





















































































































































Figure 6.18. Relative fold changes of к-receptor, Pdyn and CRHR1 gene expression in 
repeated 3 day restraint stress adult CD-1 male mice in PFC (A), NAc (B), Hip (C) and Amy 
(D). Gene changes are relative to non-stressed control group and normalized to 
housekeeper gene (18s rRNA). Results are expressed as mean ± SEM, n=3. Analysis was 

















6.7. Discussion  
   
In this chapter, 1 day and 3 days restraint stress significantly 
increased plasma corticosterone levels and induced analgesia in adult CD-1 
male mice. Pretreatment with buprenorphine/naltrexone (1 mg/kg), BU10119 
(1 mg/kg) or norBNI (10 mg/kg) (given 24 hr before restraint stress) failed to 
block the increase in plasma corticosterone observed after 3 days of stress. 
However, pretreatment with these drugs was able to block restraint stress- 
induced analgesia evident after 1 and 3 days restraint stress. In addition, 
there was little change of behavioural changes caused by restraint stress on 
EPM, SPT, and FST as compared to non-stressed groups. Moreover, 3 days 
restraint stress did not produce any significant changes in the relative 
expression of the к-receptor, Pdyn and CRHR1 gene in PFC, NAc, Hip and 
Amy when compared to non-stressed adult CD-1 male mice. 
 
Our data are in agreement with numerous studies documented that 
acute and chronic physical and/or psychological stressors such as foot 
shock and restraint causes a significant several fold increase in 
corticosterone level in mice (Rademacher et al., 2008; Sadler and Bailey, 
2013; Ide et al., 2010; Gong et al., 2015)  and in rat (Foilb et al., 2011). The 
baseline corticosterone values obtained here are within the range reported 
by others in mice (Ide et al., 2010; Sadler and Bailey, 2016). In this study, 1-
day and 3 days repeated restraint stress demonstrated that this procedure 
increased the activity of the hypothalamus-pituitary-adrenal (HPA) axis and 
caused an increase in the secretion of corticosteroids from the adrenal 
cortex. Because of that, corticosterone is usually used as an index for stress 
and depressive disorders (Chen et al., 2005; Armario, 2006; Zhang et al., 
2011). In this study, it is the first time that buprenorphine/naltrexone 
combination and BU10119 were tested to investigate its effects on restraint 
stress-induced elevation in corticosterone level. Pretreatment with these к-
antagonist failed to block the increased in plasma corticosterone by restraint 
stress. This is in agreement with previous studies (McLaughlin et al., 2006b; 
Polter et al., 2014) that found out that the prodynorphin knockout mice and 





swim stress-induced increase in corticosterone levels in mice.  On the other 
hand, norBNI (5 mg/kg) was effective in blocking U50,488H (15 mg/kg) 
induced an increase in the corticosterone in rat (Alcaraz et al., 1993; Victoria 
et al., 1994). norBNI dose, time of injection and different stress procedures 
used could explain the lack of norBNI response in blocking the restraint 
stress increase in corticosterone levels and by increasing the dose and 
giving norBNI for longer periods before restraint might result in enhancing it 
protective effect.      
 
Several studies have documented that acute and strong 
psychological or physical stressors causes a reduction in pain sensation, a 
phenomenon named stress-induced analgesia. On the other hand, chronic 
exposure to such stressors that could be anticipatory/anxiogenic in nature, 
results in less well understood phenomenon of stress-induced hyperalgesia 
in rodents (Andre et al., 2005; Quintero et al., 2011; Tramullas et al., 2012; 
Jennings et al., 2014). In this study, 1 day and 3 days restraint stress led to 
SIA in adult CD-1 male mice and pretreatment with the short and long acting 
к-antagonist blocked SIA. This is consistent with previous studies (Kavaliers 
and Innes, 1987; Miller, 1988; Butler and Finn, 2009). Its assumed that 
severe stress produce more prominent analgesia and that’s way SIA is an 
important tool as it helps in the measurement of a subjective amount of 
stress (Kurrikoff et al., 2008) and preventing this phenomena with к-receptor 
antagonists contribute in understanding the role of stress, к-receptor and 
dynorphins in depressive disorders. Moreover, the effectiveness of к-
receptor antagonists to block SIA shows their possibility to be used in 
prophylactic stress situations.    
 
It has been reported that psychological or physical stressors such as 
restraint stress, exposure to rat, foot shock and tail suspension stressors  
causes anxiogenic behavior in rodents by increasing time spent in the closed 
arms and reduce exploratory activity in the open arms of an EPM 
(Guimaraes et al., 1993; Solomonow and Tasker, 2015), decrease in 





increased immobility in a FST (Strekalova et al., 2004; Sevgi et al., 2006; 
Poleszak et al., 2006). However, our results showed little changes in 
behavioural paradigms after restraint stress. First, there was an increase in 
locomotion after 3 days of repeated restraint stress on adult CD-1 male mice 
when tested in EPM as compared to control group. This is in agreement with 
Zimprich et al (2014) who reported that restraint stress for 2 hr significantly 
increased the distance travelled in open field when compared to non-
stressed mice. The increased locomotor activity seen in both tests could 
explained by an increase in an effort to escape the aversive environment 
(Mozhui et al., 2010). Moreover, Zimprich et al (2014) and Sadler and Bailey 
(2016) suggested that the increased in total locomotion seen in open field 
after restraint stress could be used as a marker of stress-responsivity in 
mice. Secondly, after 1 day of restraint stress there was significant reduction 
in total and sucrose consumption when compared to non-stressed control. 
However, after 3 day repeated restraint stress these effects were not 
reproducible. In addition, there were no significant decreases in sucrose 
preference in 1 and 3 day restraint stress. In the other parameters in EPM 
and other behavioural paradigms, our results showed no changes after 
restraint stress compared to non-stressed mice and this is in controversy 
with other studies which shows a significant decrease in open arm 
exploration in EPM (Guimaraes et al., 1993; Solomonow and Tasker, 2015) 
in sucrose preference (Strekalova et al., 2004) and increase in immobility 
time in FST after restraint stress (Sevgi et al., 2006). One interpretation of 
our results is that the stress produced by 1 and 3 days restraint stress is 
equivalent to the stressed induced by the behavioural paradigms and there 
is no additive effects gained by restraint stress. The controversy between 
our result and others can be explained by using different strain, species and 
type of stress. In addition, the different in the timing of starting the 
behavioural test after stress my account for this controversy. Indeed, 
Padovan and Guimaraes (2000) tested several groups of rats consisted of 1, 
2, 24 or 48 h after the 2h period of acute immobilization. An additional group 
was restrained daily for 2 h for 7 days, and tested in the plus-maze 24 h after 





behavioral changes, expressed as a deficit in open and enclosed arm 
exploration of an EPM 24 or 48 h later, but not 1 or 2 h, after stress. 
 
It is known that brain areas such as the PFC, Hip, NAc, and Amy, are 
important regions involved in the stress response and regulation of emotion 
and behaviour (Spear, 2000; Mitra et al., 2009). It has been reported that 
stressing rats with Fear-Potentiated Startle test upregulates к-receptor 
mRNA in the basolateral Amy by 65% and downregulated it in the striatum 
by 22%, without affecting к-receptor levels in Hip, or dynorphin levels in any 
region (Knoll et al., 2011). Moreover, Chartoff et al (2009) reported that FST 
in rats activates dynorphin expression in NAc tissue and desipramine 
reduced it. Moreover, it was reported by Falcon et al (2016) that the 
exposure to unpredictable chronic mild stress for 3 weeks in mice 
significantly altered opioid gene expression in a number of brain regions (к-
receptor increased in striatum and decreased in Amy and reduced Pdyn in 
Hip. On the other hand, our result in the relative gene 
upregulated/downregulated expression study revealed no significant 
changes after 3 days restraint stress in all different regions tested. The 
controversy between our behavioral studies and gene expression to other 
studies could be explained by using different strain, species, duration of 
stress, starting time of experiment after exposure of stress and methods 
used. Perhaps the duration of stress and the intensity of stressor are not 
sufficient in our study to produce the expected changes in adult male CD1 
mice.   
 
In summary, buprenorphine/naltrexone (1 mg/kg), BU10119 (1 mg/kg) 
and single dose of norBNI (10 mg/kg) pretreatment were able to block SIA in 
adult male CD1 mice. However, they were not capable of blocking restraint 
stress induce elevation of corticosterone level. Moreover, there were few 
significant differences between stressed and non-stressed mice in EPM, 
SPT but not in FST. Moreover, gene expression of к-receptor, Pdyn and 
CRHR1 were not significantly altered by restraint stress or к-receptors 
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7.1. General Discussion  
The goal of this thesis is to investigate the effects of systemic 
administration of buprenorphine (1 mg/kg) and naltrexone (1 mg/kg), 
buprenorphine/naltrexone (1 mg/kg) combination and BU10119 (1 mg/kg) for 
its possible antidepressant and anxiolytic-like effects and whether they 
function as short or long-acting к-receptor antagonist in adult CD-1 male 
mice. All of these treatments produced antidepressant-like effects in FST 
and NIH. Interestingly, they were without significant effect on anxiety-related 
behaviours in the EPM and LDB. Moreover, it was established that the 
combination dose of buprenorphine/naltrexone (1 mg/kg) functions as a 
short-acting к-antagonist in the tail withdrawal test. Also, BU10119 (1 mg/kg) 
was found to be a functional к-receptor antagonist with a rapid onset and a 
duration of action not more than 24 hours. Furthermore, the combination 
dose was neither rewarding nor aversive in the CPP paradigm. In addition, 
the combination regimen and BU10119 were neither hyperactive nor 
sedative in locomotor activity assay and their actions were not mediated 
throughout by a general sedation. Moreover, buprenorphine/naltrexone (1 
mg/kg) combination and BU10119 (1 mg/kg) were able to block stress- 
induced analgesia in adult CD-1 male mice. However, the antagonists were 
not capable of blocking restraint stress-induced elevation of corticosterone 
level. The potential of these antagonists to block stress-induced behavioural 
effects could not be determined in this study since acute restraint stress did 
not induce depressive and anxiogenic-like effects in behavioural paradigms 
compared to non-stressed adult CD-1 male mice.  
 
7.2 Clinical potential of buprenorphine/naltrexone and BU10119 
These results are consistent with the growing literature which 
indicates that к-receptor antagonists could be beneficial in the treatment and 
prevention of mood disorders through blockade of dynorphin’s negative 
consequences (Shirayama et al., 2004; Mague et al., 2003; Filho et al., 
2013; McLaughlin et al., 2003). Indeed, preclinical studies have consistently 
shown that activation of the к-receptors has pro-depressant-related effects 





receptors signalling via к-receptors or dynorphin knockouts and blockade 
with к-receptors antagonists has antidepressant and anxiolytic-related 
effects (Wittmann et al., 2009).  
 
The existing literature on к-receptor antagonists has widely used 
JDTic and nor-BNI that exhibit long-lasting pharmacokinetic properties, they 
inhibit receptor signalling for weeks to months after a single dose (Béguin  
and Cohen, 2009), that complicate experimental design and interpretation of 
results. Moreover, JDTic was stopped during phase I human clinical trials 
due to the development of non-sustained ventricular tachycardia (Buda et 
al., 2015). However, the mechanism of this adverse effect is not clear. One 
possible explanation is that JDTic activate c-Jun N-terminal kinase (JNK) 
which may in turn cause disturbance in fatty acid oxidation in a human 
ventricular and cause cardiac dysfunction. Also, the unusual long-lasting 
effects of some к-receptor antagonists has been attributed to their ability to 
activate the JNK signalling pathway (Bruchas and Chavkin, 2010; Melief et 
al., 2011) (see figure 7.1 and 7.2). In addition, it has been suggested that к-
receptor antagonists that do not activate JNK could be safer alternatives. 
The LY2456302 compound, which was produced by Eli Lilly, is an example 
of a к-receptor antagonist that does not strongly activate JNK. The authors in 
their recent phase I trial reported that the product was well-tolerated (Lowe 
et al., 2014). Moreover, the nonselective к-receptor antagonists, 
buprenorphine and naltrexone are licensed in the market for other 
indications (treatment of opioid dependence) and clinical experiences with 
them have rarely reported this adverse effect and this is one of the potential 
advantages of this combination. Also, ALKS-5461 which is a combination of 
buprenorphine and samidorphan (µ- receptor antagonist) acting as a к-
receptor antagonist, which is under development by Alkermes for the 
treatment-resistant depression (Ehrich et al., 2015). Their results in phase II 
were very promising and researchers have reported that ALKS-5461 might 
work well for the treatment of major depression. In their study they evaluated 










Figure 7.1. К-receptor mediated signal transduction pathways. Activation by of к-receptor 
can result in activation of several kinase cascades. Arrows refer to activation steps, T lines 
refer to blockers or inhibition of function. Abbreviations are as follows: α G-protein alphai 
subunit, arrestin phosphorylationdependent GPCR scaffold, βγ G-protein beta-gamma 
subunit, cAMP cyclic adenosine monophosphate, ERK 1/2 extra-cellular signalregulated 
kinase, GRK3 G-protein coupled receptor kinase3, JMR JNK Modulated Regulator, JNK c-
Jun N-terminal Kinase, p38 p38 MAPK, P phosphorylation, pCREB phospho-cyclic AMP 
response element binding protein, PI3K phosphoinositol 3-kinase, PKCζ protein kinase C 
zeta, PTX pertussis toxin, Src short for sarcoma, member of the src family tyrosine kinases, 

































Figure7.2. Efficacy of JNK activation correlates with duration of action. Quantification of 
pJNK-ir from Western blots was plotted as a function of the natural log of duration of 
antagonism for each compound. Natural log was used to transform the x values because 
the recovery of response after receptor inactivation follows the asymptotic kinetics of 










A = JDTic 
J = norBNI 





samidorphan, as adjunctive therapies in a small cohort of adult subjects with 
major depressive disorder. Patients had a current episode of depression and 
experienced inadequate response to antidepressant treatment. After 7 days 
of once daily buprenorphine/ samidorphan, at a 1:1 ratio, depressed patients 
exhibited a statistically significant improvement in HAM-D17 total score 
versus placebo, with an effect size of 1.49 (Ehrich et al., 2015). In addition, 
the data from two of three core Phase III trials was recently released and 
revealed that the combination was safe and well tolerated. However, it failed 
to meet its primary efficacy endpoints, although some efficacy was observed. 
The third and final core Phase III study is currently in progress. However, 
they suggested that the buprenorphine/samidorphan combination is a novel 
and potential treatment for major depressive disorder in patients who are 
treatment-resistant with standard antidepressants (Fava et al., 2016). 
 
In this study, it has been shown that the combination of 
buprenorphine (1 mg/kg) with naltrexone (1 mg/kg) and BU10119 (1 mg/kg) 
administered intraperitoneally in adult CD-1 male mice has antidepressant 
potential. Buprenorphine and naltrexone are licensed currently for other 
indications, so may be attractive to translate to the clinic. However, 
naltrexone is administered orally and buprenorphine sublingually, so 
achieving the correct dose combination to achieve an antidepressant effect 
may not be trivial. Cordery et al (2014) have suggested that the ideal 
buprenorphine: naltrexone plasma concentration ratio is around 1:5 for anti-
addiction treatment. Further, they suggested that higher doses of both 
buprenorphine and naltrexone than those used by Rothman et al (2000) and 
Gerra et al (2006) for treatment of opioid dependence (buprenorphine 4 mg 
daily/ naltrexone 50 mg daily) may be even more effective clinically, as the 
combination would result in greater receptor occupancies. In preclinical 
studies, lower doses of buprenorphine at 0.25 and 0.5 mg/kg have been 
shown to have antidepressant-like effects in mice (Falcon et al., 2015), in 
comparison to 1 mg/kg used in this study which also produced 
antidepressant-like effects. Interestingly, clinically significant effects of 





ranging from 0.15 mg/d to 1.8 mg/d or from 0.2 mg/d to1.6 mg/d (Bodkin et 
al., 1995; Karp et al., 2014). Naltrexone would need to be carefully titrated to 
avoid inducing aversive side effects which deter use (Bouza et al., 2004). A 
further limitation of this combination approach is the risk of diversion of 
buprenorphine and its abuse liability. Also, buprenorphine and naltrexone 
could not be administered as a single formulation due to their different 
bioavailability, which might create compliance issues. Nevertheless, these 
data highlight the potential of combination buprenorphine/ naltrexone as an 
antidepressant treatment strategy and to provide an alternative route to 
achieving a shorter-acting safe and effective к-receptor antagonist. On the 
other hand, BU10119 is a single compound combining the phramacology of 
buprenorphine/naltrexone it acts as a short к-receptor antagonist and with no 
or little µ-receptor agonist activity (resemble the combination buprenorphine/ 
naltrexone) and the data here showd the potential as an antidepressant 
treatment. However, its not known if BU10119 could cause activation of JNK 
which may in turn cause disturbance in fatty acid oxidation in a ventricular 
cardiac tissue and cause cardiac dysfunction. A lot of work needed to be 
done to investigate the safety and the efficacy of BU10119 in different 
variable and multiple stress model such as the Flinders Sensitive Line rat or 
the chronic unpredictable mild stress model (Overstreet and Wegener, 2013; 
Monteiro et al., 2015).  
 
7.3 Why are к-antagonists likely to be antidepressant? 
Most of research on depressive disorders has focussed on the 
possible role of 5-HT and NA neurotransmitter system. Indeed, it has been 
reported that U50,488 produced decrease in 5-HT during local infusion into 
the dorsal raphe nucleus, median raphe nucleus, and NAc (Tao and 
Auerbach, 2002) which may take part in the explaining of the depressive and 
anxiogenic-like effects in behavioural paradigms produced by stress and к-
receptor agonist. In our FST experiments, buprenorphine/naltrexone 
combination and BU10119 treatment decreased immobility with a 
concomitant increase in swimming behaviour, without an effect on climbing 





serotonergic system increase swimming behaviour, whereas those that 
target noradrenergic systems increase climbing behaviour, thereby 
decreasing immobility (Detke et al., 1995), this may indicate that 
serotonergic pathways are implicated in the opioid-mediated antidepressant 
effects seen here, as has been suggested by others (Bruchas et al., 2011). 
On the other hand, there is evidence that other systems may play an 
important role in the development of depressive disorders. One of these 
systems is dopaminergic system. It has been reported that disturbance in DA 
function in NAc lead to anhedonia (Wise, 1982; Wise, 2008). Moreover, it 
has been reported that 5-HT, NE systems (Pasquier et al., 1977) and 
endogenous opioid system (Shippenberg and Rea, 1997; Svingos et al., 
1999) modulate DA system. Indeed, there is evidence suggests that 
activation of the к-receptors, after stress, causes a reduction in dopamine 
release in different brain regions and that may take part in the 
pathophysiology of depression (Spanagel et al., 1992; Carlezon et al., 2006 ; 
Ebner et al., 2010; Belujon and Grace, 2015). Thus, stress may disturbe the 
balance of different neurotransmitter in brain which may contrbute to the 
development of depressive disorder. On the other hand, the к-antagonists 
GNTI, norBNI and ANTI have shown antidepressant-like effects (Newton et 
al., 2002; Mague et al., 2003; Shirayama et al., 2004; Carr et al., 2009) when 
measured in FST. Moreover, it has been demonstrated that к-receptor 
antagonists such as norBNI, GNTI and the JDTic decrease anxiety-like 
behaviors in mouse tests, including the NIH and EPM (Van’T and Carlezon, 
2013; Hang et al., 2015) and increase the release of dopamine in different 
brain regions (You et al., 1999; Pliakas et al., 2001; Beardsley et al., 2005) 
Also, restoring the DA balance, by к-receptor antagonist, may lead to 
restroation the balance of NA and 5-HT in the brain, which may explain its 
antidepressant-like effects.   
 
In conclusion, the systemic co-administration of buprenorphine (1 
mg/kg) with naltrexone (1 mg/kg) and BU10119 (1 mg/kg) in adult CD-1 male 
mice function as short к-receptor antagonist in the tail withdrawal assay, 





FST, reduced the latency to drink milk in the novel cage in the NIH task and 
they were able to block SIA, suggesting that these drugs are novel and have  
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Exp start date: 15.9.16                          study: 3 days SPT 
Animal ID: 13 (stress control mice). 
Restraint stress 
9-11 Am 










  32.5 32.5 32.2 31.4 
Daily body weight (g) 0  0   
Weight loss <5% 1   1  
Weight loss 5-15% 2    2 
Weight loss >15% 3     
Appearance  Normal 0  0 0 0 
General lack of grooming 1     
Coat staring, ocular and nasal 
discharges 2     
Piloerection, hunched up 3     
Breathing  Normal breathing 0  0 0 0 
Laboured breathing   3     
Natural 
behaviour  
Normal  0  0 0 0 
Minor changes  1     
Less mobile and alert, isolated  2     
Vocalisation, self-mutilation, 
restless or still 3     
Provoked 
behavior  
Normal  0  0 0 0 
Minor depression or 
exaggerated response  1     
Moderate change in expected 
behaviour  2     
React violently, or very weak 
and precomatose  3     
Score  If you have scored a 3 more 
than once , score an extra point 
for each 3 
2-5  0 0 0 
Total 0-20  0 1 2 
Total score 3= Normal 
 
0-4= normal, 5-9=monitor carefully, 10-14= suffering, provide relief, observe regularly, seek 
second  opinion from NACWO and/ or NVS. Consider termination. 
Table 1. An example of scoring sheet for assessing animals stat during restraint stress.        



































Figure 1.  Effect of 3 days restraint stress on daily bodyweight of adult CD-1 male mice. 
Results are expressed as mean ± SEM, n=8/group.  **p<0.01 ***p<0.001 (repeated 
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